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Summary of the thesis 
Nanoparticles are under comprehensive investigation as a promising platform for 
drug delivery since three decades. However, the transition from encouraging pre-
clinical research to clinical studies and finally regulatory approval has not yet 
occurred for solid colloidal nanoparticles. This work shall contribute to bridging 
that gap. Convinced that therapeutic nanoparticulate formulations should be as 
extensively characterized and be kept as simple as possible, this thesis 
exemplarily describes analytical methods and production improvements for 
gelatin nanoparticles (GNPs) and proposes their employment in a variety of 
immunotherapeutic applications. 
Up-scaling of the original manufacturing setup was technically enabled and 
resulted in ten-fold increased batch sizes. Systematic correlation studies facilitated 
the establishment of a set of equations to predict necessary GNP preparation 
parameters for each relevant batch size. This shall contribute to future higher GNP 
demand in clinical manufacturing. 
Moreover, the feasibility of replacing well-established but initially toxic starting 
material glutaraldehyde as a cross-linking agent by the enzymatic alternative 
transglutaminase was demonstrated. Transglutaminase-crosslinked GNPs featured 
narrow particle size distributions and high storage stability. 
Ultrasonic resonator technology was demonstrated as a capable tool in relative 
GNP size analysis and DNA surface binding detection which could serve in future 
as a non-destructive tool for online in-process control in continuous GNP 
production. Within this study, a discriminative response of cationized and non-
cationized GNPs towards distinctive buffers was observed. The swelling and size 
reduction was found to be in accordance with the sequence of salts of the 
Hofmeister series. 
Of special importance was the successful radio-labeling of GNPs by radionuclides 
111In+ or 68Ga3+, respectively, to monitor their biodistribution after s.c. or i.v. 
administration both by conservative sectioning and Positron Emission 
Tomography. PEGylation was conducted and proofed for several molecular 
weights. However, no enhanced circulation properties could be obtained due the 
prevalent hydrophilic properties of the starting molecule gelatin. Nevertheless, the 
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radio-labeling technique could be beneficial in new applications such as the 
monitoring of inhaled GNPs and in the quantification of the resulting lung 
deposition.   
In continuation of promising in vitro and in vivo studies on the employment of 
GNP-bound CpG-DNA as an adjuvant in ovalbumin (OVA)-targeted cancer 
immunotherapy, initial trials on the immunostimulatory (is) RNA-mediated 
immunostimulation clearly demonstrated the potential of GNPs to assist 
addressing also the Toll-Like receptor 7. Here, isRNA superiorly entered the 
target lysosome when transport was GNP-mediated e.g. in contrast to DOTAP-
mediated transport. GNPs effectively protected the isRNA from degradation upon 
RNAse challenge. Immunostimulation was successful as revealed by activation of 
relevant cell markers such as CD69 and most important, survival of pre-
immunized and OVA-expressing tumor challenged mice was significantly 
prolonged. Ongoing studies indicate that this promising strategy is working in a 
therapeutic model setting, too. Thus, GNP-based isRNA formulations could be 
capable to cure existing tumors.  
Immunomodulating effectiveness of GNP-bound CpG-DNA was demonstrated in 
a preclinical canine study. The impressive benefit of CpG A-class delivery by 
GNPs to peripheral blood mononuclear cells in terms of antiallergic IL-10 release 
was revealed in a canine in vitro study. This laid the foundation for further, now 
starting, in vivo studies to elucidate the possibility of a therapeutic option against 
common canine atopic dermatitis by modulating CpG-based immunotherapy.  
Finally, a novel approach in therapy of common equine allergic condition of 
recurrent airway obstruction (RAO) was established, constituting the first-time 
ever immunotherapeutic clinical study associated with a colloidal carrier system. 
First, an appropriate combination of nebulizer and spacer to nebulize CpG-GNP 
formulations was developed for witch a patent was field. Then, a suitable CpG 
sequence to stimulate equine BAL cells was identified.  
On cytokine detection level, it was remarkably possible to distinguish RAO-
affected from healthy horses in vitro. Most notably, regulatory cytokine IL-10 
expression was significantly triggered in vivo by five consecutive inhalations in 
RAO-affected horses. The entirety of clinical parameters assessed after 
nanoparticle treatment indicated a partial remission of the allergic condition. In 
particular, breathing rates were lowered to physiologic level, blood oxygen partial 
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pressure was significantly elevated, the pathogenic TBS score values were 
moderately reduced and the RAO-determinant content of neutrophile granulocytes 
within the TBS was more than halved on average. Therefore, this preliminary 
clinical study showed for the first time safety and curative effectiveness of 
colloidal nanocarrier-mediated immunotherapy in food-producing animals. 
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I General Introduction 
1. On the art of drug delivery by nanotechnology 
1.1 The aim of this thesis 
“Fortiter in re, suaviter in modo”: What Jesuit general Claudio Aquaviva1 coined 
over 400 years ago with a metaphysic vision in mind can be directly transferred to 
the prime goal of drug delivery nowadays: going ambitiously for the target, but 
doing it in a smart and balanced way. Within this thesis, the “modo”, the kind of 
“magic bullets” (Paul Ehrlich) to target only the illness without harming the host, 
is carried out by gelatin nanoparticles (GNPs). Key applications of the delivery 
system GNPs as a whole were addressed and extensively and comprehensively 
assessed. Already established uses could be further strengthened leading to 
recommendations for future employments of this promising tool. Some 
applications were found to be less beneficial than other obtainable means being of 
current interest in nanotechnology research and development. Therefore, a 
contribution to a more success-orientated use by avoiding future less promising 
GNP applications was performed. Finally, completely new insights were gained in 
some basic research aspects of formulation and in new fields of administration as 
well as a considerable broadening in the recipient species from mice up to dogs 
and horses was a mayor success. 
The main mechanistic amendment to the scientific field of GNP application was 
performed by the introduction of an antiallergic immunomodulatory therapy 
through so called Cytosine phosphodiester guanidine (CpG) oligonucleotides. 
Contrasting the original pursuit to boost immune response by CpG or more 
recently by RNA analogs towards undesired structures such as tumors –or in other 
groups infectious specimens- it was possible to introduce GNPs as a crucial 
device in CpG delivery in down regulating immune responses. This was shown to 
be beneficial in events of hypersensitivity such as canine atopic dermatitis in vitro 
and equine recurrent airway obstruction (RAO) in vitro and in vivo.    
                                                 
1
 Raffaele Aurini, Acquaviva d'Aragona Claudio, in Dizionario bibliografico della Gente 
d'Abruzzo, vol. III, Teramo, Ars et Labor, 1958, e in nuova edizione ampliata, a cura di Fausto 
Eugeni, Luigi Ponziani, Marcello Sgattoni, Colledara, Andromeda editrice, 2002, vol. III, pp.55-62 
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1.2 Why nanotechnology for drug delivery? 
The development of delivery devices featuring high accuracy, safety and 
efficiency remains a main challenge towards directed drug delivery. 
Nanotechnology has been a key driving factor in the past decades’ publication 
activity started by Speiser and coworkers (Marty et al. 1978). Altogether, 
nanoparticles – generally defined as a colloidal system featuring solid particles 
sized 1- 1000 nm (Kreuter 1983) – emerged as a frequent key term in publications 
to include patents (Fig. 1a).  
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Fig. 1a: Amount of peer-reviewed publications on nanoparticles in general per 
indicated year. 
 
They cover all fields of material science related to engineering, physics and 
medicine. Within the term “nanoparticles”, the topic drug delivery accounted for 
up to 1.5% of the combined search hits “nanoparticle” and “drug delivery” in 
2008 as per CAS’s SciFinder database of bibliographic information (Fig. 1b). The 
still strengthening scientific output can be followed by these numbers of 
publications. In parallel, the number of published articles on the term 
nanomedicine increased clearly resulting from the considerable drug-delivery  
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Fig. 1b: Amount of peer-reviewed publications on nanoparticles in drug delivery 
per indicated year. 
 
aspect of nanotechnology (Fig. 1c). As a sub discipline, nanomedicine emerged 
combining fields of medicine, pharmaceutical technology, chemical analytics and 
material science. This shall enable the creation of a potent market for 
nanotechnology-enabled drug delivery which is projected to reach $26 billion by 
2012 with high two-digit annual growth rates2. 
According to the European Science Foundation’s “Forward Look on 
Nanomedicine”, Nanomedicine is characterized as depending on complex systems 
in nanometer scale consisting of at least two components.  One component is the 
active pharmaceutical part and the other is related to support or boost the special 
function in diagnosing, treating or preventing a disease, injury or pain (Duncan 
2000; Duncan et al. 2006; Duncan 2006; Lehr 2007). 
Within nanomedicine, the drug delivery sector dominates with 70% of total sales, 
76% of issued scientific publications and 59% of granted patents (Gurusamy 
2007). 
 
 
                                                 
2
 http://www.marketresearch.com/product/display.asp?productid=1692509&SID=30048100-
474535314-495102710&kw=Nanoparticle%09Drug%09Delivery%09Markets, 20-Apr-10 
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So why is nanotechnology in drug delivery a worthwhile option? Traditional 
small molecule drugs (SMD) are frequently formulated as a solid dosage form and 
administered orally. However, the new driving forces e.g. in cancer and anti-
autoimmune diseases therapies belong to the biologicals’ field which is in most 
cases subjected to non-oral administration. Biologicals are mostly protein 
therapeutics like antibodies, vaccines or cell growth factors which as a group 
constitute the most rapidly increasing categories of drugs accounting for 10.9% of  
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Fig. 1c: Amount of peer-reviewed publications on nanomedicine per indicated 
year. 
 
global therapeutics’ growth in the past five years (Yang et al. 2009). Moreover, 
according to the “Autoimmune Market Forecast to 2014”3 all over biological sales 
are projected to hit $55 billion by 2014. Further developments look at the 
introduction of more therapeutic proteins, peptides, plasmids or oligonucleotides 
as drug substances that require a multitude of special formulations (Allen and 
Cullis 2004; Solaro et al. 2010). This demand for suitable carrier systems will 
significantly increase to eventually enable drugs to be reasonably employed 
clinically. Additionally, packing existent SMDs into nanocarriers was investigated 
as an attractive method to improve their biocompatibility, bioavailability and 
                                                 
3
 http://biotechconnection.com/p=3, 20-Apr-10 
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safety (Debbage 2009) and therefore improve the therapeutic index of already 
introduced drugs (Allen and Cullis 2004). This is due to the fact that increasing 
SMD dosage translates into higher possible toxic effects once the drug encounters 
normal cells in contrast to the target. Especially for potent anticancer agents, this 
issue gets more and more addressed. These ideal carriers should prevent the 
eventually sensitive drug from early enzymatic or pH-associated degradation, 
prolong half life, reduce dosing and consequently lead to less side effects 
(Torchilin 2007). Moreover, such devices are intended to deliver the drug payload 
exclusively to the site of disease which is referred here to as “targeting” coming 
close to Paul Ehrlich’s magic bullets (Debbage 2009). Especially in the field of 
DNA-based and small interference RNA (siRNA)-based therapeutic attempts such 
as gene therapy, viral vectors were considered the ideal targeting shell (Reischl 
and Zimmer 2009). However, fundamental problems related to toxicity, 
immunogenicity and large-scale production justified the development of non-viral 
vectors in the nanometer range with individual passive or active targeting abilities 
(Mintzer and Simanek 2009). 
To enable these tasks, multifunctional nanoparticles that carry the therapeutic or 
imaging payload and possess biological surface modifiers such as targeting 
moieties or simply polyethyleneglycole (PEG) for unspecific targeting have been 
proposed. The latter is attributed to the concept that hydrophilization of particle 
surfaces (Storm 1995, (Brannon-Peppas et al. 2007) results in longer circulation 
times after i.v. administration hence increasing the chance to find the target. This 
is decisive as a failure of the drug in reaching the target constitutes a failure of the 
whole therapy (Debbage 2009).  
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2. Overview on starting materials and production methods 
2.1 Established non-proteineous starting materials 
Nanoparticulate systems such as solid spheres, micellar emulsions and liposomes 
relied on a variety of starting materials. For the former, several biocompatible and 
partly biodegradable macromolecules obtained attention. Conventional synthetic 
macromolecules were among the first used and comprised as prototypes 
poly(lactid acid) (PLA), poly(lactic-coglycolic acid) (PLGA) (Park et al. 2009) 
and poly(cyano acrylate) (Diepold et al. 1989). Particularly the latter was early 
investigated for drug loading and intracellular endosomal localization (Couvreur 
et al. 1979). Furthermore, polyelectrolytes such as poly(ethylenimine) PEI-based 
polyplexes demonstrated their non-viral gene delivery potential (Gharwan et al. 
2003) while related toxicological issues were addressed (Zintchenko et al. 2008). 
Other coated nanoparticles based on cationic polyplexes exhibited tunable tissue 
targeting for specific gene delivery (Harris et al. 2010). Among the 
polysaccharides, chitosan was investigated as a suitable nanoparticle basic 
material to carry proteins (Amidi et al. 2006), cytotoxic agents (Janes et al. 2001) 
or DNA-based drugs (Bernkop-Schnuerch et al. 2006). Metal nanoparticles 
constitute another class as inert but not biodegradable carriers e.g. for anti-cancer 
drug delivery (Brown et al. 2010) or magnetic targeting or imaging (Smith et al. 
2010). Lipids are mostly employed for gene delivery as lipoplexes (Koh et al. 
2010) but also as solid-lipid nanoparticles for diverse parenteral applications 
(Joshi and Mueller 2009). 
 
2.2 Proteins as constitutive material for nanoparticles 
A main advantage of proteins compared to synthetic polymer-based systems is 
their frequent compatibility with biologic systems and their general 
biodegradability (Wang and Uludag 2008). Furthermore, by their nature they offer 
a multitude of moieties accessible to modifications to tailor drug-binding, imaging 
or targeting entities. Safety concerns may arise from folding pattern-derived 
immunogenicity or from contamination with transmissible diseases. The latter can 
be ruled out by a careful choice of source such as natural material that went 
through intensive processing under aseptic conditions or the use of recombinant 
material.  
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2.2.1 Albumin 
The blood transporter protein human serum albumin (HSA) probably is one of the 
most recognized and intensively investigated proteineous starting materials, today 
from recombinant offspring. Beyond research and development, two HSA-based 
products successfully entered the market, AbraxaneTM and AlbunexTM (Wang and 
Uludag 2008). However, they both do not constitute a nanoparticulate formulation 
which is defined as a colloidal system of solid discrete and continuously shaped 
integrative particles in the lower nanometer range. Albunex provides clinical 
benefits and was on the market already since 15 years without implications of 
immunogenicity (Christiansen et al. 1994). 
It is an ultrasound contrast agent consisting of a slowly diffusing gas C3F6 
encapsulated by an elastic HSA shell (Postema and Schmitz 2007). Therefore, it 
constitutes a well studied microbubble formulation (MacDonald et al. 2004) with 
an average “particle” size of 3 – 5 µm (Barnhart et al. 1990). Recent promising 
development strategies of mircobubbles comprised drug targeting such as for 
doxorubicin for antitumor therapy (Tinkov et al. 2010) or the prospect of local 
gene therapy (Frenkel and Li 2006). 
Abranxane is a self-assembling nanoagglomerate (Xiao et al. 2009) of HSA and 
paclitaxel produced by high-pressure homogenization (Moreno-Aspitia and Perez 
2005). Resulting sizes account for about 130 nm. Originally designed as a 
biocompatible formulation without irritating polyethylated castor oil and 
polysorbate against metastatic breast cancer (Gradishar et al. 2005; Harries et al. 
2005), it was meanwhile preclinically evaluated for other anti-cancer 
employments (Xiao et al. 2009). 
As starting material for colloidal nanoparticles, HSA served in several in vitro 
(Kissel and Roser 1991) and in vivo studies such as to antibody-mediated target 
leukemic cells and primary T-lymphocytes (Dinauer et al. 2005) or to be delivered 
to neurons by Apo E mediated transcytosis (Zensi et al. 2009), respectively. 
Although albumin is not immunogenic per se, cross-linked particles can enhance 
the immunogenicity of antigens loaded onto these hapten-acting particles. For 
instance, anti-ibuprofen antibodies are gained by albumin particle-bound 
ibuprofen to develop ELISAs (Grafe and Hoffmann 2000). 
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2.2.2 Legumine, gliadine, elastinlike polypeptide, β-galactoglobulin, silk 
Other proteins used for nanoparticle production were plant-derived such as 
legumin and gliadin (Wang and Uludag 2008). The latter is a lipophilic protein 
with a low aqueous solubility. When preparing nanoparticles from this starting 
material, loading capacities do largely depend on the hydrophobicity of the agent 
such as vitamin E (Duclairoir et al. 2003). More studies were conducted on 
protamine which -as a cationic protein- exhibited capabilities for promising 
immunostimulatory DNA or basic fibroblast growth factor (FGF2) transport 
(Mori et al. 2010). Moreover, it exhibited size-tuning properties when employed 
in the form of different salts in HSA nanoparticle production (Mayer et al. 2005).  
Particles of tunable size were also produced from denatured whey protein by pH-
cycling treatment (Giroux et al. 2010). As an environment-responsive basic 
proteineous material, elastinlike polypeptide (ELP) was examined (Fujita et al. 
2009). Its special feature is the reversible response to thermal change which 
exhibits a soluble state below and a solid state above the transition temperature 
(Maham et al. 2009). In the latter state, sticking to target tissues is possible. The 
substance is biodegradable and proofed tumor accumulation in an in vivo model 
(Liu et al. 2006).  It holds promises to carry lipophilic drugs but attention must be 
paid to the critical temperature at which the particles start to form aggregates in 
vivo (Fujita et al. 2009).  
Globular proteins were used to associate with anionic polysaccharides to form 
particulate structures in the nanometer scale as potential delivery devices (Jones et 
al. 2010). Therefore, β-galactoglobulin was thermally treated for conformation 
changes, pH-adjusted and mixed with a pectin solution to form particles of 
discrete size properties. 
A rather new starting material of natural origin is silk protein (Zhang et al. 2007). 
Delivery of DNA was successfully reported for gene transfer in vitro (Numata et 
al. 2009). Furthermore, formulation studies revealed interesting results such as a 
sustained release and enhanced insulin stability when the covalently silk protein-
bound insulin was challenged with gastric trypsin (Kundu et al. 2010). Others 
reported successful sustained release of VEGF (Yan et al. 2009). However, 
advanced employment of this subtype of protein nanoparticles is not at hand at 
present although successful robust salting-out production method was reported 
recently (Lammel et al. 2010).  
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2.2.3 Gelatin 
Ongoing research interest was conceded to gelatin over the last years (Young et 
al. 2005b) for several reasons. Gelatin is a natural polymer derived from collagen 
recognized as a biodegradable and biocompatible starting material being in use as 
plasma expander for decades (Ward et al. 1977b). The natural source of gelatin is 
from animals. It is obtained mainly by acidic or alkaline, but also thermal or 
enzymatic degradation of the collagen. Collagen forms 30% of all vertebrate body 
protein with a majority in bone and skin. More than 90% of the extra cellular 
protein in the tendon and bone and more than 50% protein in the skin consist of 
collagen (Friess 1998). The high stability bases on the unique triple-helix structure 
consisting of three polypeptide α-chains. So far 27 collagen types have been 
isolated so far (Brinckmann et al. 2005), however, collagen type I (skin, tendon, 
bone), type II (hyaline vessels) and type III are used for the production of gelatin 
only (Babel 1996).  
Gelatin type A (acid), which is obtained from porcine skin with acidic pre-
treatment prior to the extraction process, can be distinguished from type B (basic), 
that is extracted from ossein and cut hide split from bovine origin. Here an 
alkaline process, also known as “liming” is applied. Amide groups of asparagine 
and glutamine are hydrolyzed into carboxyl groups during this process, therefore 
many of the residues are converted to aspartate and glutamate (Young et al. 2005; 
Tabata and Ikada 1998). As a result, the isoelectric point (IEP) of type B gelatin is 
not at pH 9.0 like type A and collagen itself, but the higher number of carboxyl 
groups per molecule reduces the IEP to pH 5.0.  
While gelatin and the delivery systems based on this polymer are biocompatible 
and biodegradable without toxic degradation products (Tabata and Ikada 1998; 
Kawai et al. 2000; Yamamoto et al. 2001; Ward et al. 1977), they are since a long 
time known for high physiological tolerance and low immunogenicity. The 
overall beneficial properties of gelatin contributed to its proven record of safety as 
food supplement which is also documented by the classification as “Generally 
Recognized as Safe” (GRAS) by the US Food and Drug Administration (FDA). 
Moreover, intravenously administered applications like plasma expanders (e.g. 
Gelafundin™, Gelafusal™) consist of gelatin derivatives. Other uses of gelatin 
include sealants for vascular prostheses (Kuijpers et al. 2000). Furthermore, due to 
its biodegradeability molecular weight is not restricted to 40 kDa for renal 
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elimination. Hence, the larger particles build a suitable platform for numerous 
structural potential modifications on the surface coupled to the many accessible 
functional groups. Lysine provides accessible prime amino groups e.g. for 
crosslinking and marker coupling as described in due course. 
Nanoparticles prepared by a two step desolvation technique and subsequent 
chemical cross-linking (Coester et al. 2000) maintained their non-toxic properties 
while featuring a higher storage stability than liposomal liquid formulations and 
good in vivo stability upon administration (Coester et al. 2006). Although no 
undesired effects which could be attributed to GNPs were observed in vitro or in 
vivo, two issues are worth being discussed: safety of the starting material gelatin 
and secondly safety of the chemical particle cross-linking by glutaraldehyde. The 
unlikelihood of transmittable diseases to endure the collagen processing steps was 
evaluated in the peak-time of the mad cow disease. To rule out this matter 
completely, gelatin of porcine origin was used in many studies throughout. 
Although not reported for this gelatin offspring, immunogenicity is a possible 
point to consider with all protein formulations. Replacing animal-derived gelatin 
by recombinant human gelatin did not result in different serum chemistry 
parameters in humans (Won and Kim 2009). Furthermore, no overall significant 
benefit related to in vitro cell viability is gained when animal-derived gelatin is 
replaced by rHG and glutaraldehyde by genipin (Won and Kim 2009). Other 
concerns included the potential reactivity of imines resulting from the 
glutaraldehyde cross-linking. However, a chemical reduction of the imines to 
imides did not result in a higher stability of GNPs (see III.2). Furthermore, a 
complete removal of GA by repeated purifications steps in the production of GA-
cross-linked GNPs was the most probable reason for non-toxicity. Due to many 
years of safe experience with glutaraldehyde both in vitro and in vivo, at present 
additional costs are not justified by the potential advances. Nevertheless, 
promising alternatives to glutaraldehyde to facilitate possible human applications 
in future are at hand. Recently, we reported suitable process conditions in which 
recombinant transglutaminase effectively cross-linked GNPs (Fuchs et al. 2010). 
Optimum size and size distributions comparable to those cross-linked by 
glutaraldehyde were received and suitable storage stability was proven. While the 
possible therapeutic applications are discussed later in detail, it is worth to be 
mentioned that the gelatin matrix with diverse moieties facilitates the surface 
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decoration with targeting functions such as antibodies (Balthasar et al. 2005). 
Furthermore, GNPs allowed a matrix loading even with proteins like insulin 
which was evaluated recently (Ofokansi et al. 2010). 
 
2.3 Preparation methods of protein nanoparticles 
2.3.1 Coacervation process 
Due to relatively mild conditions the coacervation or equally coined desolvation 
process turned out to be the most appropriate and frequent method to prepare 
protein-based nanoparticles. In brief, a colloidal system is created when the 
solvent in which the protein was initially dissolved is gradually extracted into an 
anti-solvent phase. Thereby a phase separation occures which results in a phase of 
solid colloid dispersed in a second phase consisting of the anti-solvent and the 
initial solvent (Weber et al. 2000). Consequently, solvent and anti-solvent must be 
miscible such as water as solvent and ethanol or acetone as anti-solvent whereof 
the latter was often used to produce GNPs by a two step desolvation technique 
(Coester et al. 2000; Langer et al. 2003). While a stable size is reached after an 
initial process period the further addition of anti-solvent leads to increased 
particles yield in the course of desolvation (Weber et al. 2000).  Furthermore, the 
pH value of the protein solution prior to desolvation has an impact on the resulting 
particle size and yield due to higher probability of protein coacervation at net-zero 
surface charge at the isoelectric point. This was observed for particles derived 
from gelatin, HSA, BSA and β-lactoglobulin (Coester et al. 2000; Ko and 
Gunasekaran 2006; Langer et al. 2003) To stabilize colloidal nanoparticles by 
establishing covalent bonds between prime NH2-groups by chemical cross-linkers 
such as glutaraldehyde or glyoxal were widely employed without negative side 
effects (Weber et al. 2000). As the carcinogenic properties of free glutaraldehyde 
is a known issue, methods like high-temperature cross-linking (Chen et al. 1994) 
or macromolecular cross-linking (Lin et al. 1994) were discussed but imply the 
risk of harming possible drug load. Therefore, we currently investigate the 
possibility of enzymatic cross-linking of protein nanoparticles.  
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2.3.2 Solvent extraction or emulsion process 
Adopting the emulsification and solvent extraction methods from synthetic 
polymer-based nanoparticle production to proteins as a starting material, the latter 
needs to be present in solution in an aqueous buffer. By adding an anti-solvent, a 
W/O emulsion is prepared from which nanoparticles are received after solvent and 
anti-solvent removal. A double emulsion technique involving W/O/W emulsions 
allows encapsulation of proteins and hydrophilic drugs (Sussman et al. 2007). In 
general, the method lacks from relatively large particle sizes which were reported 
between 100 - 800 nm for BSA nanoparticles depending on protein concentration 
and solvent to non-solvent ratio (Mishra et al. 2006). On the other hand, high 
encapsulation rates were achieved (Chawla and Amiji 2002).  
 
2.3.3 Salt precipitation 
The salting out method proteins was described e.g. for HAS as a simple method to 
gain protein aggregates and eventually nanoparticles (Coester 2000). Proteins with 
therapeutic properties can be transferred into nanoparticles without the need of 
further particulate auxiliary particles. Therefore, the protein gets cross-linked with 
multivalent ions (Yang et al. 2009). 
However, this method retains the risk of changed bioactivity and lost 
conformation which is more an issue when therapeutic proteins are involved like 
insulin (Fan et al. 2006) compared to proteins with solely carrier functions 
(Coester et al. 2000). Reported higher heterogeneity in particle sizes makes this 
method inferior to above described (Wang and Uludag 2008). 
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3. The administration route 
3.1 Intravenous application 
Intravenous injection is the standard form of application for all delicate 
formulations that are intended to be bioavailable immediately and distribute to an 
otherwise difficult to reach pathologic part of the body. 
Several obstacles exist that nanoparticles encounter once administered into the 
blood stream that a soluble SMD in comparison experiences to a lower degree.  
The tasks can be abbreviated to four steps: the unspoiled navigation through the 
blood stream, the evasion of biological barriers, the site- or cell specific 
localization and finally the exclusive targeting of the biological pathway to treat 
the pathological condition the whole system was made for (Ferrari 2008). 
Intravascular application is immediately followed by quick dissemination as one 
pass in human circulation accounts for about 15 seconds. The chance that a drug 
reaches the target “en bloc” is thereby almost ruled out. SMDs can easier diffuse 
through membranes or around barriers while nanoparticles more easily get 
trapped. Furthermore, they have to escape the engulfment of the 
reticuloendothelian system (RES) also more recently known as the mononuclear 
phagocyte system (MPS) (Vonarbourg et al. 2006). This installation lowers blood 
concentrations even of anticipatory engineered nanoparticles to 5-10% after 8 
hours compared to the initial dose (Gaur et al. 2000) and consequently lead to 
liver, spleen and lung accumulation (Ferrari 2005). PEGylation still is one of the 
major techniques said to counter fight early phagocytosis and prolong free 
circulation of nanoparticles (Gref et al. 2000; Vonarbourg et al. 2006). PEG was 
identified to lower opsonization by shielding effects. PEGylation mechanisms 
have been studied in detail to include the deshielding process once the carrier 
reached the pathological site (Romberg et al. 2008). In 1994, the first PEGylated 
protein therapeutic entered the market to be administrated systemically in contrast 
to SMANCS’s local application. Oncaspar® (PEGylated l-asparaginase) was used 
to treat acute lymphoblastic leukaemia (ALL). (Fuertges and Abuchowski 1990) It 
appeared to cause significantly less hypersensitivity reactions and showed more 
than fifteen fold higher blood residence times. The concept of nanoparticle 
PEGylation is later discussed in detail in chapter III.4.  
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Once the nanocarriers survived the MPS infringements, they have to evade the 
vessel via the endothelial cell barrier to include the subepithelial basement 
membrane, transverse the extra-cellular matrix and enter the target cell. The 
details of nanoaparticles’ opportunities to enter cells is discussed comprehensively 
elsewhere (Hillaireau and Couvreur 2009). As mostly receptor mediated 
endocytosis occurs here, the nanoparticles get trapped in the endosomal-lysosomal 
intracellular compartment and are separated from the cytosol. As long as the target 
is not within the endosome, which is discussed later for toll-like-receptor 
targeting, endosomal escape is needed without any damage to the carried drug 
payload. Strategies included pH associated endosomal burst or the introduction of 
specific molecules like melittin (Meyer et al. 2007). The accessibility varies 
largely between single organs or just tissues. While the hepatocytes in the post-
vascular space are immediately accessible, strong barriers towards the testis and 
the central nerve system are effectively protective (Debbage 2009). The 
permeation of the latter, the blood brain barrier (BBB) is a promising but 
challenging chapter of nanoparticulate targeting on its own (Zensi et al. 2009). 
Especially here, newly developed large molecule drugs like recombinant proteins 
depend on a carrier to get selective access to the brain. Gelatin and albumin-based 
nanocarriers demonstrated their capabilities when being modified by polysorbate-
80 or apolipoprotein E (apoE) (Barbu et al. 2009). Polysorbate-80 increased the 
apoE concentration adsorbed to the nanoparticle surface which could 
subsequently make use of the LDL-receptor mediated endocytotic pathway to 
enter brain endothelial cells (Wong 2010). Direct coupling of apoE onto protein 
nanoparticle surface omitted the polysorbate-80 link and resulted in at least 
comparable therapeutic effects when a drug was delivered in a murine in vivo 
model (Michaelis et al. 2006). Others used surface-bound transferring to facilitate 
PEGylated albumin nanoparticles to target a drug substance to the brain (Mishra 
et al. 2006). 
 
On the other hand, pathologic conditions can ease the accessibility for 
nanoparticles. For example, inflammation increases vascular permeability and 
thus endothelial barrier functions are reduced. The most prominent example was 
observed in tumors, where non-proliferating and non-fenestrated blood vessels 
with intact barrier properties get transformed into proliferating vessels featuring 
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fenestrated endothelium and thus reduced barrier properties (Roberts and Palade 
1997). As fenestration can reach 200 – 600 nm gaps, transition of nanoparticles is 
facilitated. Additionally, reduced lymphatic drainage allows accumulation of 
entered material (Sharma and Sharma 2008) which together led to coining the 
phenomenon enhanced permeability and retention effect (EPR) (Matsumura and 
Maeda 1986). Yet, this effect is in concurrence with the still in place obstacles 
mentioned above.  
Examples that successfully included this mechanism were long-circulating 
PEGylated liposomes (Torchilin 2005; Torchilin 2007). 
However, if the target is within the MPS, an i.v. application is indicated. Recently, 
GNPs were shown to selectively deliver NF-κB inhibiting decoy oligonucleotides 
to liver resident macrophages (Kuppfer cells) after administration via the portal 
vain in male Sprangue-Dawley rats (Hoffmann 2006; Hoffmann et al. 2009). 
Within the Kupffer cells the intracellular targeting of the GNPs to the endosome 
could be proven by selective fluorescent staining of the carrier, the payload and 
the cellular compartment and subsequent CLSM analysis (Zillies 2007). 
Consequently, NF-kappaB activation was inhibited which resulted in an reduced 
liver injury in experimental fulminant hepatitis but conversely increased in an 
ischemia-reperfusion model (Hoffmann et al. 2009). 
 
Besides the currently all absorbing delivery role as a passive drug carrier, 
nanoparticles might act as nanomedicine themselves (Ferrari 2008). Therefore, 
shape and size depending distribution and self-toxicity are detrimental (Decuzzi 
and Ferrari 2007). Consequently, nanoparticles which are toxic due to their basic 
material and which specifically address target cells could be used as 
chemotherapeutic. Size is a major determinant for circulation and specific cellular 
uptake properties but also shape is influential. Disk-like or hemispherical particles 
evade phagocytosis better than spherical ones and are more likely to adhere to 
endothelium (Geng et al. 2007). These properties might contribute to future 
cancer therapeutics acting by the virtue of outer form after i.v. administration.  
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3.2 Subcutaneous application 
In contrast to the i.v. route, subcutaneous administration offers the feature of no 
rapid dissemination of the injected nanocarriers (Debbage 2009). Therefore, a 
depot effect can be achieved and the MPS is not an immediate threat. On the 
contrary, this route is just of advantage, if the system is known to be capable to 
the target this way. For example, targeting draining lymph nodes is by far easier 
than i.v. because a slow interstitial flow of 0.1-1 µm s-1 sweeps s.c. injected 
material towards the lymphatic capillaries in most tissues (Swartz 2001). 
Furthermore, the route of injection can have a crucial influence on the release of 
immunogenic and inflammatory cytokines. An illustrative example constitutes the 
use of CpG-oligonucleotides (CpG-ODNS) which serve as immunostimulatory 
adjuvants by addressing endosome-based Toll-Like Receptors 9 (TLR9) in 
antigen presenting cells with promising applications in cancer and allergy therapy 
(Krieg 2006). Intravenous injection of CpG-ODN could result in general immune 
stimulation with side effects such as spleen cirrhosis. On the contrary, s.c. 
administered GNP-bound CpG-ODN was not distributed systemically due to the 
locally restricted distribution and remained at the site of injection where 
phagocytosis by APCs occurred.  As the latter migrated to the nearest lymph nod, 
a local yet potent immunization against an employed model antigen could be 
achieved by the CpG-ODN adjuvant there without the risk of systemic side effects 
such as a septic shock or immune responses against the carrier material gelatin. 
(Bourquin et al. 2008; Zwiorek 2006).  
A heavily investigated field of new drugs that required advanced drug delivery 
systems is nucleotide-based therapeutics (Patil et al. 2005).  A thought significant 
advantage of this class of therapeutics is their determined specific way of action 
once the target is related to a certain disease. Strategies include gene transfer, gene 
silencing or antisense therapy and selective immunostimulation. Gene silencing 
by siRNA for cancer therapy initiated a research cascade on suitable delivery 
strategies mostly administered locally (Ozpolat et al. 2009). The latter was 
boosted by the understanding of CPG-ODNs (Krieg 2006) witch are mostly 
administered subcutaneously. The same route is applicable to plasmid-based TLR 
agonists delivered by cationic liposomes (Dow 2008). However, due to some 
clinical drawbacks, promising trials on Dynavax (DeFrancesco 2008) and other 
anti-cancer ODN-based drugs (Schmidt 2007) lowered the speed towards market 
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approval by the regulatory bodies significantly. Nevertheless, encouraging 
information still comes from ongoing clinical trials on allergy to involve CpG-
ODNs formulated with VLP drug delivery nanosystems (Senti et al. 2009).  
The related importance of the immunomodulation by ODNs by impacting 
cytokine release profiles is stressed by the fact that this year’s Paul Ehrlich prize 
was awarded to Charles Dinarello for his pioneering work on cytokines which 
holds great potential to further improve treatments4. Other groups focused on 
ODN and isRNA-based nucleosides as adjuvants delivery by GNPs to trigger 
controlled immune responses to model antigens such as Ovalbumine in vivo. 
Thereby, pre-immunized mice received model-antigen expressing tumors which 
were significantly reduced in size the course of the GNP-bound CpG therapy 
which led to longer survival rates, too (Bourquin et al. 2008; Zwiorek et al. 2008). 
The challenge of curing existent tumors in mice without any pretreatment is 
currently met which should reflect clinical therapeutic conditions in a more real 
manner.   
 
3.3 Pulmonal application 
The inhalative route constitutes a very attractive alternative to deliver API by 
nanoparticles both locally and systemically. Direct targeting of the therapeutic 
area of interest enables a reduction in administered drug amount compared to e.g. 
the oral or i.v. route (Vaughn et al. 2006) leading to reduced systemic side effects 
(Keller 1999). Investigated non-pressurized application systems cover dry powder 
inhalers (DPIs), pneumatic jet inhalers, ultrasound nebulizers and most recently 
vibrating mesh (VM) devices (Waldrep and Dhand 2008). Employed examples 
were polyacrylate nanoparticle-bound Salbutamol sulfate (Hadinoto et al. 2007), 
PLGA (Beck-Broichsitter et al. 2010) and Chitosan-NP-bound Insulin (Grenha et 
al. 2005). However, pure nanoparticle formulations cannot be delivered that way 
due to too small particle size (< 1µm) and resulting low lung deposition and likely 
exhalation (Sung et al. 2007). Therefore, excipients like micronized lactose are 
needed (Finlay et al. 2005). Hence, GNP aerosols were successfully formulated as 
DPI after spray drying loaded with a placebo drug (Sham et al. 2004).  
                                                 
4http://www.ucdenver.edu/about/newsroom/newsreleases/Pages/Dinarello%E2%80%99s%E2%80
%9Cfevermolecule%E2%80%9DbreakthroughsearnEhrlichPrize.aspx 
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However, initial interest in the nanoparticle-pulmonal research focused on 
nanotoxicology as concerns arose on carcinogen properties of industrial 
combustive dusts. Furthermore, toxic properties of carbon nanotubes were 
intensively investigated in this context (Warheit 2009). Nevertheless, protein 
nanoparticles have to be considered less a toxicological issue due to 
biocompatibility and -especially- biodegradability. Besides branched polymers, 
GNPs were of considerable interest (Tseng et al. 2007). Tseng et al introduced jet-
nebulized cisplatin loaded nanoparticles in vivo (Tseng et al. 2009). Chapter VI.4 
of this thesis further examined the possibilities to nebulize GNPs either via 
pressurized metered dose inhalers or vibrating mesh (VM) devices. It could be 
clarified that VM devices are more suitable in creating GNP vapor to reach the 
deep airways and to deliver intact ODNs in order to perform local immunotherapy 
(Fuchs 2010). Based on these results, we moved to introduce the system in vivo 
for the first time in a veterinarian clinical study. 
 
3.4 Oral application 
The oral administration of protein-based nanoparticles remains challenging due to 
the proteolytic and acidic environment the formulation has to pass. Nevertheless, 
the route constitutes a worthy access due to the ease of application and the non-
requirement of specific application devices. Delivering delicate drugs by 
protective nanoparticles is an obvious aim. Insulin as the presently most 
frequently parentally used drug substance consequently is a promising candidate. 
Ofokansi et al succeeded in developing a gelatin-based slow release formulation 
capable of surviving the harsh stomach conditions and received for this work the 
“CRS consumer and diversified products paper award” 2008, New York City, 
USA. 
Also attempts to explore the possibilities of mucosal immunization via the oral 
route were conducted (Chadwick et al. 2010; Chadwick et al. 2010). Ovalbumine 
as a carrier protein for CpG-ODNs induced a Th1 polarized immune response 
with resulted in typical IFN-γ release and elevated IgG2a titers (Alignani et al. 
2005).  
To eliminate the risk of proteolytic degradation of protein-based carriers, they can 
further encapsulated in a protective resistant shell. These nanoparticle-in-
microsphere oral systems (NiMOS) consisted of outer poly(epsilon-caprolactone) 
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microspheres of 8 – 30 µm which included 80 – 300 nm GNPs that were eligible 
for plasmid delivery (Chadwick et al. 2010; Bhavsar and Amiji 2007). Local 
transfection therapy was for instance proofed against inflammatory bowl disease 
in a murine in vivo model (Bhavsar and Amiji 2008). 
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II Formulation development of plain Gelatin Nanoparticles 
1. Upscaling the established GNP production method 
1.1 Rationale of the upscaling process 
Upscaling is a common challenge in the biopharmaceutical development and 
production (Cacciuttolo and Arunakumari 2006). Motivations to engage this 
challenge include an effective decrease in unit costs as well as to satisfy a higher 
product demand e.g. if a product promotes from clinical to commercial 
manufacturing. Moreover, the prospect of fewer variations if the demand for one 
project is satisfied out of a large batch instead of several small ones often appears 
convincing. However, frequent challenges to overcome are the possible alteration 
of the product by changes in employed materials (surfaces), instruments (sheer 
forces), excipients (buffers, organic solvents) and cleaning strategies (Cacciuttolo 
and Arunakumari 2006). These considerations should be more and more applied 
on the still emerging field of targeted drug delivery devices. 
 
The first GNP preparation methods lacked robustness in reproducibility and 
homogeneity of the produced particles (Oppenheim 1981). Gelatin as a 
biopolymer featured not only appealing properties like biocompatibility and low 
price but also a very high heterogeneity in terms of molecular weight distribution. 
Therefore, manufacturing of gelatin drug carrier systems of sufficient quality were 
not at hand until the two step desolvation technique was developed by Coester et 
al. Therein, a higher molecular weight fraction with a cut-off of roughly 65 kDa 
(Zwiorek 2006) was separated from a lower one during a first step, before the 
particles were formed in a second desolvation step. This protocol offered the 
possibility to produce homogeneous colloidal gelatin spheres which can easily be 
surface modified due to their variety of functional groups according to the 
different amino acids (Coester et al. 2000). Furthermore, this method allowed the 
employment of commercially available gelatin instead of special batches with a 
narrow MW distribution (Zwiorek 2006).  
This advanced preparation method was established for a relatively small 
laboratory scale employing an initial mass of 1.25 g of gelatin per batch. In order 
to enlarge this process and the resulting particle yield, a series of upscaling 
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experiments up to ten-fold batch size was initiated. Based on the standard process 
parameters, the influence of various laboratory equipments was investigated and 
preliminary GNP stability tests were run. Furthermore, an evaporation step was 
introduced to cope with the large organic solvent volumes resulting from the 
upscaled desolvation process. Moreover, the amount of toxic glutaraldehyde that 
is finally used to crosslink the nanoparticles was halfed and the impact on particle 
integrity was examined. Finally, it was evaluated whether statistical correlations 
between the most important production parameters existed and a reciprocal 
interdependent network was established to make projections for further upscaling 
plans. As delivering nucleic acid-based therapeutics emerged as the driving factor 
for GNP employment, the related cationization as the prime particle surface 
modification deserved special attention. Therefore, the feasibility to cationize 
GNPs from upscaled batches was tracked likewise. 
 
 
1.2 Materials and methods 
1.2.1 Standard preparation of gelatin nanoparticles via two step desolvation 
technique 
GNPs were prepared according to the original preparation method by dissolving 
1.25 g of gelatin type A (Bloom 175, Sigma, Taufkirchen, Germany) in 23.75 g of 
0.2 µm filtered (Acrodisc, Pall, Dreieich, Germany) high purified water (HPW) 
under gentle heating to  50 °C. Constant stirring (500 rpm) was maintained during 
the whole preparation procedure. A first desolvation step was initiated by the 
addition of 25 ml of acetone. After sedimentation of the precipitated gelatin 
fractions for about 20 s, the supernatant consisting of dispersed as well as 
dissolved gelatin was discarded. Then, the sediment was weighed and redissolved 
by the addition of 0.2 µm filtered HPW up to 25.0 g under heating to 50 °C. The 
pH (pH Meter MP 220, Mettler Toledo, Greifensee, Switzerland) was further 
adjusted to 2.5 with 2 M HCl. GNPs were formed in situ during a second 
desolvation step by drop wise addition of about 90 ml of acetone (3-5 ml/min) by 
a burette. After ten minutes, 175 µl of glutaraldehyde (25 %) were added to the 
reaction vessel, an Erlenmeyer flask, to crosslink the nanoparticles. Finally, after 
overnight stirring in an extractor hood, the particles were purified by two-fold 
centrifugation (19000 g for 18 min; Sigma Laborzentrifugen, Osterode, 
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Germany), redispersion in 0.2 µm filtered HPW and filtration through a 5 µm 0.2 
µm filtered HPW rinsed filter (VWR, Fontenay sous Bois, France). The purified 
nanoparticles were stored as dispersion in HPW at 8 °C1. 
 
1.2.2 Scale-up of the gelatin nanoparticle standard preparation method 
 
In order to scale up the GNP standard preparation method, the batch size was first 
doubled. Consequently, 2.50 g of gelatin type A (Bloom 175) were dissolved in 
47.50 g of 0.2 µm filtered HPW. Accordingly, the volume of acetone added for 
the first desolvation step, the mass of HPW added to redissolve the sediment and 
the amount of glutaraldehyde finally added to crosslink the nanoparticles were 
duplicated whereas temperature, stirring speed, pH, speed of acetone addition, 
centrifugation speed and centrifugation time were adopted from the standard 
preparation protocol. The sedimentation time and the volume of acetone added for 
the second desolvation step were each adapted to the batch size by visual judging 
of sediment formation and grade of turbidity, respectively. Turbidity was 
additionally measured by a nephelometer (Nephla, Dr. Lange, Berlin, Germany). 
In further experiments the batch size was increased three-, five- and ten-fold. 
 
1.2.3 Modifications of the upscaled gelatin nanoparticle preparation 
method: Equipment changes. 
 
The glass burette (Brand, Wertheim, Germany) used for the addition of acetone 
during the second desolvation step (see 1.2.1.) was first replaced by a peristaltic 
pump (4.9 ml/min; Sotax, Basel, Switzerland) employing acetone-proofed flexible 
tubes (Ismatec, Wertheim, Germany). Further, the previously used Erlenmeyer 
flask was replaced by a round bottom flask of an adequate volume. 
 
For batch sizes greater or equal than three-fold an evaporation step was introduced 
to exclude residual acetone. Therefore, the non-purified GNP dispersion was 
transferred into a round bottom flask (1 l) and acetone was removed by a rotary 
evaporator (Heidolph Instruments, Schwabach, Germany) at a temperature of 
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40°C under low vacuum. The particles were then purified as described in the 
standard preparation protocol. 
Moreover, the amount of glutaraldehyde (25 % V/V), added after the second 
desolvation step to crosslink the nanoparticles, was halved and the stability of the 
resulting particles was monitored. 
 
1.2.4 Characterization of gelatin nanoparticles 
1.2.4.1 Determination of concentration 
About 20 µl of the aqueous GNP dispersion were dropped in a little aluminum 
vessel. That way, three samples were prepared. They were then dried in a drying 
chamber heated to 60 °C until their masses reached a constant level. In order to 
calculate the concentration of the dispersion (m/m), the aluminum vessels had to 
be weighed in empty, full and completely dried status (microbalance, Mettler 
Toledo, Greifensee, Switzerland). 
 
1.2.4.2 Determination of particle size 
An expendable cuvette was twice rinsed with 0.2 µm filtered HPW, before it was 
filled up to a height of about 1 cm with 0.2 µm filtered HPW again. Then, 15 µl of 
the aqueous GNP dispersion were added and mixed. Particle size and 
polydispersity index (PDI) were finally measured with a Zetasizer Nano ZS 
employing photon correlation spectroscopy (PCS; Malvern Instruments, 
Worcestershire, United Kingdom). Each indicated value was the mean of at least 
15 subruns. 
 
1.2.4.3 Determination of zeta potential 
A zeta cuvette comprising two electrodes was once rinsed with 0.2 µm filtered 
HPW, before 65 µl of the aqueous GNP dispersion (see 2.2.) were filled in. Then, 
650 µl of phosphate buffered saline (PBS) or 10 mM NaCl were added. Zeta 
potential was finally measured with a Zetasizer Nano ZS at a measuring voltage 
of 40 mV employing the standard Smoluchowski model. Each indicated value was 
the mean of 50 subruns. 
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1.2.5 Cationization of upscaled GNPs 
First, standard conditions as established for single size batches (Zwiorek et al. 
2008) were applied on a threefold up-scaled batch to include a reaction volume of 
20 ml at room temperature with an incubation time of 30 minutes and an 
effective concentration of 0.50 mg of each cationization reagent (Cholamin and 
EDC) In parallel, the pH value was adjusted to values of 3.5, 4.0, 4.25, 4.5, 4.75, 
5.0 and 5.5 for samples subjected to the above mentioned conditions. 
Furthermore, reaction volume was adjusted to adjust the starting GNP 
concentration (1.0 and 2.0 mg/ml) and cationization reagent concentrations (1.0, 
2.0 and 3.0 mg/ml for cholamin and 1.1, 2.2 and 3.3 mg/ml for EDC). Monitored 
quality parameters included visible particles, GNP size and size distribution as 
well as the zeta potential.  
 
 
1.3 Results and discussion 
1.3.1 Effects of equipment changes 
First, the influence of equipment changes on GNP properties were determined. 
Therefore, GNPs in one- to three-fold batch sizes were prepared employing an 
Erlenmeyer flask and burette, Erlenmeyer flask and peristaltic pump and finally 
round bottom flask and peristaltic pump as combinations of laboratory equipment. 
GNPs that were manufactured that way were examined by PCS to determine 
particle size and PDI. Further, drying loss experiments were run to determine the 
concentration of the GNP dispersion and the particle yield, respectively. 
 
1.3.1.1 Effects on particle size and polydispersity index 
In general, particle size is an important parameter for the characterization of 
nanoparticles, especially when they are intended for clinical use e.g. in cancer 
applications. In this case, particle size should preferably not exceed a target value 
of 200 nm when administrated i.v. to benefit from the enhanced permeability and 
retention effect (EPR) which is characteristic for tumor vasculature (Torchilin 
2007). Larger particles also increase the risk for thrombosis and should 
consequently be avoided. However, for s.c. delivery, particles up to 350 nm can 
be suitable when a local presentation of drugload is indended (Zwiorek 2006). 
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Fig. 1 displays the particle size resulting from the different employed preparation 
methods that were each used for one-, two- and three-fold batch size. Fortunately, 
all the manufactured particles do not exceed a size of 200 nm. 
The columns on the left side (Erlenmeyer flask, burette) indicate that an upscaling 
of the standard preparation method is generally possible. Although the particle 
size increases with the batch size, the GNPs seem to be of high quality. So, the 
PDI values of two- and three-fold batch size average 0.030 and 0.027, 
respectively whereas the one of the standard batch size averages 0.096. Values 
below 0.1-0.15 can be regarded as strong indication for monomodal particle 
distribution (Pishvaei et al. 2006). 
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Fig. 1. Particle size resulting from three different GNP preparation 
methods, each employed for one-, two- and three-fold batch size. Each data 
point displays the mean of three single batches (n=3, ± S.D., altogether nine 
individual measurements). 
 
In order to semi automate the GNP production process, the burette was replaced 
by a peristaltic pump. That way, the speed of acetone addition was exactly 
adjusted to 4.9 ml/min and maintained during the whole second desolvation step. 
As a consequence, slightly smaller particle size standard deviations of the 
upscaled batches than by using the burette were observed as it can be see columns 
in the middle). Furthermore, the related mean PdI values are still in a range 
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indicating high GNP quality. Once again, the particle size increases with the batch 
size. Although this seems to be characteristic for the scale-up in Erlenmeyer 
flasks, we could confute this hypothesis in further experiments including five- and 
ten-fold batch sizes.  
Finally, the Erlenmeyer flask was replaced by a round bottom flask of an adequate 
volume. So, we could further improve the particle size standard deviations (see 
columns on the right side) while the mean PdI values remained nearly constant. 
Nevertheless, the production of nanoparticles in round bottom flasks is not as easy 
to handle as in Erlenmeyer flasks during the desolvation process as they need 
additional fixation for safe positioning. On the other hand, employment of round 
bottom flasks allows the removal of organic solvents without the need of 
intermediate vessel change. 
Summarizing, each investigated method is appropriate for an upscaling of the 
GNP standard preparation method and leads to particles of high quality.  
 
1.3.1.2 Effects on particle yield 
One of the main objectives of an upscaling process is to increase the yield of the 
manufactured product while its high quality is maintained. For the scale-up of the 
GNP production process the latter was already demonstrated so that the GNP 
yield can exclusively be focused in the following. 
 
Fig. 2 shows the GNP yield resulting from the different preparation methods 
described in 3.1. that were each employed for one-, two- and three-fold batch size. 
Referring to the initially employed gelatin mass, the yield was invariably specified 
in %. Thus, the resulting normalized values of the different batches couldn be 
checked against each other. They generally varied between 1.5 % and 13.0 %.  
The black columns which display the GNP yield of the standard-sized batches 
indicate that the preparation process could be optimized, first by replacing the 
burette by a peristaltic pump, then by replacing the Erlenmeyer flask by a round 
bottom flask. That way, the GNP yield almost decupled. Unfortunately, this trend 
did not proceed in two- and three-fold batch sizes. 
The columns on the left side (Fig. 2) show that the applied method employing 
Erlenmeyer flask and burette led to mean GNP yields smaller than 5 % and 
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relatively high standard deviations, which were both inapplicable for further 
scale-up experiments. 
Regrettably, the GNP yields of the upscaled batch sizes were not optimized by 
replacing the burette by a peristaltic pump (see columns in the middle). Quite the 
opposite, the particle yields further declined. However, the standard deviations 
could clearly be reduced. 
When the Erlenmeyer flask was finally replaced by a round bottom flask (see 
columns on the right side), the GNP yield of the two-fold batch size markedly 
increased by 5.4% up to 9.4%. Nevertheless, it did not measure up to the mean 
yield of the standard batch size (13.0%). Its standard deviation also worsened 
again. 
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Fig. 2. GNP yield relating to the initially employed gelatin mass, which resulted 
from three different GNP preparation methods, each employed for one-, two- and 
three-fold batch size. Each data point displays the mean of three single batches 
(n=3, ± S.D., altogether nine individual measurements). 
 
With the exception of the first dark column, the particle yield decreased with an 
increasing batch size meaning that the efficiency of the GNP production process 
declines. This was probably due to the sedimentation time starting after the first 
desolvation step, which was adapted to the batch size by visual judging of the 
sediment formation. Presumably, with respect to larger total volumes and 
therefore longer particle sedimentation distances this time needed to be prolonged 
in future upscaling experiments. Additionally, both the centrifugation speed and 
time greatly influenced the GNP yield. Consequently, they should not be handled 
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as constant process parameters but dynamically be adapted to the requirements of 
each batch. However, a “one fits all” procedure would be more desirable to avoid 
time consuming pre-studies to optimize each single batch.  
Summarizing, each investigated upscaled GNP preparation method employing a 
peristaltic pump provided heretofore non-satisfactory yields in comparison to 
those of the standard-sized preparation methods. Although the GNP preparation in 
round bottom flasks seemed to be more effective than the preparation in 
Erlenmeyer flasks, we continued our experiments using Erlenmeyer flasks 
because of an easier and hence time-saving handling. However, a future use of 
round bottom flaks should not be excluded due to the ease of subsequent organic 
solvent evaporation whithout the need of in between vessel change. 
 
1.3.2 Stability of gelatin nanoparticles of upscaled batch sizes 
In the development of new dosage forms stability plays a decisive role as it acts as 
an indicator for storability. Former studies that were carried out by Coester et al. 
evinced GNP stability over a time period of at least three months (Coester et al. 
2000). As those particles resulted from standard-sized batches, here the upscaled 
batch sizes, particularly at two- and three-fold batch sizes, were aimed at, 
involving Erlenmeyer flask and burette. 
Fig. 3 depicts such a stability study over a time period of 35 and 37 days, 
respectively. The nanoparticles were stored as dispersion in HPW at a temperature 
of 4 °C and periodically measured with a Zetasizer Nano ZS. Both, particle size 
and zeta potential are parameters providing stability information. If for example 
an agglomeration took place, the particle size and also the appropriate PdI values 
would increase. Moreover, the zeta potential would presumably rise to zero 
indicating a loss of electrostatic repulsion between the single GNPs. 
It was fortunately possible to demonstrate particle stability over the whole period 
investigated. Thus, GNPs of both upscaled batch sizes showed constant size 
values. The corresponding PdI values of 0.041 ± 0.014 for two-fold batch size and 
0.015 ± 0.017 for three-fold batch size also provided satisfactory results as they 
indicate high GNP quality and remained relatively unaltered over the course of 
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time. When the zeta potential was regarded in the same context, slight variations 
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Fig. 3. Stability study over a time period of at least 35 d of GNPs 
(Erlenmeyer flask, burette) resulting from an upscaled batch size (two- and 
three-fold, respectively). Particle size and zeta potential were considered. 
Each data point represents a single batch with three individual 
measurements (n=3, ± S.D.). 
 
were detected, which were probably due to the interference-prone zeta cuvettes. 
Nevertheless, all the detected values stayed in an acceptable range. 
 
As this study provides very promising results concerning short-term stability, it 
should be continued to get some results for long-term stability. Furthermore, the 
storage conditions of the GNP dispersion could be modified in future experiments 
to find out whether the temperature or the pH values do have some influence on 
stability.  
 
1.3.3 Introduction of an evaporation step 
The standard preparation protocol demanded the purification of GNPs by two-fold 
centrifugation. As each centrifugation step claims a time of 18 min, the 
purification procedure is relatively time-consuming. The total capacity of the used 
centrifuge is further limited to an overall maximum of about 70 ml so that only 
GNP dispersions of standard-sized batches can be treated at once. In the case of 
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upscaled batch sizes, the common overnight loss of acetone is not sufficient to 
reach total volumes less or equal than 70 ml. Therefore, a time-saving evaporation 
step removing acetone under vacuum at a temperature of 40 °C was introduced. 
The particles could afterwards be purified as described in the standard protocol 
and size and zeta potential could finally be measured by a Zetasizer Nano ZS. 
 
Fig. 4 displays particle size and zeta potential of GNPs of 5.6-fold batch size, 
which were either purified according to the standard protocol or to the advanced 
method including an evaporation step. Therefore, the GNP dispersion of one 
single batch (Erlenmeyer flask, burette) was divided into two parts.  
Whereas the zeta potential remains absolutely constant when a rotary evaporator 
is additionally used, the particle size slightly increases. Nevertheless, the 
appropriate PdI value (0.031) indicates high GNP quality. 
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Fig. 4. Comparison of particle size and zeta potential of GNPs of an upscaled 
batch size (5.6-fold) that were either prepared by the standard protocol or by 
an advanced method including an evaporation step. Each data point represents 
a single batch (n=1, altogether three individual measurements ± S.D.; 
Erlenmeyer flask, burette). 
 
Summarizing, the introduction of an evaporation step does not diminish GNP 
quality and can hence be recommended for the preparation of upscaled batch 
sizes. The increase of particle size is small and considered irrelevant.  
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1.3.4 Correlation studies 
With the objective to figure out whether connectednesses between the single 
process parameters such as batch size or sediment mass do exist, we run further 
upscaling experiments employing Erlenmeyer flask and peristaltic pump again. 
Therein, five- and ten-fold batch sizes were included. The particle size as well as 
the concentration of the GNP dispersion, both necessary for the evaluation of the 
following correlation studies, was determined as described. 
 
1.3.4.1 General correlation studies 
The correlation studies below generally refer to one-, two-, five- and ten-fold 
batch sizes. Each data point therein displays the mean of altogether three single 
batches. 
 
The sediment mass and volume of acetone added for the second desolvation step 
in correspondence to the batch size 
 
Fig. 5 demonstrates strong linear correlations in both cases, emphasized by 
coefficients of determination of 0.9953 (sediment mass) and 0.991 (volume of 
acetone), respectively. Hence, the appropriate linear equations can be used to 
predict either the sediment mass or the volume of acetone that has to be added for 
the second desolvation step of heretofore non-investigated batch sizes (n-fold):  
 
• sediment mass [g] = 1.1671 · n + 0.4988   [1] 
• volume of acetone [ml] = 68.844 · n + 25.204   [2]  
 
According to this, we are now also able to predict the volume of acetone when the 
sediment mass is already known: 
 
• volume of acetone [ml] = 58.987 · sediment mass [g] - 4.2186   [3] 
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Fig. 5. Correlation between sediment mass and n-fold batch size and 
correlation between volumes of acetone added for the second desolvation 
step and n-fold batch size, respectively. Each data point displays the mean 
of three single batches (n=3, ± S.D.; Erlenmeyer flask, peristaltic pump). 
 
Summarizing, this mathematical analysis facilitates the planning of further 
upscaling experiments as the sediment mass and the consumption of acetone can 
easily be prognosticated. Especially the latter leads to an advantage: the addition 
of acetone during the second desolvation step can now completely be automated 
because a visual judgement of turbidity or a nephleometric measurement  is not 
necessary any more. Future upscaling studies may eventually require a validation 
of this production step referring the the particle size.  
 
The particle size and yield in correspondence to the batch size 
 
Fig. 6 shows a linear correlation for the first case, which is characterized by a 
coefficient of determination of 0.9357. This permits the prediction of the particle 
yield of heretofore non-investigated batch sizes (n-fold): 
 
• particle yield [mg] = 27.68 · n + 51.146   [4] 
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Allowing for the mathematical formulas developed in 3.4.1.1. (see [1] and [2]), it 
is possible to calculate the absolute particle yield when either the sediment mass 
or the volume of acetone added for the second desolvation step is known: 
 
• particle yield [mg] = 23.72 · sediment mass [g] + 39.316   [5] 
• particle yield [mg] = 0.402 · volume of acetone [ml] + 41.012   [6] 
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Fig. 6. Correlation between particle size and n-fold batch size and correlation 
between absolute GNP yield and n-fold batch size, respectively. Each data point 
displays the mean of three single batches (n=3, ± S.D., altogether nine individual 
measurements; Erlenmeyer flask, peristaltic pump). 
 
In contrast, the particle size seems not to depend on the batch size and is therefore 
also independent of the sediment mass, the volume of acetone added for the 
second desolvation step and the particle yield. It generally varies between 133 nm 
and 157 nm. 
Summarizing, the absolute particle yield depends on the batch size whereas the 
particle size does not show a comparable relationship. Future experiments should 
clarify the role of the sedimentation time as well as the centrifugation speed and 
time which may have an influence on both, absolute particle yield and size. 
Relative particle yield would be of interest from a commercial point of view but 
would require MW analysis before and after the first desolvation step and before 
and after the purification process. However, preliminary estimation indicate a 
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percental loss of particle yield during the purification process by centrifugation of 
20 – 30%. 
 
1.3.4.2 Correlation studies within batches of the same size 
The following correlation studies refer to one-, two- and five-fold batch sizes. 
Each data point therein represents a single batch within a series of three batches of 
the same size. 
 
The volume of acetone added for the second desolvation step in correspondence to 
the sediment mass 
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Fig. 7. Correlation between volumes of acetone added for the second 
desolvation step and sediment mass. Each data point represents a single 
batch within a series of three batches of the same size (n=3, ± S.D.; 
Erlenmeyer flask, peristaltic pump). 
 
Fig. 7 confirms a linear correlation between the volume of acetone that was added 
for the second desolvation step and the sediment mass within a series of batches 
of the same size. Hence, the volume of acetone decreased with increasing 
sediment mass which in turn has a crucial impact on the achieved particle size 
(Zwiorek 2006). Although the corresponding coefficients of determination were 
Formulation development of plain gelatin nanoparticles    36 
 
 
increasingly satisfactory (one-fold batch size: 0.7816, two-fold: 0.9945, three-
fold: 0.9849), it was hitherto not possible to exactly predict the behaviour of non-
investigated batch sizes because of differing slopes of the already existing trend 
lines. 
 
The particle size in correspondence to the sediment mass 
 
In contrast to the general correlation study above where a connectedness between 
particle size and any other considered factor such as volume of acetone had to be 
excluded for simplification, we are now able to relate particle size to the sediment 
mass. Fig. 8 shows a linear correlation between the two, which is characterized by 
coefficients of determination between 0.6406 (two-fold batch size) and 0.9653 
(five-fold). Once again, the exact prediction of the GNP size of heretofore non-
prepared batch sizes remained unfortunately impossible as each already 
investigated batch size brought along a different trend line slope. Nevertheless, it 
was evidenced that the particle size within batches of the same size increases with 
an increasing sediment mass confirming earlier findings based on a lower number 
of non-validated batches (Zwiorek 2006). 
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Fig. 8. Correlation between particle size and sediment mass. Each data point 
represents a single batch within a series of three batches of the same size (n=1, 
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altogether three individual measurements ± S.D.; Erlenmeyer flask, peristaltic 
pump). 
 
The particle yield in correspondence to the sediment mass 
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Fig. 9. Correlation between GNP yield and sediment mass. Each data point 
represents a single batch within a series of three batches of the same size (n=3, ± 
S.D.; Erlenmeyer flask, peristaltic pump). 
 
The final step aimed at clarifying whether there was also a relationship between 
the sediment mass and the particle yield within batches of the same size. 
Regarding the standard and two-fold batch sizes (Fig. 9) strong linear correlations 
were obtained emphasized by coefficients of determination of 0.984 and 0.9987, 
respectively. Surprisingly, the GNP yield of one-fold batch sizes increased with 
an increasing sediment mass whereas the yield of two-fold batch sizes decreased. 
Five-fold batch sizes further behave similarly to two-fold batch sizes, but have to 
be considered critically as their coefficient of variation accounts for only 0.5464. 
Nevertheless, despite this difficulty to predict yield from five-fold upscaling the 
higher alsolute yield justifies future employment of this approach due to the 
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avoidance of particle size variances between multitudes of regular small-sized 
batches. 
 
1.3.5 Preliminary constitution of an interdependency network of production 
parameters  
The finding of above discussed single interdependeces between each paired 
individual parameters already facilitated simple related projections. However, 
obtaining a full overview of relations between all involved parameters accessible 
for quantification would be highly desirable. In case a statistical context existed 
between the various decisive steps in the manufacturing process, a predictable 
scale up from threefold to tenfold or even higher could become possible. 
Therefore, a preliminary set of 8 threefold up-scaled batches was produced 
parallely and 8 key production parameters were recorded. These did not include 
the initial mass of starting material gelatin A which was kept constant at about 
3.75 g. Furthermore, the sediment mass resulting from the first desolvation step, 
the volume of added acetone in the second desolvation step, the dispersions’ 
turbidity after accomplishment of the second desolvation step, the size of the 
obtained particles, the percental loss of particle mass during purification, the 
applied gravitation forces (speed) by centrifugation during particle purification, 
the time that was allowed for the addition of acetone until occurrence of turbidity 
in the second desolvation step and finally the yield given as absolute mass of 
nanoparticles as the final outcome (Tab. 1).   
 
Mass 
[mg] 
Sediment 
[mg] 
Volume 
of 
acetone 
[ml] 
Turbidity 
/ml 
[FNUs/ml] 
Size 
[nm] 
Percent 
loss 
[%] 
Speed 
[g] 
Time 
[min] 
Yield 
[mg] 
3.75 7.97 300 2.390 179.0 15.06 20100 50 783.619 
3.79 6.60 275 2.255 197.7 19.07 19530 52 528.031 
3.75 5.97 325 1.800 169.2 10.56 20100 50 562.754 
3.88 5.27 250 2.864 157.1 8.32 20500 24 715.414 
3.77 4.38 252 2.377 160.1 14.59 20333 24 486.911 
3.82 3.70 265 2.389 163.4 4.31 21475 22 424.547 
3.75 2.05 260 0.301 147.6 38.29 20904 73 122.980 
3.77 3.23 260 0.469 143.2 35.91 20904 73 262.020 
 
 
Tab. 1: Survey of the investigated process parameters from threefold upscaled 
batches (n=8). 
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The 8 chosen parameters offer altogether 28 pairwise senseful interrelationships. 
Values were plotted against each other and linear coefficients of determination 
were obtained (Tab. 3). Coefficients of determination R2 > 0.8 were considered as 
indicators of strong correlation while 0.8 > R2 > 0.5 were such of weak correlation 
(Schnell et al. 2007). Values below 0.5 were not regared as indicators of any 
correlation and were not reflected in the following equations. 
 
Number x/y Best fit equation Coefficient of 
determination 
3 Percental 
loss/turbidity 
lnY=-0.064x+1.558 0.862 
4 Percental 
loss/yield 
lnY=-0.039x+6.777 0.661 
5 Time/ percental 
loss 
Y=1.48x+18.97 0.777 
9 Turbidity/ time Y=-19.11x+81.46 0.756 
10 Turbidity/ yield lnY=-0.516(1/x)+6.577 0.895 
11 Sediment/ 
percental loss 
lnY=30.34(1/x)-3.966 0.512 
13 Sediment/ 
turbidity 
lnY=-
2.520(1/lnx)+2.234 
0.741 
15 Sediment/ yield lnY=-4.982(1/x)+7.259 0.930 
17 Turbidity/ size lnY=0.069(1/lnx)+5.054 0.535 
24 Speed/size Y=9E+06(1/x)-291.1 0.588 
26 Speed/ sediment Y=1E+06(1/x)-45.00 0.578 
27 size/sediment Y=-2568(1/x)+20.64 0.681 
 
Tab. 2: Equations with corresponding coefficients of determination obtained from 
linear plotting (n=8) of relevant production parameter results. Numbers in the 
first column represent the attributed experiment number in the consecutive trial 
equivalent to those shown in Fig. 3. Equations missing featured R2-values < 0.5. 
 
Consequently, all coefficients of determination as the prime reference to proof 
correlation –but not necessarily causality- could be visualized in a network 
between the 8 major process parameters (Fig. 10). Strong correlations were e.g. 
found for the pairs turbidity and yield (R2 =0.895) or sediment and yield (R2 
=0.930). The former is of particular importance because turbidity is an easily and 
quickly accessible measurand. Therefore, in process controls would be possible 
and the production could be stopped at a point of time when a sufficient yield is 
conceivable long before the consuming purification process with subsequent 
gravimetrical concentration determination and yield calculation is performed.   
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A less strong but still significant correlation (R2=0.681) was found between the 
resulting particle size and the sediment. This result confirmed earlier reports in 
our group (Zwiorek 2006) which led to the conclusion that a higher yield is 
potentially at the expense of a small particle size. Moreover, the higher the 
applied gravitation force during the purification centrifugation was, the larger 
became the particles most likely to occasionally forced aggregation (R2=0.588). 
Interestingly, no significant correlation was found between the volume of added 
acetone and the resulting yield. This indicated that once the process is running, at 
a later stage (the second desolvation step) the yield could hardly be enlarged 
anymore. Moreover, the volume of acetone e.g. the addition of an excess of 
desolvant did not influence the particle size which led to the conclusion that the 
size was already predetermined and more influenced by the earlier applying 
parameters such as sediment mass. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: Network of interrelations of major process parameters. Solid arrows 
indicate linear coefficients of determination above R2>0.5 while dashed arrows 
represent respective values below R2<0.5 meaning a lack of linear correlation 
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In summary, helpful projections could be made such as the correlation between 
turbidity and yield which had practical significance in the investigation in 
chapter II.3.  
However, in this trial the statistical basis was still rather narrow and should be 
significantly enlarged before moving to a potential future clinical manufacturing 
to obtain data suitable for robust process validation. Moreover, more complex 
mathematical models of correlation could probably express relations better than 
this simple linear-only model applied herein. They would help to adequately meet 
pre-set GNP target properties such as upper size limits while optimal yields and 
the lowest possible amounts of organic desolvent are obtained at the same time.   
 
1.3.6 Reducing the amount of glutaraldehyde 
Besides glutaraldehyde, the reagents necessary for the production of GNPs are 
non- or minor toxic and relatively inexpensive, which displayed an advantageous 
precondition for upscaling experiments. However, glutaraldehyde which was 
finally employed to crosslink the nanoparticles counts among environmentally 
hazardous substances, as discussed comprehensively in chapter II.3. Although no 
toxicity was revealed both in own in vitro and in vivo studies so far, its use should 
be pared down to the minimum and therefore eventually be employed in lower 
quantities than in the so present standard protocoll. 
Fig. 11 shows particle size and zeta potential of GNPs of three-fold batch size that 
were either prepared by the standard protocol or by an advanced method 
employing only half of the regularly used amount of glutaraldehyde. 
Both preparation methods led to particles of high quality, emphasized by mean 
PdI values of 0.036 (standard method) and 0.028 (advanced method), respectively. 
However, the GNPs of the standard method were slightly smaller. As this 
difference amounted to less than 15 nm, it should be neglected and a GNP 
production with halved amount of glutaraldehyde should be recommended in 
order to save expenses and to reduce the risk of working with toxic substances. Of 
course, the stability of GNPs prepared by the advanced method is further crucial 
for a recommendation like this.  
So, it was further examined whether nanoparticles prepared by the glutaraldehyde-
saving method were as stable as commonly prepared GNPs within the first days 
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post-production. Therefore, particle size and zeta potential were measured again 
three days after the first measurement (see 2.4.) as we expected to collapse the 
dispersion, if at all, in an early post-preparation state. Fortunately, particle size as 
well as zeta potential did not markedly vary in comparison to the first 
measurement, which indicates GNP stability. According to these promising 
results, long-term stability could be presumed, but has certainly to be verified in 
future experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11. Comparison of particle size and zeta potential of GNPs of an upscaled 
batch size (three-fold) that were either prepared by the standard protocol or by 
an advanced method with halved amount of glutaraldehyde. Each data point 
displays the mean of three single batches (n=3, ± S.D., altogether nine individual 
measurements). 
 
With regard to particle quality and stability, on the present data the halving of the 
amount of glutaraldehyde seems to be unproblematic. Control experiments after 
three and six months confirmed the stability in particle size. Therefore, a further 
reduction of glutaraldehyde could be taken into be consideration from a toxicolic 
point of view. However, glutaraldehyde free residuals offer aldehyde free 
functional groups which turned out to be crucial in some post-manufacturing 
processing like surface PEGylation (Zillies et al. 2007). Consequently, each case 
requires a careful consideration of priorities.     
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1.3.7 Cationization of upscaled GNPs. 
The delivery of nucleic acid-based active ingredients constituted one of the main 
driving factors to initiate the up-scaling of GNP production in order to provide 
sufficient amounts of the carrier for potential clinical studies. Therefore, the 
possibility to cationize also GNPs from up-scaled batches for subsequent nucleic 
acid surface loading needed to be elucidated. To obtain robust information if the 
conducted cationization resulted in GNPs of sufficient colloidal stability, crucial 
parameters such as particle size, size distribution (PDI) and visible particle 
impurities were assessed in dependence of variable process parameters such as 
starting particle concentration, pH value and concentration of cationization agents. 
First, the impact of altering the pH value was analyzed while the other production 
parameters were left as standard for the original batch size to include a GNP 
concentration of 3-5 mg/ml and reagent concentrations of 0.5 mg/ml.  
 
 
 
 
 
 
 
 
Fig. 12: Impact of process pH value on resulting particle size during cationization 
of a threefold up-scaled batch (n=3 ± S.D.). 
 
As revealed by Fig. 12, the particle size remains constant for the observed range 
of pH 3.5 – 4.75 at 200 nm. When passing the threshold of pH 4.75, particle sizes 
rose to more than 600 nm indicating massive aggregation and dispersion 
instability which should be avoided. Moreover, visual inspection of the relevant 
dispersions was performed (Tab. 3). 
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Tab. 3: Impact of process pH value on GNP dispersion stability (visual 
inspection) during cationization of a threefold up-scaled batch with “-“ for 
absence of relevant phenomenon up to “++++” for heavy occurrence. 
 
Although pH 4.75 emerged as a threshold value for colloidal stability based on 
instantly measured particle sizes, visual inspection revealed inconsistencies even 
below this point. Flocculation occurred down to pH 4.75 and (slight) 
sedimentation tendency down to pH 4.0 (Tab. 3). At this low value, sufficient 
cationization could no longer be granted. Therefore, further parameters but the pH 
value were varied to obtain stable cationized GNP batches.  
 
 
 
 
  
 
 
 
 
 
 
 
 
Tab. 4: Impact of starting GNP and reagents’ concentration on particle and 
dispersion quality. 
 
While the prevalent pH value was constant at 4.5, starting GNP concentration was 
lowered to 1 and 2 mg/ml respectively. However, the influence of this parameter 
was marginal in comparison to the concentration of the applied cationization 
agents cholamin and EDC. When raising their concentration to 3 and 3.3 mg/ml, 
++++++++----flocculation
++++++++++++-sedimentation
tendency (48 h)
5.55.04.754.54.254.03.5pH
-7.870.041296.53.0 / 3.32
+7.070.081289.62.0 / 2.22
+++4.860.255349.171.0 / 1.12
-7.560.100327.43.0 / 3.31
-6.860.060292.42.0 / 2.21
++2.910.093270.271.0 / 1.11
Visible
particles
Zetapot.
[mV]
PDIsize
[nm]
c (Cholamin / EDC)
[mg / ml]
c(GNP) 
[mg / ml]
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respectively, aggregation (visible particles) was avoided (Tab. 4). This was due to 
a sufficient elevation of the zeta potential. The given values (Tab. 4) were 
measured in PBS and translate to about threefold higher values when measured in 
otherwise (chapter III.2) used 10 mM NaCl. The maintenance of particle size was 
demonstrated impressively for the 2 mg/ml GNP starting concentration which 
should be regarded as the maximum to avoid excessive interparticulate interaction 
as seen when employing the standard GNP concentration (3-5 mg/ml). 
Furthermore, keeping the pH at a maximum of 4.5 ensured EDC-mediated 
catalysis while a still secure distance from gelatin A IEP was sustained. 
Summarizing, cationization reagent’s addition needed to be adapted to the volume 
of the reaction batch and the particle size. As a minimum, reagent:GNP ratio 
should account for 1:1 and 1.5:1 to ensure sufficient cationization in large 
volumes. Finally, effective cationization prevents aggregation electrostatically as 
revealed by sufficiently high zeta potential values. 
 
1.4 Conclusion 
In order to scale up the established GNP preparation method (Coester et al. 2000), 
we first run some basic experiments showing that an upscaling was generally 
possible without reducing particle quality. Then, we investigated the influence of 
different laboratory equipments, finally deciding in favor for the combination of 
Erlenmeyer flask and peristaltic pump. Further experiments confirmed the 
stability of GNPs of upscaled batch sizes for at least 35 days and revealed that the 
introduction of an evaporation step did not affect GNP quality. 
Supported by these promising results, initial correlation studies up to ten-fold 
batch size were started, which enabled development of several mathematical 
formulas linking batch size, sediment mass, volume of acetone added for the 
second desolvation step and particle yield. These formulas contribute to facilitate 
future upscaling experiments as the outcome of the preparation of heretofore non-
investigated batch sizes can be predicted by calculation. Moreover, the 
combination of all involved process parameters and their interdependence-
expressing coefficients of determination allowed the visualization of a network 
making predictions in several cases reliable. Therefore, a precondition for further 
upscaling for clinical manufacturing was established although more work is 
needed to guarantee robustness over larger populations of batches. Furthermore, 
Formulation development of plain gelatin nanoparticles    46 
 
 
the cationization of up-scaled GNP batches succeeded after small process 
modifications 
With the objective to finally optimize the upscaled GNP production process, it 
was tried to reduce the amount of toxic glutaraldehyde. Fortunately, it could be 
demonstrated that both, particle quality and stability do not suffer from halving 
the amount of glutaraldehyde. 
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2. Hydration of  GNPs 
2.1 Scope of the hydration project 
According to the original GNP manufacturing protocol (Coester et al. 2000), 
GNPs were stabilized in the final production step by glutaraldehyde-mediated 
cross-linking. Resulting permanent chemical bonds between ω-amine groups of 
lysines in adjoined gelatin molecules prevented freshly formed particles from 
early disintegration. Consequently, the involved elimination reaction classified as 
an alkylimino-de-oxo-bisubstitution of the ω-amines and the aldehydes led to the 
formation of imines. The acidic condition from the second desolvation step was 
beneficial to catalyze the nucleophilic addition-type reaction. The product was 
considered stable (March 1992) but could potentially be subjected to consecutive 
reactions such as hydrolysis, Diels-Alder reactions or reactions with amines to 
aminals. However, the occurrence of the related necessary reaction conditions in 
vivo is unlikely. Furthermore, since glutaraldelyde was first used to cross-link 
protein-based nanoparticles (Weber et al. 2000), no toxic side reactions or gelatin-
associated immunity reactions were observed (Zwiorek 2006). Nevertheless, the 
abolishment of imines would constitute a worthwhile option to rule out a residual 
risk in the light of a later use in humans. Yet, the stability and integrity of the 
resulting imine-free particles needed to be ensured before any toxicological 
investigations appeared as reasonable. The most appealing method to transform an 
imine to a functionality of lower reactivity is a reduction from which secondary 
amines are obtained (March 1992). The appropriate way of hydrogenation must 
reflect the possible threat the reaction constitutes towards other functionalities and 
bindings within the molecule. The widely used reducing agent sodium 
borohydride reduces amides as well which would unselectively result in a 
breakdown of the primary structure of the gelatin protein matrix. Therefore, 
sodium cyanoborohydride with the formula NaBH3(CN) was chosen as a reducing 
agent with lower nucleophilic properties and consequently higher selectivity 
towards imines (Borch et al. 1971). Furthermore, hydration by hydrogen gas 
catalyzed by palladium fixed on large surface carbon beads in a 10% (w/w) ratio 
was considered due to its weak amide but potent imine reducing properties.  
Therefore, the aim of this experiment was to confirm if a successful 
hydrogenation occurred and if the resulting particles maintained sufficient 
stability for in vivo settings later. Analytically, the first point was engaged by 
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nuclear magnetic resonance spectroscopy (NMR) as the state-of-the-art method to 
identify functional groups by tracking spins of atomic nuclei. The nanoparticle 
stability was assessed via PCS. 
 
2.2 Materials and Methods 
2.2.1 Hydrogenation by sodium cyanoborohydride 
As the preferential reaction milieu for hydrogenation by sodium 
cyanoborohydride was pH 5.5 - 6, 100 ml of a 0.1 M potassium 
hydrogenphthalate buffer and 100 ml of a 0.1 M sodium acetate buffer were 
prepared. Therefore, 2.042 g potassium hydrogenphthalate (Sigma, Taufkirchen, 
Germany) and 1.36 g sodium acetate (Merck, Darmstadt, Germany) supplemented 
by 5.22 ml of 0.1 M acidic acid were diluted in 100 ml of HPW, respectively. For 
a quantitative selective catalytic reduction, a 1 : 1.6 molar ratio of glutaraledhyde 
and sodium cyanoborohydride was employed. Preparations were incubated in 
Eppendorf caps in aliquots of 300 µl at 22°C for 17 h at 300 rpms. After finished 
incubation, samples were purified by four subsequent centrifugation and washing 
steps, respectively. Purification in terms of reducing the amount of residual 
catalyst was monitored photometrically at 254 nm in each washing step.  
 
2.2.2 Hydrogenation by hydrogen/carbon-bound palladium 
As an example, an aliquot containing 10 mg GNP dispersion from the up-scaled 
batch was transferred to a reaction flask with gas inlet. 444 mg of carbon-bound 
palladium (Pd) catalyst were added and dispersed in 150 ml of methanol. 
Hydrogen gas was provided at a pressure of 2 bars. The incubation time was set to 
24 h and the consumed hydrogen volume was 480 ml. The coarse carbon catalyst 
particles were separated from the GNPs by filtration through an established 
cellulose acetate filter featuring a 5 µm pore size which was previously validated 
to have low GNP retention properties in contrast to common organic solvent-
proofed filter alternatives. However, due to the sensitivity of the filter material 
towards the dispersant, the methanolic particle dispersion was diluted 1 : 10 
before filtration and concentrated afterwards by three subsequent centrifugation 
and washing steps. The concentration was raised hereby again to the original 
value. 
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2.2.3 Assessment of particle stability by PCS after hydrogenation 
Hydrogenated and non-hydrogenated samples were first subjected to 4 particle 
size measurements (n=3, S.D.) over a time period of 72 h to obtain preliminary 
particle size data at room temperature to identify the better suited method related 
to particle stability. Particle size and size distribution alterations were assessed. 
Furthermore, samples were stored for 330 h at three distinctive temperatures (4°C, 
25°C and 37°C) at physiologic pH value (pH 7.4) to obtain extended stability 
data. Per reading point, 10 µl of GNP formulation were sampled and added to 500 
µl HPW in a PMMA halfmicro cuvette and susbsequently analyzed by a Zetasizer 
ZS Nano (Malvern Instruments, Malvern, UK). Results were intensity weighted.   
 
2.2.4 Scanning electron microscopy of GNPs 
Aqueous dispersions of GNPs were centrifuged, the supernatant was removed and 
redispersed in 96% (v/v) ethanol (VWR, Ismaning,Germany). 50 µl of ethanolic 
dispersion where applied on an adhesive carbon grid mounted onto a scanning 
electron microscopy (SEM) probe holder. Subsequently, the samples were carbon-
sputtered and therefore ready for SEM analysis. To identify the composition of 
chemical elements within the hydrogenated samples, SEM with enhanced 
(semi)quantitative elementary analysis was conducted by a JSM 6500 F equipped 
with an energy dispersive x-ray (EDX) technology (JEOL, Tokyo, Japan). Related 
element calculation was performed via INCA software (Oxford Instruments, 
Oxford, UK)  
 
2.2.5 Liquid 13C-NMR for hydrogenation proof 
For each single 13C-NMR analysis, an aliquot of GNP stock solution containing 
3 mg GNPs was centrifuged and subsequently redispersed in D2O (Merck, 
Damrstadt, Germany). NMR glass tubes were filled with respective samples up to 
a filling height of 5 cm and finally sealed with rubber stoppers. Samples were 
measured at 400 MHz over 20000 scans by an NMR spectrometer (Bruker, 
Karlsruhe, Germany).  
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2.2.6 Solid state magic angle spinning NMR for hydrogenation proof 
To avoid any potentially disturbing dispersant- nanoparticle interaction before or 
during the measurement, 13C magic angle spinning (MAS)-NMR was chosen as a 
feasible alternative. MAS-NMR is an established method to perform solid-sate 
NMR spectroscopy (Schaefer and Stejskal 1976). By employing the magic angle 
θm, dipole-dipole interactions, chemical shift anisotropy and partly quadrupolar 
interactions are averaged out. This leads to a far narrower signal (chemical shift) 
compared to other forms of NMR. The θm was set to 54.74° in all measurements. 
The chemical shift results were given in parts per million (ppm). 
Here, initially 1 mg of the lyophilized samples was filled into the designated 
special rotor as a dry substance and subsequently measured by an Avance 500 
NMR spectromter (Bruker, Karlsruhe, Germany).  
 
2.2.7 Lyophilization of GNPs 
In order to perform MAS-NMR, GNPs needed to be employed as a solid matter 
instead of the standard aqueous dispersion. Therefore, dispersions of GNPs were 
diluted down to a concentration of 1.5 mg/ml. To achieve a higher yield of 
finished product, 50% of samples of batches hydrogenated by one of the two 
described methods and of a 50% reference non-hydrogenated batch were 
supplemented with sucrose (Sigma, Taufkirchen, Germany) as a lyoprotector as 
previously introduced for GNPs (Zillies et al. 2008). The final sucrose 
concentration was 10% /w/w). The other 50% of samples were not supplemented 
with a lyoprotector and left as a pure GNP dispersion. Resulting formulations 
were filled as 1 ml aliquots into 2R lyophilisation vials (Schott, Germany). This 
was applied both for batches from the standard-sized manufacturing process as 
well as batches from upscaled processes. Subsequently, samples were freeze-dried 
over a 48 h period in an 2 Epsilon freeze dryer (Christ, Osterode, Germany) at       
- 50°C and 0.03 mbar in the primary drying step to ensure full water removal. The 
process was modified from the previously established protocol for GNPs (Zillies 
et al. 2008). Following the drying cycle, vials were re-pressurized by nitrogen gas 
up to atmospheric conditions (1000 mbar) to avoid an applied vacuum because 
otherwise the low-densitiy GNP powder employed without cryoprotectant sucrose 
would have aerozolized and vanished upon opening.    
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2.3 Results and Discussion 
Due to its high toxicity, complete removal of the catalyt sodium 
cyanoborohydride was a crucial task after the accomplishment of hydrogenation. 
Therefore, each supernatant resulting from centrifugation of each washing step 
was analyzed photometrically.  
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Fig. 1: Optical density at 254 nm indicates a sharp decrease in NaCN(BH)3 
supernatant concentration between subsequent washing steps and a degradative 
reaction over time. 
 
As an example, Fig. 1 depicts the decrease in absorption and consequently in 
catalyst concentration found in the supernatants which were gained from washing 
step one down to step four. It was demonstrated that at least four subsequent 
washing steps were required to ensure absence of toxic catalyst residuals. 
Furthermore, a distinctive fall in absorption was observed within the two higher 
concentrated supernatants after 170 h. This reflects the reported slow degradation 
sodium cynoborohydride is subjected to (Borch et al. 1971). However, as the 
incubation period was set much shorter than 170 h, this degradation presumably 
had no disturbing impact on the catalytic process itself.  
For hydrogenation by the heterogeneous catalyst hydrogen gas /carbon-bound 
palladium, no photometric determination of residues could be performed. 
Moreover, the visual inspection of the filters alone was not sufficient although 
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filters exhibited black carbon-associated colouring only on the educt but not on 
product side. Therefore, EDX elemental analysis data was taken into 
consideration.  
 
 
 
Fig. 2: Elemental analysis by EDX. 
 
Here, the absence of palladium and of boron could be proven for 
hydrogen/carbon-bound palladium and for sodium cyanoborohydride-catalyzed 
samples, respectively (Fig. 2a, 2b). Furthermore, the elemental composition did 
not change considerably before and after hydrogenation (Fig. 2c). 
 However, a major change was observed when comparing the impact of the two 
chemical reduction methods’ impacts on particle sizes (Fig. 3). 
a 
b 
c 
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Fig. 3: Comparison of particle sizes of non-hydrogenated and hydrogenated 
GNPs (n=3, ± S.D). 
 
While hydrogen/carbon-bound palladium hydrogenated GNPs maintain the size of 
non-hydrogenated GNPs (200 nm), sodium cyanoborohydride triggered a huge 
10-fold increase in particle size (up to 2000 nm). Moreover, fluctuations between 
reading points were higher as well as the particle size distributions were broader 
(Fig. 3). Most likely the gelatin protein structure was chemically broken-up and 
consequently the particle integrity was affected. Therefore, hydrogenation by 
hydrogen/carbon-bound palladium was not followed anymore. 
13C NMR analysis was initially performed with liquid samples as no extensive 
sample preparation besides medium exchange (D2O for HPW) was required. As 
GNPs were not exposed to D2O previously, a brief GNP compatibility evaluation 
was introduced beforehand. However, Fig. 4 visualizes that particle stability and 
integrity was negatively affected by the pro-aggregation effect of D2O onto GNP 
integrity. As soon as more than 50% of the dispersant were constituted by D2O, 
particle sizes were dramatically rising. This trend even increased over the 
monitored time period (Fig. 4). Visible inspection revealed changes in the 
respective dispersions such as aggregate-forming and flocculation which 
supported PCS data which in turn indicated massive aggregation. 
Formulation development of plain gelatin nanoparticles    54 
 
 
0
400
800
1200
1600
0 25 46.5 68.5 91 235
time from first contact [h]
pa
rt
ic
le
 
si
ze
 
[n
m
]
0% 25% 50% 75% 100%
 
Fig. 4: GNP particle sizes in dependence of the applied percentage of deuterium 
oxide (D2O) within the aqueous dispersant to over time at 25°C (n=3 ± S.D.).  
 
Consequently, NMR measurements from liquid samples, although prolonged to 
26 h and 20000 scans, did not result in meaningful data. Very broad amide bonds 
could only be supposed while possible imin bonds were superposed by the 
background noise (Fig. 5).  
 
Fig. 5: 13C NMR at 400 MHz over 20000 scans of NaCN(BH)3-hydrogenated 
GNPs D2O dispersion. 
 
Consequently, all further hydrogenation-proving NMR analysis was replaced by 
solid matter-considering MAS-NMR. This required the generation of dried GNPs. 
amide 
bands imine 
band ? 
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Therefore, lyophilization as a validated method for GNP drying was conducted 
(Zillies et al. 2008).  
 
 
Fig. 6: 13C MAS-NMR of non-hydrogenated GNPs without (a) and with 
cryoprotectant sucrose (10% w/w) (b). 
 
The NMR spectrum of a 500 mg GNP sample in Fig. 6a revealed too low band 
intensity and amplitude compared to background noise to conclude even the 
presence of the expected imine band at 163 ppm (Fig. 6a). The amide band at 171 
ppm was broad but low in amplitude and hence could not be considered for any 
a 
b 
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subsequent comparisons. Moreover, addition of the sucrose as lyoprotector led the 
related signal to cover other bands (Fig 6b). Therefore, only sucrose-free 
lyophilisates were used afterwards.   
 
Fig. 7: 13C MAS-NMR spretrum of NaCN(BH)3-hydrogenated GNPs. 
 
Subsequently, the hydrogenated samples were subjected to MAS NMR. However, 
problems arose related to the limited mass of 0.3 mg GNP dry substance. The void 
volumes were filled with Teflon strip to ensure balanced rotation of the employed 
MAS rotors. Fig. 7 illustrates the impact of NaCN(BH)3-mediated hydrogenation 
on the chemical structure of the gelatin. Amide bands were no longer detectable at 
171- 175 ppm. Thus, a complete reduction of these groups was obvious leading to 
the conclusion that the protein structure was degraded at least in part due to 
excessive chemical reduction. This corresponds to the findings of heavy storage 
aggregation depicted in Fig. 8. Particle sizes increased 10-fold from initial 200 nm 
even when GNPs were stored at 4°C. Higher storage temperatures led to even 
higher mean sizes indicating a complete loss of nanoparticulate morphology. 
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Fig. 8: NaCN(BH)3-hydrogenated GNP mean sizes (n=3, S.D.) over time at 4, 25 
and 37°C storing temperature and pH 7.4 (n=3 ± S.D.). 
 
Fig. 9: 13C MAS-NMR spretrum of H2/carbon-bound Pd-hydrogenated GNPs. 
 
In contrast, H2/carbon-bound Pd-hydrogenated GNPs featured a peak at 175 ppm 
indicating the presence of amide bands. Therefore, the primary protein structure 
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was not eliminated as with the former homogenoius catalyst. This was also 
reflected by the particle size monitoring over 330 h storage time (Fig 10).   
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Fig. 10: H2/carbon-bound Pd-hydrogenated GNP mean sizes (n=3, S.D.) over 
time at 4, 25 and 37°C storing temperature and pH 7.4. Artefacts are present in 
4°C samples at 305 and 330 min storage time (n=3, ± S.D.). 
 
GNPs featured size stability at least for 281 h when stored at 4°C. Storing at 25 
and 37°C led to marginally significant higher particle sizes and size fluctuations 
between the reading points. No indication of complete loss of nanoparticulate 
morphology was found in contrast to the other catalyst-treated GNPs (Fig. 8). The 
reductive strength was thereby appropriate from a stability point of view. 
However, due to the overall poor signal-noise-ratio, no conclusion could be drawn 
neither to the existence of an imine band nor to its elimination in comparison to 
the non-hydrogenated GNPs (Fig. 6a). Therefore, a new series of experiments was 
required to obtain higher signal intensity by the employment of higher sample 
masses. Consequently, the previously introduced up-scaling process was used to 
employ higher amounts both of native and of H2/carbon-bound Pd-hydrogenated 
GNPs. A 10-fold higher mass input led to the avisaged improved signal-noise 
ratio. Fig. 11a depicts the non-hydrogenated GNPs with regular amide bands at 
171 ppm and the target structure of imines bands at 156 ppm. 
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Fig. 11: 13C MAS-NMR spretrum of native (a) and H2/carbon-bound Pd-
hydrogenated (b) GNPs. 
 
The imine band was successfully eliminated after the hydrogenation process 
confirming the effectiveness of the selected process (Fig. 11b). Moreover, all 
other bands remained unaffected supporting the identification of the method’s 
selectivity. Again, this finding was in accordance with the observed short-term 
a 
b 
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stability of H2/carbon-bound Pd-hydrogenated (b) GNPs (Fig. 10). However, 
stability was not increased compared the native non-hydrogenated GNPs. 
In summary, the additional efforts were not justified by the resulting properties of 
hydrogenated GNPs. Although the hydrogenation process itself finally turned out 
to be successfully conducted, the particle mid-term stability was not superior. 
Furthermore, the hydrogenation itself and the subsequent –eventhough possible- 
purification at least double the GNP manufacturing time and costs per batch 
compared to the non.treated GNPs which already demonstrated their 
biocompatibility in several in vivo trials. Therefore, if a replacement of currently 
used glutaraledhyde-generated imins was required in future, other strategies 
should be followed. Nevertheless, this evidence would not have been possible 
without upcaling the GNP manufacturing process which was established by the 
present work.  
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3. Enzymatic cross-linking of GNPs 
3.1 Introduction 
Applying the two-step desolvation method for manufacturing gelatin 
nanoparticles, the tendency of aggregation of the GNPs could be reduced and 
particle production of reproducible size, size distribution and yield could be 
gained (Coester et al. 2000). The prepared GNPs showed a high stability and were 
up-scalable during manufacture.  
While GNPs chemically cross-linked by glutaraldehyde did not trigger undesired 
immune or toxicological reactions, a reduction in biocompatibility of cross-linked 
gelatin-films was reported earlier (Van Luyn et al. 1995) and slight toxicity in 
peroral toxicology studies as well as contact dermatitis if applied on the skin were 
shown (Ballantyne and Jordan 2001). Otherwise, glutaraldehyde was widely 
employed for a range of industrial and biomedical applications to include cold 
sterilization and biocidal use in production sites (Ballantyne and Jordan 2001). As 
glutaraldehyde is consumed during the GNP cross-linking reaction and residuals 
are removed by particle purification, consequently no adverse effects could be 
observed. 
Nevertheless, aiming at potential future applications of GNPs in humans 
(pharmaceuticals like food), substances like glutaraldehyde with a theoretical 
residual risk deserve attention in terms of “generally regarded as safe” 
replacements (Chau et al. 2005).  
Hence, as a non-toxic alternative to the chemical cross-linker glutaraldehyde the 
enzyme transglutaminase (TG; E.C. 2.3.2.13), an enzyme whose subspecies 
microbial TG (MTG) is already used as a biocatalyst to covalently cross-link 
proteins in food chemistry (Boenisch et al. 2007), tissue engineering (Bertoni et 
al. 2006) and others (Zhu and Tramper 2008), is investigated here for GNP 
preparation.  
The mammalian TGs are Ca2+-depending enzymes which play various roles such 
as in blood clotting, HIV entering into target cells and the pathology of the celiac 
and Huntington diseases, but they are also generally stabilizing and protective in 
the cells (Griffin et al. 2002). In contrast, the microbial TGs isolated from 
Streptomyces are easier to produce, more feasible in biotechnologic applications 
due to their Ca2+ independence and have broader substrate specificity than 
mammalian tissue TGs (Cui et al. 2008; Lantto 2007). 
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These acyltransferases form intra- and intermolecular isopeptide bonds in and 
between many proteins by cross-linking the ε-amino groups of the amino acid 
lysine to the side chain amide group of glutamine thereby releasing one molecule 
of ammonia per crosslink (Figure 1) (Boenisch et al. 2007; Heidebach et al. 2008; 
Lantto 2007; Griffin et al. 2002).   
 
Fig. 1: Protein cross-linking by transglutaminase between primary amino groups 
of the amino acids glutamine and lysine in course of which one molecule of 
ammonia is generated per crosslink (courtesy of Fuchsbauer, Darmstadt 
University of Appl. Sc., Germany) 
 
Enzymatic cross-linking is an attractive approach due to its high specificity of the 
enzyme catalysis controllable to a certain degree by changing pH and temperature. 
The pH activity curve for MTG for instance shows an optimum between pH 5 and 
8 (Boenisch et al. 2007; Lantto 2007). Furthermore, it was reported that MTG 
showed no degradation but in contrast a slightly increased activity in the presence 
of low ethanol concentrations (Cui et al. 2008). This was in accordance with 
previous reports on the mammalian form of the enzyme being stimulated by 
organic solvents (Plishker et al. 1978).  
To date, beyond food processing, MTGs demonstrated their ability to 
mechanically cross-link highly resistible gelatin-based scaffolds (Broderick et al. 
2005), whereby cytoxicity was reduced compared to formation of gelatin-based 
scaffold by radical polymerization. (Barbetta et al. 2006) Further well 
documented examples for cross-linking with MTG are milk proteins like casein 
(Boenisch et al. 2007), hydroxyethyl starch conjugation (Besheer et al. 2009), 
gelatin barrier films (de Carvalho and Grosso 2004), fish gelatin-nanoclay (Bae et 
al. 2009) and matrix proteins in potential medical applications. (Collighan and 
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Griffin 2009) The use of transglutaminase was already considered in patents for 
nanoparticle crosslinking (Aimi et al. 2007; Aimi et al. 2007). However, no actual 
result data was ever published on this potential process attempt. Therefore, the 
stabilization of GNPs by MTG was investigated and discussed for the first time in 
this study. 
 
3.2 Materials and methods 
3.2.1 Materials 
All used chemicals like gelatin type A from porcine skin (175 Bloom), 
glutaraldehyde and acetone were of analytical grade and purchased from sigma 
Aldrich GmbH (Taufkirchen, Germany). The recombinant microbial 
transglutaminase (rMTG) was produced by the group of Prof. Pietzsch, 
Department of Pharmaceutical Biotechnology Halle, Germany. The wild-type 
transglutaminase (ActivaTM MTG) was manufactured by Ajinomoto Co. (Tokyo, 
Japan). Whereas the phosphate buffered saline (PBS) buffer was obtained ready to 
use from invitrogen GmbH (Karlsruhe, Germany), 12.11 g Tris(hydroxymethyl)- 
aminomethane (Sigma Aldrich GmbH) were dissolved in 1 l highly purified water 
(HPW) to prepare the 0.1 M Tris-buffer.  
HPW was generated by a purelab® device (ELGA LabWater, Celle, Germany) 
and filtered with an acrodisc® 0.2 µm steril syringe filter (PALL lifescience, 
Dreieich, Germany). All employed media were sterilely filtered prior to use to 
prevent impurities. 
 
3.2.2 Enzyme preparation 
Cultivation of E. coli BL21(DE3) containing the plasmid pDJ1-3 (Marx et al. 
2007) was carried out in the group of Prof. Pietzsch, Halle using a minimal 
medium according to Wilms et al. (Wilms et al. 2001). E. coli pDJ1-3 cells were 
adapted to the minimal medium by passaging cells grown on LB medium (Marx 
et al. 2007). In six consecutive cultivations, the portion of the complex medium 
was reduced to below 0.1 %. Cultivation was carried out at 37°C. For enzyme 
expression, the main culture was induced with 0.7 mM IPTG at a post-induction 
temperature of 29°C. Cells were harvested and rMTG was isolated using affinity 
chromatography as described elsewhere (Marx et al. 2008) with the following 
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modifications. 20% bio wet mass was suspended in disintegration buffer, 
Proteinase K was used for activation (12 U/g bio wet mass, incubation at 37°C for 
2h). Eluted fractions were dialyzed against Tris-buffer and stored at -20°C after 
addition of glycerol and glutathione (GSH, final concentrations 50% glycerol, 
2mM GSH). 
 
3.2.3 Production of gelatin nanoparticles 
Plain gelatin nanoparticles were prepared by a two step desolvation technique 
according to the established protocol (Coester et al. 2000; Zwiorek et al. 2004) 
without subsequent cross-linking by glutaraldehyde. 
For controlled addition of acetone to the gelatin solution a Gilson peristaltic pump 
Miniplus 3 (ABIMED Analysentechnik GmbH, Langenfeld, Germany) was 
utilized. 
In the process, feeding rates of acetone were 12 ml/min for the first and 5 ml/min 
for the second desolvation step. Sediment built after the first desolvation step was 
kept below 2.5 g while the pH-value after the second desolvation step was kept 
below 3.0.  
As transglutaminase is sensitive to organic solvents, a purification of the acetone 
containing particle dispersion was considered crucial after the second desolvation 
step. To eliminate the acetone from the dispersion, five approaches were 
evaluated.  
Firstly, vacuum evaporation was used as a commonly known and mild method. 
Therefore, 100 ml of dispersion were transferred to a round bottom flask 10 min 
after completion of the second desolvation step. Parameters were set either to 
50°C, 200 rpm and vacuum for at least 30 min or to 25°C, 200 rpm and reduced 
vacuum for which a Laborrota 4001 (Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany) was used. 
As the original protocol devises slow evaporation of acetone over night through 
constant stirring at room temperature, this was considered as the second 
alternative. Furthermore, evaporation at elevated temperature was performed as a 
third alternative to vacuum evaporation by transferring 30 ml of original 
dispersion to 1 l flat bottom flasks and stirred over night at 37°C.  
Next, the option of direct centrifugation after the second desolvation step as a 
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rapid method was investigated. 
Finally, the last approach comprised a significant dilution of acetone to allow 
sufficient enzymatic activity. Hence, 10 ml of the original post second desolvation 
particle dispersion were diluted with 65 ml of one of the three different media 
HPW, PBS or 0.1 M Tris-buffer. The 10 ml contained 0.2 g non-cross-linked 
GNPs, 5.7 g acetone and 2.8 g HPW on average.  
 
3.2.4 Cross-linking methods 
Subsequently, the nanoparticle dispersions from the above described methods 
were equally adjusted to pH-value 7.4 and temperated at 16°C, 25°C or 37°C. 
Thereupon, the cross-linking enzyme was added either as a solution or in powder. 
100 µl solution of the recombinant enzyme (≙ 60 U in 50% glycerol, 1 mM GSH, 
150 mM NaCl, 25 mM Tris-HCl, pH 8.0) or 600 mg commercial powder (1 % 
MTG stabilized with 99 % Maltodextrin), equally containing 60 U of enzyme, 
were added. Temperature of both enzyme preparations was either 4°C or -20°C at 
the moment of addition to the reaction dispersion and incubation time was set to 
48 h. 
 
3.2.5 Particle analysis by PCS and turbidity measurement 
To determine the size of the prepared particles, standard Malvern Zetasizer® ZS 
nano device (Malvern, Worcestershire, United Kingdom) was used for analysis by 
PCS. Particle sizes were intensity weighted results (z-average) and size 
distributions were given as polydispersity indexes (PdI).  
For evaluation of particle sizes during cross-linking incubation time, prior to all 
measurements 100 µl of the relevant dilution were transferred to halfmicro 
PMMA cuvettes and completed with HPW to a final volume of 600 µl. 
Correspondingly 10 µl of readily purified and concentrated dispersion for 
subsequent stability studies were added to 590 µl of HPW in the cuvettes. Mean 
sizes and size distributions (PdI) were defined as mean of three measurements, 
each consisting of at least 14 subruns.   
Additionally, the turbidity of the samples was measured with a Nephla Dr. Lange 
turbidimeter (Hoch Lange GmbH, Düsseldorf, Germany) to compare the different 
rudiments during incubation. Results were given in formazine normalized units 
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(FNU). Therefore, 2 ml of each sample were filled into round glass cuvettes and 
inserted into the turbidimeter at defined intervals. The preceding method of 
turbidity measurement gave evidence of the particle formation. However, the 
designated product of discrete particles on the one hand and undesired aggregates 
on the other hand both contributed to turbidity and could not be distinguished by 
this method.  
 
3.2.6 Stability tests 
Purified and filtered nanoparticle dispersions were divided into equal volumes for 
stability testing at 4°C and 37°C, stored in a refrigerator and accordingly in a 
Certomat® IS (B. Braun Biotech International now Sartorius BBI Systems, 
Göttingen, Germany). 
After certain time intervals, samples were taken and analyzed for stability by PCS. 
 
3.2.7 Statistical analysis 
Data was analysed for difference in turbidity between time points of incubation or 
between defined temperatures or medium composition using a paired t-test 
performed by Prism 5 (GraphPad Software Inc., La Jolla, USA). 
 
 
3.3 Results and discussion 
3.3.1 Effect of purification method on particle integrity 
In standard purification of GNPs cross-linked by glutaraldehyde, vacuum 
evaporation was previously found to be beneficial as a method to shorten 
processing time. Therefore, it was assumed that this method could be used in 
purification of not yet cross-linked particles to remove large amounts of residual 
acetone of the second desolvation step, too. However, as soon as acetone started 
to evaporate at the chosen standard conditions (vacuum, 50°C and reduced 
vacuum at 25°C), dispersion turbidity started to fade. After clouding, the whole 
dispersion became a transparent viscous gelatin solution. The particle 
characteristic of the dispersion was completely lost. Preliminarily, it was assumed 
that phase transition and altered solubility led to the increasing particle 
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deformation. As this obviously was a consequence of the applied thermal and 
mechanical stress onto the not yet stabilized particles, further attempts aimed at 
less harsh conditions. Hence, vacuum was omitted and temperature was reduced. 
Still, no considerable amounts of particles were recovered after this process. The 
same effect was observed when directly centrifuging the particle dispersion 
without any prior thermal stress. Obviously, the resolvation was quicker than the 
acetone evaporation rate which finally led to gelatin dissolved in an acetone–water 
solution.  
As purification after particle formation in the second desolvation step was 
impossible without loss of particle integrity, the last alternative was to reduce the 
percentile amount of contained acetone. Previously, Cui et al. demonstrated that 
low amounts of organic solvents such as ethanol do not influence the enzymatic 
activity of transglutaminase in a negative way. On the contrary, percentile 
concentrations of 10% Ethanol increased the activity, while amounts of up to 20% 
added volume of ethanol had no adverse effect (Cui et al. 2008). This was in 
accordance with earlier findings, that acetone known to be relatively aggressive in 
inducing protein precipitation (Yoon and Mckenzie 2005) was tolerated by human 
TG in low concentrations as well (Plishker et al. 1978). Consequently, as acetone 
is known to inactivate enzymes in lower concentrations than ethanol, the acetone 
concentration in all following trials was kept as low as at 10% (v/v) by applying a 
1:7.5 (dispersion : water) dilution. Therefore, sufficient enzyme activity by 
diluting the dispersion with the different media was presumably ensured. 
 
3.3.2 Effect of cross-linking parameters during incubation 
The intention of analysing various cross-linking process parameters was to 
optimize yield of well characterized particles within a short period of time and to 
define simple and reproducible cross-linking conditions. 
 
3.3.3 Turbidity monitoring during enzymatic cross-linking time 
Nephelometry (turbidity measurement) was previously described as feasible to 
quantify low concentrated GNP dispersions below 1 mg/ml (Fuchs et al. 2009). 
Due to the requirement to keep the acetone percentage low, GNPs consequently 
were existent in concentrations of 0.25 mg/ml or less. Hence, nephelometry was 
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performed as a quick method to estimate particle quantity. In HPW, highly 
significant differences in turbidity were found between the three investigated 
temperatures over each incubation period. However, no significant differences in 
turbidity were found between samples incubated at 25°C and 37°C at the end of 
the incubation process after 48 h. Therefore, subsequent batches were treated at 
25°C for good cross-linking yield in order to reduce thermal stress on the newly 
formed particles and consequently to preserve their structure and stability. 
Comparing the turbidity over time in the three different media HPW, PBS and 0.1 
M Tris-buffer it can be deducted that the enzymatic reaction led to the highest 
GNP yield as by turbidity in HPW (Figure 2). For PBS, turbidity stayed low after 
21h of incubation and roughly triples until the final assessment time point at 48 h. 
However, turbidity remained at only a seventh of the turbidity achieved in HPW 
in the same time. The higher electrolyte concentration in PBS led to a significant 
decrease in enzyme-mediated particle stabilization. Results for Tris-buffer are 
significantly higher than those of PBS reaching more than 20% of the turbidity 
value achieved in HPW after 21 h (Figure 2). Tris-buffer is known as a good 
stabilizing medium as it does not have any oxidizing properties and maintains a 
pH value of 7.4 beneficial for TG activity. Furthermore, Tris-buffer is employed 
since 1966 to house reactions with TG and to assess enzymatic activity. However, 
even Tris-buffer cannot achieve the same turbidity as HPW. This effect might be 
related to the impact of ions on the particle size and matrix structure. It was shown 
earlier that GNPs start to decrease in size once confronted with ions (Fuchs et al. 
2010). Consequently, the gelatin matrix allows less solubilised rMTG to penetrate 
the gelatin matrix and finally stabilize the particles over all by cross-linking. PBS 
featuring a higher ionic strength in comparison to 0.1 M Tris performed worst in 
the cross-linking process. HPW surprisingly appeared most suitable in this 
comparative study at 25°C with the maximum turbidity reached within 21 h. No 
significant reduction was subsequently detected from the second to the third 
sampling point. Therefore, the enzymatic reaction was regarded already 
completed after 21 h at the second sampling point (Figure 2). A quantitative 
gravimetrical concentration determination of post-centrifugation purificated 
particle dispersions (1.5 mg/ml ± 0.3 mg/ml) was only possible for the samples 
incubated in HPW. Concentrations of PBS or Tris-buffer derived particles were 
too low after purification by centrifugation to be quantified.  
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Fig. 2: Turbidity is significantly depending on cross-linking incubation time with 
rMTGin the three different media equally temperated at 25 °C (n=3, ± S.D.). n.s. 
indicates no statistical significance. 
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Fig. 3: Turbidity is significantly different in HPW and PBS depending on cross-
linking incubation time and the applied reaction temperature (n=3, ± S.D.).  
 
Besides the appropriate medium, the most effective reaction time in terms of 
achieved particle yield was of interest. Therefore, a lower temperature (16°C) and 
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physiologic temperature (37°C) were tested. It can be stated that turbidity 
increased over time and with the applied reaction temperature (Figure 3). In HPW 
only at 37°C the turbidity increased further from the second to the third recorded 
sampling point. 37°C as incubation temperature is recommended to achieve high 
yields.   
The turbidity of dispersions prepared with the commercial ActivaTM enzyme 
fomulation could not be evaluated because remaining coarse powder particles 
disturbed the results. Furthermore, an additional purification step was required to 
eliminate remaining maltodextrin particles. Consequently, the approach to 
crosslink the particles with commercial powder ActivaTM was not further 
followed. 
Additionally, the temperature of the added enzyme solution was critical for the 
yield of resulting particles and the particle building process itself. In case of drop-
wise addition of sub 0°C temperated enzyme solution, particle stability over time 
can not be held up which was also demonstrated by high PdI values in the relevant 
batches (data not shown). Nevertheless, the temperature of the dispersion has a 
modulating impact. Consequently, batches prepared at higher temperatures like 
37°C are less impacted by the colloidal dispersing effect of sub-cooled drops of 
enzymatic solution. The chosen amount of MTG was based on the employment of 
glutaraldehyde in standard GNP production where 43.75 mg GT were used per 
batch (Zwiorek et al. 2008). This equals 0.438 mol and consequently can crosslink 
a maximum of 0.876 mol residual amino groups within the gelatin. Due to the 
above described necessary 1:7.5 dilution of the acetone-containing GNP 
dispersion after the second desolvation step, the resulting amount of amino groups 
is 0.1168 mol per batch based on above calculation. The added 100 µl of 
recombinant enzyme solution with a given stock enzymatic activity of 600 
µmol/min/ml should theoretically transform this amount in 31.5 h. However, 
enzymatic activity was not expected to entirely last that long. Accordingly, as it 
could be derived from Figures 2 and 3, a longer incubation time than the interval 
till the first control sampling point is not indicated due to the lack of a relevant 
yield increase thereafter.  
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3.4 Particle size analysis during the enzymatic cross-linking time 
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Fig. 4: Size (bars) and size distribution (curves) during initial particle formation 
time with pH-value adjusted to 7.4 and temperature of added enzyme of 4°C. 
(n=3, ± S.D.). 
 
GNPs quality attributes were monitored over an incubation period of 48 h. The 
chosen time frame was longer than the enzymatic reaction presuming took place 
in order to provide a safety margin for the detection of possible reverse reactions 
and resulting dissolution of the nanoparticles. Initially, formed particles featured a 
PdI of about 0.4 indicating an unfavourably broad particle size distribution 
(Figure 4). However, this is significantly diminished to monomodality indicating 
values close to 0.1 at all three following control sampling points while 
temperatures and stirring at about 300 rpm were kept constant (Figure 4). In 
addition to the decreasing particle size, this demonstrates sufficiently increasing 
particle stability within the enzymatic cross-linking period. Particle quality 
attributes remained constant after contact with the enzyme over 15 h. Within this 
period, the reaction was presumably completed as enzyme catalyzed reactions are 
accomplished quicker than the standard non-catalyzed glutaraldehyde-mediated 
cross-linking process.  
Combined size and yield results suggest an incubation time of at least 12 h but do 
not point to additional effectiveness of the here employed maximum 48 h 
incubation period.     
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3.4.1 Effect of storage temperature on particle stability 
Consistency in size and size distribution is an important indicator for particle 
integrity. A resolvation of insufficiently cross-linked particles’ gelatin impacts 
these key parameters obtained by PCS analysis. Despite two measurement 
artefacts at 4°C (Figure 5a), high storage stability of rMTG-cross-linked particles 
was found (Figure 5a and 5b). In detail, standard deviations remained low, 
particle sizes constant and PdIs mostly under 0.2. Towards the end of the 
monitoring period, PdIs even fell below 0.1 in all cases indicating particle 
monodispersity. Consequently, obtained particles are suitable for standard storage 
conditions at 4°C as well as at 37°C being the physiologic temperature and 
therefore enabling the particles to be used in vivo and in 
vitro.
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Fig. 5: Particle properties size (bars) and size distribution (curves) upon on 
storage stability testing over 4 weeks at 4°C (a) and 37°C (b) (n=3, ± S.D.). 
 
 
3.5 Conclusions 
Feasibility of transglutaminase as a cross-linking agent in gelatin nanoparticle 
production was demonstrated in principle. The initial obstacle, to cope with the 
residual acetone, was overcome. Particles of defined size below 250 nm and 
narrow size distribution stable in a short range stability set up were produced 
successfully. The preferable medium for cross-linking was identified as water 
while preferable incubation time and temperature were 48 h and 25°C - 37°C 
respectively. Further improvements in product yield and various process 
parameters such as a reduction in incubation time are subject of later formulation 
development and upscaling. Summarising, transglutaminase widely used in food 
chemistry and biomaterial research is also a promising alternative in 
pharmaceutical GNP production to glutaraldehyde and other chemical cross-
linkers’ use in clinical studies. Concerning the potential immunogenicity, for drug 
formulation the application of a human transglutaminase is favourable. Therefore, 
further experiments are promising using this biocatalyst. 
 
 
b 
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III Enlarging the analytical toolbox for gelatin nanoparticles 
1. Basic setpoints in PCS-based nanoparticle size measurement 
A crucial precondition for the entire set of following experiments that involve 
PCS-based size measurements, was the knowledge of a possible concentration 
influence onto received results. Due to the intrument’s 173° backscattering design 
(Zetaziser ZS Nano, Malvern, UK), the manufacturer’s specification promised a 
wide concentration and turbidity range of applicable dispersions accessible for 
substantial data collection. However, detailed information to confirm relevant 
concentration independence in nanoparticle size determination was not obtained 
and discussed previously. Especially, the circumstance if the frequently conducted 
cationization had an interfering impact should be ruled out as a precondition for 
all further investigations such as standard QC by PCS.  
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Fig. 1: Correlation between the GNP concentration and the PCS-determined sizes 
of non-cationized (closed circles) and cationized (closed triangles) GNPs (n=3, ± 
S.D.). 
 
Obviously, the particles size did not change along within the applied range of 
GNP concentration but stayed constant (Fig. 1). The same was found for the 
particle size distribution, characterized for Taking the PCS’ measurement fault 
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tolerance (2%) and the very small error bars into account, no changes are 
detectable for the cationized GNPs and almost no changes for the non cationized 
GNPs. Alterations in viscosity were too small at concentrations below 0.1% (m/v) 
to influence the particles’ Brownian molecular movement and consequently their 
determined hydrodynamic diameter. The cationization imposed a heavy influence 
on the particle size though. A 30 – 40% increase in particle size was found for this 
batch but even larger increases were found in other trials (Fuchs et al. 2010). The 
direct comparison was appropriate due to the fact that the examined cationized 
GNPs were derived from the batch of non cationized GNPs and thus, were of the 
same origin. The found influence of cationization on the particle size is 
furthermore discussed in detail with the insights gained from the ultrasound study 
(see chapter III.2). 
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Fig. 2: Correlation between the GNP concentration and the PCS-determined PDI 
of non-cationized (closed circles) and cationized (closed triangles) GNPs. 
(n=3, ± S.D.) 
Along with the size and PDI of GNPs, the conductivity of the applied GNP 
dispersion was followed as a side result from Zeta potential measurements. 
(Fig. 3)  
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Fig. 3: Linear Correlation between the GNP concentration and the PCS-
determined conductivity of cationized GNPs in HPW (n=3, ± S.D.).                           
  
However, even though the increae in conductivity is linear and significant, the 
obtained values are still very low in comparison to electrolyte solutions like PBS. 
For comparison, water featuring conductivity below 0.055 µS / cm was employed 
as highly purified water throughout all herein reported studies. On the contrary, 
PBS exhibited values for conductivity and consequently covered all GNP-derived 
increases in particle concentration-dependent conductivity.   
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2. Ultrasonic resonator technology as a new quality control method 
evaluating GNPs and nucleic acid loading 
2.1 Introduction 
Analytical methods to determine the all decisive nanoparticle value, the size, 
consist of scanning electron microscopy (SEM), photon correlation spectroscopy 
(PCS), often also referred to as dynamic light scattering (DLS) and asymmetrical 
field flow field fractionation (AF4) coupled with multi angle light scattering 
(MALS) (Fraunhofer et al. 2004). Concentrations of nanoparticles are determined 
by turbidity, gravimetry or, in some limited cases, by absorption spectroscopy 
(Hurst et al. 2007). However, some of these methods suffer from time consuming 
protocols or a limited detection ranges. These deficiencies could pave the way for 
an alternative method like Ultrasonic Resonator Technology (URT). 
In this study, size of cationized GNPs and their loading by ODNs was evaluated. 
The feasibility of GNPs as ODN carriers has been demonstrated previously 
(Zillies and Coester 2004). 
More precisely, a double-stranded NF kappa B decoy DNA was predominantly 
used in the present study which was proven therapeutic efficiency in 
ischemia/reperfusion injury animal models. Assessment of quantitative ODN 
loading is a precondition for ratable in vitro or in vivo effects of the employed 
formulation, although in some cases loading was judged from the transfection 
efficiency only (Sokolova et al. 2007).  However, to meet quality standards 
employable in further up scaling or approval by regulatory authorities, detailed 
knowledge of the loading status is essential. Therefore, various attempts have 
been made so far to quantify the effective payload on nanoparticles (Table 1). 
method advantageous disadvantageous
centrifugation and spectrometric well established; depending on low in precision, time consuming
analysis of  supernatant supernatant analysis:cheap indirect measurement
size - loading correlation quick low in precision
surface charge - loading correlation quick low in precision
AF4 universal, precise time consuming, expensive
 
Table 1. Advantages and disadvantages of present nanoparticle surface loading 
analytics. 
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Separating ODN loaded nanoparticles from the unbound, soluble ODN by 
ultracentrifugation (with or without size cut off membranes) has assumed a 
prominent role in assessing the loading yield.   
The subsequent quantitative analysis of the supernatant for the soluble portion is 
performed by absorption measurement of unmodified ODN (Zwiorek et al. 2004). 
This can be done by quantitative fluorescence analysis of previously labeled DNA 
(Hurst et al. 2007) or post separation labeling and spectroscopic quantification by 
PicoGreen® quantification kit (Bivas-Benita et al. 2003; Gu et al. 2006; Huang et 
al. 2006; Kaul and Amiji 2005; Perez et al. 2001) or other fluorescent setups 
including Hoechst dyeing (Sun et al. 2005). Radioactive 32P ODN labeling is 
another reported means (Chavany et al. 1992). In case of encapsulation, the carrier 
has to be disintegrated first to set free the total quantifiable ODN (Kaul and Amiji 
2005) or the DNA can be chemically displaced by cutting the bonds from the 
nanoparticle surface with consecutive quantification after centrifugation 
purification (Hurst et al. 2007). 
Other studies conducted were based upon a correlation between particle size 
change and varying loading efficiency (Jang et al. 2006), a decrease of surface 
charge (Giljohann et al. 2007) or on the optical FRET technique (Roy et al. 2005). 
The same technical approach by centrifugation is widely common for 
determination of protein with follow up ELISA testing (Cetin et al. 2007) or small 
molecule drug loading onto nanocarriers (Petri et al. 2007). 
A totally different approach to identify and quantify DNA, in its early stage of 
development, is the employment of nanopore devices (Archakov and Ivanov 
2007). By pulling DNA through the nanopores, its electrical structure changes and 
emerges a ratable electrical resistance signal specific for the relevant nucleotide. 
Nevertheless a detachment of the DNA from the carrier is mandatory. 
 
To summarize, the available methods for quantifying DNA loading of 
nanoparticles are partly time consuming and batch wise separation prior to 
determination method could suffer from a lack in accuracy (Table 1).  The error in 
accuracy is likely due to contamination of the supernatant with non-sedimented 
particles that cannot be ruled out completely by cut off filtration. Furthermore, 
there is a potential risk that the preparation is no longer usable afterwards because 
of high sheer forces that impact on particle aggregation during complete 
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centrifugation, depending on the employed carrier system.  
Alternatively, AF4 is a proven valuable method to separate and determine 
fractions of a formulation (Fraunhofer et al. 2004b; Zillies et al. 2007). Pursuant 
to its universal use the surface polyethylenglycol modification (PEGylation) of 
nanoparticles is quantitatively assessable even in the presence of ODN loading. 
Nevertheless, AF4 analysis of polymers and polymer particles is challenging and 
time consuming and not suitable for continuous production surveillance. 
Therefore, an additional new analytical method in combination with the 
established techniques for quality assessment of nanoparticulate loading shall be 
hereby proposed. 
The spectroscopic methods described beforehand (UV, VIS, fluorescence and 
absorption) as well as commonly employed infrared spectroscopy (IR) and 
nuclear magnetic resonance (NMR) makes use of electromagnetic waves in 
analysis.  However, ultrasonic spectroscopy used as a further spectroscopic 
method reveals relationships between acoustical patterns and sample’s properties. 
It was used for a long time in medical diagnostics and entered into material 
science later (Chalikian et al. 1994; Funck et al. 1993; Sarvazyan 1991). Due to 
data resolution, specimen handling and design hold-ups to it has taken time for the 
ultrasonic spectroscopy to find its way into biomedical application (Negredo et al. 
2007). In general, a high-frequency acoustical wave is passed through the sample 
leading to material properties related oscillating compression or decompression in 
the wave which causes again oscillations of the sample’s molecular structure 
(Buckin et al. 2003). The total energy of sound employed for this study is 
extremely low and is classified as non-destructive. Furthermore, as sound waves 
(unlike optical waves) permeate turbid fluid formulations and they are applicable 
to practically all pharmaceutical relevant liquid preparations. 
Ultrasonic spectroscopy calculates the absorption of the sound wave and speed of 
sound through a given sample (Buckin et al. 1989; Eggers 1992). Both properties 
are sensitive to changes in intermolecular interaction and molecular organization 
within the sample (Negredo et al. 2007). While the sound attenuation depends on 
chemical relaxation phenomena and bulk modulus of the sample, in this study 
resonating ultrasound is used to determine the sound velocity.  The speed of sound 
(U) is directly linked to the thermodynamic property density (ρ) and mechanical 
property adiabatic compressibility βs via the Newton Laplace equation:  
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ρβ s
U 1=
   
The thermodynamic considerations used to determine the equation of state from 
the Laplace equation and the thermodynamic properties of the solution have been 
conducted previously in detail (Tikhonov et al. 1995). For dilute solutions, as 
investigated in this study, it is sufficient to use the linear term of the La Place 
equation only. 
Using differential measurements (Sound velocity of sample minus sound velocity 
of reference, e.g. the corresponding buffer) the relationship between specific 
components of the sample and the propagation of the sound can be determined. In 
aqueous solutions water bound in hydration shells increase the overall speed of 
sound. This is due to the fact that hydration contributes negatively to the adiabatic 
compressibility while cavities do so positively (Gekko and Noguchi 1979; Gekko 
2002). As the adiabatic compressibility βs is reciprocally proportional to the speed 
of sound, an increase in hydration leads to an increase in the speed of sound. This 
is a simplified model since the contributions of all components are measured 
simultaneously. In this study, the surface loading of GNPs was examined and 
changes in ultrasonic velocity in the context of changes in surfaces exposed to the 
aqueous media were discussed. Hydration shells were also characterized by an 
increase in density. This effect was minor compared to the decrease in 
compressibility. Hence, an augmentation in the ultrasonic velocity signal stood for 
an increase in agents enlarging the hydration shells in the sample, which consisted 
of GNPs, ODN or ODN loaded GNPs in this study (Gekko 2002). Besides loading 
strategies, stability issues of the colloidal system as well as soluble ODN deserved 
attention. As an alteration in structure –due to aggregation or decomposition- will 
likely lead to hydration shell changes. Hence, monitoring the velocity of sound 
might provide valuable information on formulation stability. 
Different ultrasonic velocimetry methods for biomolecules have been developed 
in the past. Sarvazyan distinguished the sing around method and the fixed-path 
interferometer (resonator) method (Sarvazyan 1991). While the first method was 
precise, the required high sample volume made it inefficient. By contrast, the 
resonator method combined high precision measurements with low required 
sample volumes below one milliliter. The resonator method or URT used in the 
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present study was incorporated in the ResoScan® System (Shah et al. 2007). It 
was equipped with a temperature-controlled twin sample cell of about 200 µl 
volume. A standing ultrasonic wave was created between two lithium niobate 
piezo electric transducers (Figure 1). 
 
 Fig. 1: Creating and maintaining the standing ultrasound wave by continuous 
supply of electrically generated energy between the two gold coated transducers 
in the two instrument’s chambers. 
 
One cell was used as the reference cell, the other one as the sample cell. The 
instrument measured the ultrasonic velocity in both cells and the software 
calculated the difference (dU). Positive values indicated a faster sound velocity in 
the sample than in the reference. 
This study should demonstrate that the URT is generally suited to assess GNP – 
medium interactions as well as ODN loading by monitoring the interaction 
between the particle surface and the ODN. Encapsulations were not addressed by 
this method, as hydration shells were presumably just affected by surface 
phenomena. Furthermore, it was investigated if URT met the need for a sensitive 
analytical method for routine analysis of such nanoparticle dispersions without 
sample pretreatment.  
 
2.2 Materials and Methods 
2.2.1 Preparation and characterization of gelatin nanoparticles  
Plain non-cationized and cationized GNPs were prepared according to the 
established protocol (Zwiorek et al 2004; Coester et al 2000) as described in 
chapter II, 1.2.1. Gelatin, cholamine and 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide, (EDC) were obtained from Sigma Aldrich (Taufkirchen, Germany) 
and Glutaraldehyde from Fluka (Switzerland). The cationization (modified from 
Zwiorek et al. 2008) was carried out by attaching permanent positive charges by 
quaternary cholamine (1 mg / mg GNPs) to the surface of readily prepared 
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spherical plain and processing at a pH of 4.5 and ambient temperature for 30 min. 
The cholamine binds via amid bonds to EDC activated residual carboxyl groups 
of the gelatin constituting the particles. Thereby the zeta potential of the GNPs 
changes from negative to positive values. 
GNP concentration was determined gravimetrically. Therefore, a GNP dispersion 
aliquot of 25 µl was weighed with a Mettler Toledo UMX2® microbalance 
(Mettler, Greifensee, Switzerland). After evaporation of the solvent at 60°C the 
dry residue equaling the particle content was determined and the concentration 
calculated in mg / ml. 
Intensity weighted particle sizes were gained by PCS using a Zetasizer Nano ZS® 
(Malvern Instruments, Worcestershire, England). To exclude the viscosity impact 
on PCS particle size results, the viscosity of particle dispersions of all applied 
media was determined individually with an Anton Paar AMVn® viscometer 
(Anton Paar, Graz, Austria). The viscosity values were entered in the Malvern 
software prior to each PCS measurement. Nanoparticles were diluted in sterile 
filtered, highly purified water (HPW) (purelab, ELGA LabWater, UK) or in 
isotonic phosphate buffered saline pH 7.4 (Dulbecco’s® PBS, Invitrogen, Paisley, 
UK), in isotonic aqueous 2.5% glycerol or 5% glucose solution and measured in 
concentrations below 100 µg/ml at 25°C. As a reference and viscosity 
independent method, laser diffraction analysis of 1 mg / ml GNP dispersions was 
performed using a LA-950® laser diffraction particle size distribution analyzer 
(Horiba, Kyoto, Japan). For Zeta potential measurement before and after loading, 
GNP stock dispersions were diluted in PBS in a 1:10 ratio (V/V), filled in folded 
capillary cells (Malvern Instruments, Worcestershire, England).and measured in 
monomodal mode for high concentrated salts. Alternatively, measurements were 
conducted in HPW or 10 mM NaCl employing the general purpose mode for data 
processing of samples in low conductivity media.  
 
2.2.2 DNA loading onto gelatin nanoparticles  
22 base pairs double stranded (MW 7143 g / mol strand 1 and 7023 g / mol strand 
2) nuclear factor (NF) kappa B decoy DNA or 30 bases single stranded 9418 
g/mol DNA (Biomers GmbH, Ulm, Germany) were loaded onto GNPs in HPW in 
various concentrations (w/w). In case of cationized GNPs this process should be 
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predominantly electrostatically and self-assembling, while concerning non 
cationized GNPs only weak surface interactions as van der Waals bonds can be 
taken into consideration. The aseptically prepared samples of cationized or non-
cationized GNPs were subsequently incubated for 2 h at 22°C and 750 rpm using 
a Thermomixer® (Eppendorf, Hamburg, Germany) device. As the cationization 
only addresses the surface of the GNPs, there is no significant incorporation into 
the GNPs bulk expected. Loading efficiency was checked photometrically at 260 
nm wavelength (UV1, Thermo Fisher Scientific Inc., Waltham, USA) of samples’ 
supernatant after ultracentrifugation and accepted, if loading was at least 97% 
(w/w).  
 
2.2.3 Turbidity, URT and density measurements  
Turbidity measurement was conducted with a Nephla® turbidimeter type CPG 
239.52 operating at 860 nm and detecting scattered light at 90° angle. (Hach 
Lange GmbH, Düsseldorf, Germany). Results are given in formazine 
nephlometric units (FNU) as equivalents of turbidity. 
The ultrasonic measurements were made with an acoustic interferometer (TF 
Instruments GmbH, Heidelberg, Germany) featuring a twin interferometer with 
two identical parallel resonance cavities holding sample volumes of 200 µl each. 
(Khan 2007) The wavelength of the ground wave is 14 mm (λ0). This corresponds 
to a fundamental frequency of approximately 107 kHz. For the determination of 
the sound velocity overtones of the order 73 to 75 were used. The reproducibility 
of the measurement is ∆U = 0.020 m/s, while the temperature of the cell is 
adjusted to 25 ± 0.015 K with a temperature stability of ± 1 mK. GNP 
concentration was varied in size-concentration relation experiments while kept 
constant at 2 mg/ml in all loading settings. 
Density measurements of GNPs dispersion and with ODN solution were 
conducted with a DMA-4500® device (Anton Paar GmbH, Graz, Austria). 
If not stated otherwise, all measurements were performed from low to high 
concentrations in triplicate. If error bars are not indicated in figures, they are 
below resolution. 
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2.3 Results and Discussion 
2.3.1  Particle size and concentration evaluation  
The first aim of this study was to assess the capability of URT to distinguish 
different known particle sizes and correlate ultrasonic velocity with rising particle 
concentrations. 
GNPs of 245 nm and 442 nm diameter as determined by PCS were diluted to 
several concentrations ranging from 0.1 to 10 mg / ml and characterized by 
turbidity measurement as a reference for the concentration evaluation by URT.  
A linear relation between turbidity and concentration was found for 
concentrations below 1.25 mg/ml (R2 = 0.9948). Above that, saturation was 
observed (Figure 2). This finding limits turbidity measurement because even 
rather low concentrated GNP dispersions are too opaque to be analyzed by light 
spectrometric based devices. Furthermore, this method cannot distinguish between 
even largely varying particle sizes in the relevant size range.   
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Fig. 2: Concentration curve obtained by turbidity measurement of two GNP 
batches sized 245 and 442 nm over a concentration range from 0.1 to 10 mg/ml 
showing limited linearity (n=3). 
 
When monitoring the compressibility of a dispersion by measuring the ultrasonic 
velocity, the influence of the density has to be investigated and be determined in 
advance. Therefore, density measurements of GNPs in HPW were carried out. 
The density of the dispersions increased linearly with concentration from 0.99720 
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to 0.99975 g / cm3. (R2 = 0.9981).  
The increase in density results, according to the Newton Laplace equation, in a 
reduction of velocity.  This shows that a decrease in compressibility of the 
dispersions is responsible for the overall increase in sound velocity.  
The latter signifies that the particles overall enhance the propagation of sound in 
the dispersions.  The effect may be attributed to an increase in hydrated surfaces. 
However, this model neglects the intrinsic compressibility of the particles and 
should therefore be considered with caution. 
To demonstrate the linear relation between sound velocity and concentration over 
a wider range than the turbidity measurement, three dilution series concentrated 
up to 5, 10 and 15 and mg / ml (as determined gravimetrically beforehand) of 
three differently sized GNP batches (165, 280, and 630 nm diameter) where 
prepared, respectively. Additionally, the dilutions were investigated with the 
intent to distinguish between the dU values of differently sized particles. The 
difference in velocity (dU) between HPW and the particle dispersions with 
increasing concentrations of GNPs was measured and plotted against 
concentration. 
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Fig. 3: Difference in ultrasonic velocity (dU) of GNPs with three different 
diameters plotted against concentration: 165 nm (   ), 280 nm (   ) and 630 nm      
(   ). n=3 for each data point with R21-3 > 0.99 
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For all particle sizes the ultrasonic velocity (dU) increased linearly (R2 > 0.991 in 
all cases) with the particle concentration (Figure 3). Direct measurements were 
possible from low (0.25 mg / ml) to high concentrations (5, 10 or 15 mg / ml, 
respectively) extending the linear range up to ten-fold compared to turbidity 
measurements without need for dilution. Linearity was reached up to a 
concentration of 40 mg / ml (data not shown). Furthermore, the slope decreased 
with the particle size. It is postulated that with known concentrations previously 
determined gravimetrically it is possible to make deductions on particle size 
distributions by analysis of dilution series of a given and even very turbid batch of 
GNPs. 
However, intensive validation work would be required prior to size estimation by 
URT of each single particle batch being under investigation. On the one hand the 
particles’ total surface area accounts for the size representing slope. On the other 
hand URT cannot differentiate whether this surface is of evenly sized or highly 
disperse particles. Yet, as monodispersity was demonstrated in this trial by PDI 
values below 0.15 for the examined GNPs, the slopes of the batches can be 
compared among themselves for size correlation.  
Predominantly, as a consequence of the lower compressibility of the hydration 
shell in a GNP dispersion, sound velocity is increased in comparison to free water. 
Therefore sound velocity U rises linearly with higher particle concentrations and 
smaller particle sizes which likely build larger hydration shells compared to larger 
particles at the same concentration (Figure 3) (Gekko 2002).  
 
The delivery of ODNs is one of the main purposes of GNP usage. Therefore, the 
employed cationized form of GNPs allows ODN loading onto the surface via 
electrostatic interactions. Furthermore, the positive charge of the carrier facilitates 
the cellular uptake of the bound DNA, which, due to its negative charge, cannot 
penetrate cell membranes on its own (Fraley 2006).  
Because GNPs are designed not to act in HPW but in physiological conditions 
featuring an ionic strength of about 299 mosm / kg and at a pH of 7.4, the dU of 
non cationized GNPs sized 180 nm dispersed in PBS (imitating physiologic 
conditions) was furthermore compared to corresponding dU results in HPW. Two 
batches of cationized GNPs (with average diameters of 167 and 297 nm) were 
analyzed, accordingly (Figure 4).  
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Fig. 4: Linear concentration curve obtained by URT measurement showing 
dependence of dU on GNP diameter and dispersion medium with 180 nm non 
cationized GNPs in PBS (  ), 180 nm sized non cationized GNPs in HPW (   ), 167 
nm sized cationized GNPs in PBS (   ) and 297 nm sized, cationized GNPs in PBS 
(   ), respectively (n=3, ± S.D.).  
 
Non-cationized GNPs dispersed in HPW display a small but significant higher dU 
value than in PBS. In contrast, negative dU/dc values were found for both 
cationized batches. The slope of the larger particles sized 297 nm was steeper than 
the slope of the GNPs sized 167 nm (Figure 4). The positively charged amine 
groups are presumably neutralized by the chloride and phosphate ions present in 
the PBS (zeta potential is about 30 mV lower than GNPs in HPW). This partly 
explains the reduction of the hydration effect.  
Assuming a density increase with increasing concentration as found for the non 
cationized GNPs with an average diameter of 214 nm (data not shown), this 
would mean that the influence of the hydration layer is much reduced compared to 
the density effect. It is known that addition of electrolytes compress the double 
layer around the particles. 
Examining the Laplace equation, the observed declining dU values of cationized 
GNPs correlate to rising compressibility, likely related to the particle size. To 
assess this newly observed particle phenomenon, PCS and laser diffraction were 
used as essential cross references for particle size monitoring.  
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Therefore, 15 µl stock dispersion of cationized and non-cationized GNPs 
originating from the same batch were added each to 1 ml solution blends of HPW 
and increasing percentile amount of PBS, glycerol 2.5% (m/m) or glucose 5% 
(m/m) ranging from 100% HPW to 100% additive. 
In this setup, cationized GNPs (> 7 mV measured in PBS) lost up to 17% of their 
diameter in PBS measured by PCS. In contrast, cationized GNPs in the other two 
isotonic media and non-cationized GNP (< -2 mV measured in PBS) in all three 
examined media, including PBS did not significantly change the particle diameter 
(Figure 5).  
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2.11 nm (mean +/- S.D. n=3) 
179.6 nm 
0.46 nm (mean +/- S.D. n=3) 
169.7 nm 
7.91 nm (mean +/- S.D. n=3) 
152.2 nm 
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  cationized 
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Fig. 5: Hydrodynamic diameter development upon surface charge and dispersion 
medium of Gelatin nanoparticles all made of the same batch. 
 
These findings were confirmed by laser diffraction analysis where the same 
cationized GNPs decreased in size even by 35 % while non-cationized remained 
constant in size (data not shown). To get more insight into the swelling and 
shrinking behaviors of GNPs upon ionic change, a further setup employed a side 
by side PCS measurement with the non-cationized and cationized GNPs sized 
slightly larger than the previously tested batch. 15 µl GNP stock dispersions were 
diluted and sectioned into 1 ml batches, each with HPW and PBS respectively, for 
PCS measurement.   
The cationized GNPs of the same batch show a 45% larger diameter in HPW than 
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in PBS. If exposed to the almost zero osmotic pressure ambience of HPW (0.4 
mosm / kg), cationized GNP swell by this value. For non-cationized particles this 
effect is significantly reduced as their size is only increase by 18%, compared to 
PBS). (Figure 5) 
This swelling experiment was repeated with the same cationized GNP batch to 
investigate the reversibility and time course of the size effect. Three samples of 
GNPs were stored in PBS for one week at 25 °C. Three further GNP samples in 
PBS were purified by centrifugation (18000 g, ’20, 25°C), redispersed in HPW 
and stored alike. 
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Fig. 6: Curves obtained by PCS measurement of cationized and non-cationized 
GNPs revealing size-dispersion media (PBS, glycerol, glucose) dependence 
(n=3, ± S.D.). 
 
PCS analysis revealed that small percentages (below 10%) of PBS in the 
dispersion have an immediate effect on the size of the particles (Figure 6). This is 
similar for the GNPs that underwent medium exchange to HPW. After exchanging 
PBS for HPW medium the cationized GNPs swell to an extent which is 
comparable to GNPs stored in HPW form the beginning (Table 2).  
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cationized GNP cationised GNP PBS treated GNP PBS treated GNP
in PBS  in PBS   redispersed   redispersed in 
initial value 1 week storage in HPW HPW 1 week storage
at 25 °C initial value  at 25 °C 
[nm] 159.68 157.68 221.78 220.80
S.D. 0.81 0.99 1.90 1.05
 
Table 2. Cationized GNP sizes upon storage in PBS and after medium exchange 
in HPW. 
 
The 10% difference in diameter might originate from residual PBS after 
centrifugation. As shown in Figure 6, small amounts of PBS lead to shrinking. 
Therefore, the shrinking and swelling processes are reversible. Due to the fact that 
non-ionic but isotonic dispersions show no significant impact on the particle size 
(Figure 5), the osmotic pressure can be ruled out as the main driving force. This 
effect would presumably lead to a less compressible structure and an increase in 
dU/dc which is not evident in this case. Instead, it is hypothesized that anions of 
the PBS medium electrostatically interact with the cationized GNP surface. 
Apparently, GNP positive surface charge is compensated and, as counter ions the 
anions reduce the electrostatic repulsion within the polymer matrix and partly 
condensation is no longer prevented. This principle was previously described by 
Bloomfield et al. detailing DNA condensation by polyelectrolytes based on 
Manning’s counter ion condensation theory (Bloomfield et al 1980). 
 
2.3.2 Determination and evaluation of ODN loading onto GNPs  
After clarifying plain particle properties accessible by URT in relevant media, the 
binding of ODNs to GNPs of known concentration by URT was subsequently 
investigated. Previously, to draw conclusions on changes in compressibility from 
velocity measurements the density of ODN solutions dependent on concentration 
was investigated. Exemplarily, for a 22 base pair ODN in HPW (0 to 0.35 mg/ml) 
it was found that the density increased linearly (R2=0.9811) over the given 
concentration range (supplementary material). Therefore, plotting of dU data 
against ODN concentration is appropriate as well. 
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Fig. 7: dU of a diluted 22 base pairs ODN as a function of concentration from 
0.005 to 0.2 mg / ml representing 0.25 to 11 % (w/w) in following loading 
experiments. Cell 1 = HPW, cell 2 = ODN. (n=3, ± S.D.) 
 
The URT measurements were performed with a 22 base pair double stranded (ds) 
ODN (Figure 7). The difference in velocity dU between HPW and the 22 base 
pair ds ODN with increasing concentrations is shown in Figure 7 where dU 
increases linearly with percentile ODN loading onto GNPs (0 to 11 % (w/w)) 
representing a ODN concentration from 0 to 0.2 mg / ml. These data and the 
density measurements indicate that the compressibility increases linearly with 
concentration.  
The graph’s x-axis shows the percentile (w/w) ODN loading based on the weight 
of GNP in the respective dispersion. The constant GMP concentration is 2 mg / 
ml. This allows the calculation of each ODN concentration step in mg / ml. 
High linearity over the entire concentration range is demonstrated. Single stranded 
ODN reveals higher dU values (data not shown). This is likely due to the fact that 
the longer single strand can build up more encompassing hydration shell. The 
double stranded ODN has less free surfaces for hydration because of the intra 
ODN interaction. Therefore, an increase in dU over time of a ds ODN solution of 
known concentration could indicate a strand separation and therefore negative 
stability affections. However, this idea was not further pursued in this study. 
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Instead, the supplementary use of URT was focused on the interaction of ODNs 
with GNPs to gain information about optimal loading parameters and to monitor 
inconsistencies related to a suboptimal loading of ODN onto GNP. A first 
experiment with GNPs in the presence of 10% (w/w) of a 30 bases ss ODN led to 
an overall instable formulation. Visible flocculation and sedimentation of 
macroscopic GNP-ODN aggregates occurred. This can be explained by a 
complete compensation of the GNP surface charge by binding of ODNs. It could 
be shown by a reduction of the zeta potential of the formulation in PBS from +7 
mV to 0 mV in the presence of ODN.  
The dU value in the presence of 10% (w/w) 30 bases ss ODN measured directly 
after mixing decreased sharply (Fig. 8). Repeated redispersion by a micropipette 
in the sample cell led to a short interruption of this trend of approximately 100 
seconds. Using the simple hydration model explained above, the decrease in 
velocity can be explained by the aggregation and following sedimentation of 
particles, thereby removing surface area from the solution and reducing the 
overall water bound in hydration shells. A decrease in hydration means an 
increase in compressibility and consequently a decrease in ultrasonic velocity 
assuming that changes in density can be neglected. 
In addition, subsequently occurring sedimentation will affect the propagation of 
sound. Since the sediment collects at the bottom of the cell, where the sound 
generating piezoelectric crystals are located the effect on sound propagation is 
difficult to predict. Sedimenting particles will collect in areas of the cell that are 
outside the sound path, further reducing the sound velocity. However, as soon as 
more and more particles build up in the bottom the cell this may lead to an 
increase in velocity due to an increase in concentration between the sound 
generating crystals. On the other hand an increase in large macroscopic particles 
will lead to an increase in scatter of the sound wave that will lead to a decrease in 
sound velocity due to non-adiabatic scattering (Pinfield et al 1997). Consequently, 
excessive sedimentation halts the dU signal completely. 
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Fig. 8: dU values plotted against the reaction time for three subsequently cell 
fillings of samples with 10% (w/w) (  ) and 5% (w/w) (  ) 30 bases ss ODN loaded 
GNP. Cell 1 = HPW; cell 2 = ODN-GNP sample. Arrows represent refilling (   ) 
or redispersion (     ) respectively. 
 
As GNP aggregation and subsequently sedimentation occurs, the dU signal 
concurrently decreases. Without further experiments it cannot be derived to what 
extend both events contributed to the signal. However, conversely this 
phenomenon can be of use to confirm formulation quality: the absence of a falling 
dU signal indicates the absence of sedimenting aggregates. Figure 8 also shows 
the difference in ultrasonic velocity between HPW and a stable 5% (w/w) ODN-
dispersion over time. The ultrasonic velocity is constant over the analysed period. 
URT can therefore be proposed for monitoring stability of pre-characterized 
colloidal systems.  
The final goal of this study was to demonstrate URT as a suitable tool to 
determine ODN loading and to distinguish it from non-successful loading of ODN 
onto GNP surfaces. 
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Fig. 9: dU in dependence of (a) cationized GNP and (b) non-cationized GNP 
incubated with increasing amounts of ODN.  (GNP concentration constant at 2 
mg/ml. cell 1: ODN equivalently concentrated, cell 2: ODN loaded GNP 0.5 -10% 
(w/w, ODN/GNP) (n=3, ± S.D.). 
 
Since URT technology is unspecific and detects all changes in dispersion (e.g. 
concentration of any component) a protocol which minimizes effects from 
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volumetric and concentration errors was devised. Cationized and non-cationized 
GNPs (in the sample cell 2), which were previously incubated with ODN, were 
measured each against the ODN solution (in the reference cell 1) in the same 
concentrations (w/w) (ODN/GNP) as employed for the loading. The difference 
between the references and the sample is therefore a fixed amount of GNPs 
present in the sample cell. If there is no interaction between the ODN and the 
GNPs, the GNPs should lead to a constant difference in ultrasonic velocity 
independent of the ODN concentration. If an interaction occurs the difference in 
ultrasonic velocity will change with increasing ODN concentrations. 
Figure 9a shows the signal for cationized GNPs. The difference in ultrasonic 
velocity decreases with increasing ODN concentration. Using the hydration model 
this can be explained by a reduction of GNP and ODN surfaces exposed to the 
buffer by binding of the ODN to the particles. Figure 9b shows the signal of the 
non-cationized GNPs. There is no effect on the difference in velocity with 
increasing ODN concentration. This is an indication that there is no interaction 
between the particle and the ODN. To conclude, for GNP preparations well 
characterized in concentration and size, the ODN loading can be estimated after 
calibration and subsequently used in routine analysis.  
As a final comparison, the extent of loading was further followed by monitoring 
the zeta potential values measured in HPW of loaded cationized versus non-
cationized particles and in 10 mM NaCl as a control (data not shown). As 
mentioned in the introduction, measuring the surface charge was described in 
literature as a possible loading surveillance method. In the present setting, 
cationized particles in HPW exhibit a reduction in zeta potential from 36.2 mV 
with a 1 % (w/w) ODN loading to 19.2 mV with a 10 % (w/w) ODN loading 
(Table 3). Non cationized GNPs show a reduction from 22.3 mV to 10.6 mV for 
the same loading conditions. Linear plotting of the data leads to a coefficient of 
correlation (R2) of 0.9229 while plotting the zeta potential data of non-cationized  
GNPs leads to a regression with R2 = 0.7778. These two R2 values differ 
significantly because the p-value is 0.01 as determined by one factorial ANOVA 
analysis from comparison of all R2 values from all single measurements. This 
indicates a different ODN – particle surface interaction most likely due to a 
different level of ODN loading onto the GNP surface.  
96                                     Enlargi  the analytical oolbox for gelatin nanoparticles                          
Formulation development of plain gelatin nanoparticles    97 
 
 
    non-cationized GNPs            cationized GNPs
loading [%] (w/w) Zeta [mV] S.D. Zeta [mV] S.D.
1 22.30 1.66 36.20 2.76
2 19.20 1.32 34.80 2.73
3 19.30 1.40 33.90 2.08
4 17.10 2.57 27.50 2.16
5 14.10 1.11 28.20 1.05
6 16.20 1.31 24.20 0.81
7 17.00 0.45 24.30 1.68
8 16.40 0.44 24.30 0.51
9 12.40 0.20 22.80 1.04
10 10.60 0.98 19.20 1.86
 
Table 3. Zeta potentials of ODN loaded cationized and non cationized GNPs. 
Therefore, the zeta potential method backs URT findings, yet seems to be less 
convenient and accurate (linear decrease with rising loading, see Table 3), while 
conversely URT provides linear and consistent results in our examples.  
As the standard control method, UV-spectrometric analysis of the two GNP 
samples was used and revealed the ability of URT to distinguish clearly between 
successful and non successful loading. According to the spectroscopic method, 
only 2% of the total ODNs were found in the supernatant of the cationized GNPs, 
which supports the URT data of successful loading. Concerning the non-
cationized GNPs, 40% of the ODN were found in the supernatant. Remarkable 
60% were presumably bound to the GNPs by unspecific and weak interactions 
and/or trapped in the pellet by the fast sedimentation of the particles during 
centrifugation.  
To summarize, on the one hand URT depends as a relative method on existing 
absolute methods like PCS, gravimetry and UV-spectrometric analysis of 
previously centrifuged samples. As described, these methods partly feature 
disadvantages e.g. for formulations sensitive to centrifugation. On the other hand, 
once these methods have been successfully employed to validate a specific URT 
setup they are no longer necessary for this very process and could advantageously 
be stinted in routine analysis.  
 
2.4 Conclusions 
URT is ranked a potential quick, non-destructive method with a high dynamic 
measuring range to determine GNP concentrations of known size as well as the 
surface loading status of hydration shell building agents like ODNs of GNPs. 
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However, URT needs to be calibrated for each nanoparticle system by comparison 
with described methods like PCS and spectroscopy. Therefore, the method is 
feasible and well applicable for QC of nanoparticle but not of microparticle 
procedures in the course of formulation development of clinical supplies. 
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3. Evaluating salts of the Hofmeister series regarding their impact on 
GNP particle size alteration and initial immunostimulatory trials 
3.1 Introduction and objectives 
Findings of the media-depending GNP sizes within the URT study promoted the 
question whether there was a systematic impact of the dispersant media 
composition on swelling and shrinking of the colloidal carrier system. Previously, 
PBS turned out to influence the particle size. Because PBS consists of a multitude 
of salts, a more in-detail study on which particular salts contribute to which 
extend to the changes in apparent GNP properties. The most prominent approach 
for protein swelling experimentation, the Hofmeister series was used as a 
systematic basis for media-associated size alterations. The Hofmeister concept 
describes the impact of several salts on precipitation of proteins and swelling of 
biological material ending up with a “typical ordering” as depicted in Fig. 1 (Kunz 
2010). Yet, it has to be mentioned that the initial series was based on salts and not 
on individual ions. Moreover, several series were developed over the past 120 
years and the relative importance of direct ion-ion interactions versus ion-water 
interactions are matter of ongoing debate (Kunz 2010). In the present study, 
cationized and non-cationized particles were diluted in relevant salt solutions over 
a low to high concentration range. On the high end, the employed concentrations 
represented the double osmolarity compared to physiologic milieu referring to a 
high value of 0.3 M. The extend of size alteration was expected to be in 
accordance with salting-in or salting-out properties of the applied ions (Fig.1). 
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Fig. 1: Sequencing ions in the Hofmeister series according to their salting-in and 
salting–out effects (Kunz 2010). A selection of representative salts was employed 
in the present study. 
 
3.2 Materials and Methods: 
The GNPs were produced according to the original procedure (Coester et al. 
2000). However, the change of manufacturing site from Munich to Denver, CO, 
irequired to adapt some standard production parameters or tools employed. 
As acetone tended to boil already below 50°C at 1609 meters altitude, the two 
desolvation steps in the nanoparticle formation process had to be carried out at 
about 40-45°C which resulted in so far unassessed potential particle property 
deviations. Furthermore, deviations in flask and stirring bar size and/or surface 
characteristics, as well as in the temperature of added reagents speed and control 
of heating and stirring varied from validated protocols. Centrifugation tubes had 
to be reused over the relevant time period for particle purifications as all 
commercially availably single-use sterile 50 ml tubes would not fit into the 
available Beckman JA-17 rotor while the original Beckman containers were 
incompatible with acetone. 
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3.2.1 Deviations in GNP preparation from the standard protocol 
Particles were made from porcine gelatin A (Sigma, St. Louis, USA) under 
aseptic conditions in a safety hood with desolvant agent acetone (Fisher, USA) 
and cross linked with thawed glutaraldehde 25% (V/V, Sigma). Adjustments of 
pH values were conducted with 0.1 N NaOH and HCl with a pH meter (Denver 
instruments, Denver, USA). A Beckmann Centrifuge with JA-17 insert was used 
for particle purification by ultracentrifugation at a force of 14000 – 22000 g 
depending on the applicable particle size. 50 ml centrifugation tubes (Millipore, 
USA) were washed and autoclaved for reuse. 
All particle sizes were determined by a PCS device (PAS particle sizing system, 
Santa Barbara, USA) and calculated involving a Nicomp 388 software. Particle 
sizes are given as a mean of three subsequent measurements each involving at 
least 10 -20 subruns. Standard deviations (SDs) are given as means of the SDs 
calculated by Nicomp 388 software in the Gaussian particle distribution analyzing 
mode. 
Particles were measured in an aqueous dispersion of 2.5 µl particle dispersion in 
600 µl HPW if not indicated otherwise. 
 
3.2.2 Methods regarding Hofmeister series 
Solutions of relevant salts representing prominent points in the Hofmeister series 
were diluted in HPW according to table 1 in order to create solutions in a 0 to 
0.3 M molar concentration range. Stock solutions of each salt were prepared 
according to the instruction in table 1. 
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Type of salt Salt dry substance [g] HPW [ml] 
Na2SO4 2.131  50  
Na-citrate 1.548  20  
NaCl 0.350  20  
NaClO3 0.638  20  
NaI 0.899  20  
NaSCN 1.216  50  
 
Table 1: Composition of applied salt stock solutions making concentrations of 
each 0.3 M, listed top down from low to high salting-in salt properties. 
 
2 µl of non-cationized and 4 µl of cationized GNP dispersion was diluted to a total 
volume of 600 µl and transferred into a round single-use borosilicate cuvette for 
subsequent PCS measurement. An anticlimactic dilution series of the media were 
carried to obtain a dilution row of each individual salt solution with molarities of 
0.3, 0.2925, 0.2875, 0.275, 0.25, 0.2, 0.15, 0.1, 0.05, 0.025, 0.0125 and 0.0075 
mol/l. Solutions were filtered by 0.22 µm cellulose acetate filters and checked for 
particle precontamination by PCS. GNPs were added to the ready solution (n=3) 
instead of adding salt to a salt-free GNP solution to guarantee complete salt 
dissolution. 
 
3.3 Results and Discussion 
The selection of salts represents the extremes of salting-in and salting-out as well 
some intermediates. Only common sodium salts were assessed at this initial stage 
as anions are supposed to be the driving force in making proteins to aggregate or 
to be solubilized according to the Hofmeister series (Zhang 2006). 
First, particles were subjected to size measurements on a pH scale from 3.3 (in 
HPW) which represented the storage pH of freshly prepared GNPs up to 10.4. No 
significant size change was observed for the non-cationized GNPs while 
cationized GNPs exhibited a size reduction of up to 5% at the higher pH values. 
However, as the employed salts feature pH values in the 4 – 6 range, this does not 
apply to the subsequent size measurement results. Next, non-cationized GNPs’ 
sizes were examined in presence of the selected salts as given in the figures below 
(Fig. 2-6) in the sequence from salting out towards salting in salts. 
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Fig. 2: size and variance of size distribution of non-cationized GNPs in Na2SO4  
(n=3 ± SD) 
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Fig. 3: size and variance of size distribution of non-cationized GNPs in Na-citrate 
(n=3 ± SD) 
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Fig. 4: size and variance of size distribution of non-cationized GNPs in NaCl 
(n=3 ± SD) 
 
GNP non-cationized in NaI solution
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Fig. 5: size and variance of size distribution of non-cationized GNPs in NaI. 
(n=3 ± SD) 
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Fig. 6: size and variance of size distribution of non-cationized GNPs in NaSCN. 
(n=3 ± SD) 
 
Regarding the above demonstrated results, it can be stated that the type of anion 
has a significant impact on the particle size and its distribution. With the 
exception of sodium citrate (Fig. 3) all salts lead to an “initial peak” of increased 
size below 0.05 M salt concentration. The extent of this peak increases with the 
salt’s “salting in” properties within the Hofmeister series. This positioning 
indicates that besides the salting in effect, reduced surface tension, less protein 
stability and an increased risk of aggregation is prevalent (Kunz 2010). It is not 
yet understood why this phenomenon is restricted to the very low part of the 
applied concentration range. Obviously, it is always the first and lowest measured 
amount of salt that results in the peaks. Viscosity and osmolarity alterations are 
supposed to be the lowest here, but due to less hindrance diffusion processes of 
the anions into the GNP matrices are probably most efficient in this low 
concentration range. Therefore, viscosity and osmolarity measurements need to be 
performed along with this consistent finding in order to clarify the anions 
positioning and impact.  
Furthermore, the cationized GNPs were subjected to the same salt solutions as the 
non-cationized GNPs and measured alike. 
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Fig. 7: size and variance of size distribution of cationized GNPs in Na2SO4. 
(n=3 ± SD) 
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Fig. 8: size and variance of size distribution of cationized GNPs in Na-citrate. 
(n=3 ± SD) 
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Fig. 9: size and variance of size distribution of cationized GNPs in NaCl. 
(n=3 ± SD) 
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Fig. 10: size and variance of size distribution of cationized GNPs in NaI. 
(n=3 ± SD) 
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Fig. 11: size and variance of size distribution of cationized GNPs in NaSCN. 
(n=3, ± S.D.). 
 
The size and size distribution measurement results of cationized GNPs differ from 
those obtained from non-cationized ones. An “initial peak” is not occurring with 
the one exception of NaI where size is increased at a concentration of 0.0125 M to 
a smaller extend of about 5% compared to up to 200% with the non-cationized 
particles. A possible reason for this finding is that cationized GNPs “absorb” the 
medium anions by ion pairing and prevent them to have a surface tension and 
subsequent aggregation inducing effect as being solvated. However, as the 
concentration of the salting-in salt is increased heavily, aggregation tendencies are 
dominant as soon as the “absorbance” reservoir is depleted. The only exception is 
NaSCN showing heavy size increase most likely due to aggregation (Fig. 11). 
This finding is again in accordance with the Hofmeister series as NaSCN is the 
most salting-in one on the list. However, the nature of aggregation of this finding 
needs to be proven in an additional trial on the reversibility of size change. If the 
size change is completely reversible, this is the proof for swelling instead of 
aggregation. If a combination of swelling and aggregation is the reason, an 
incomplete size remission in combination with an elevated PI is expected. 
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3.4 Conclusion 
Finally, it can be stated that the anion type strongly influences the particle size 
and size distribution while - based on this preliminary data- the pH alone does not. 
It is proposed to conduct follow up experiments to check consistency of the newly 
found size changes and aggregation tendencies over various batches produced 
under standard conditions and to rule out interfering oxidative and reductive 
processes. Nevertheless, the present data is in accordance with the initial findings 
on the existence and reversibility of ion-induces GNP size changes (Fuchs et al. 
2010). Methods such SEM for absolute size conformation would be desirable in 
future. However, careful validation would be required to assure that the obtained 
GNP sizes in dispersion translate to dry samples which are required in SEM.  
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4. Imaging techniques for nanocarriers 
4.1 Survey on options to track nanoparticle biodistribution  
A successful therapy is globally characterized by reaching the pathogenic target in 
vivo (Debbage 2009). Nanoparticles offer a multitude of available techniques not 
only to target but also to effectively monitor the system’s in vivo fate (Pauwels 
and Erba 2007). Imaging can generally be provided by a signal emitted by a 
modification responding to external excitement -such as fluorescence or 
ultrasound resonance- or an intrinsic signal like magnetic or radioactive radiation. 
Especially fluorescence imaging is a very quickly evolving field in in vivo 
analysis with a focus on oncology (Weissleder and Pittet 2008). But certainly 
fluorescence contributed to cellular imaging as well, clarifying cellular uptake and 
intracellular localization both in fixed and living cells (Thurn et al. 2007). For 
instance, the fluorescence signal of tetramethylrhodamine conjugated dextran 
labeled GNPs allowed the endolyzosome localization in murine dendritic cells by 
confocal laser scanning microscopy (Coester et al. 2006). This was the 
precondition for further endosome-based TLR-9 targeting for immunostimulating 
strategies (Zwiorek et al. 2008). The same technique revealed the uptake of Alexa 
labeled GNPs by isolated liver resident Kupffer cells as decisive for decoy 
oligonucleotide delivery (Hoffmann et al. 2009; Zillies 2007).  
Knowledge about the intracellular location of the administered drug delivery 
system in total is crucial to correlate its effects with the observed physiologic 
outcome. In this case, the immunostimulatory action of NP-bound isRNA 
presumably needs interaction with the pharmacodynamic target receptor, the 
endosome-based TLR-7. Previously, Coester et al. first demonstrated a possible 
endosomal targeting of plain, unloaded GNPs in dendritic cells generated from 
murine bone marrow cells (Coester et al. 2006). Therefore, murine DCs were 
incubated for 24h with TMR-dextran GNPs and followed by fluorescence-
labeling with FITC-concanavalin A for cytoplasm membrane staining and with 
lysotracker blue DND-22 for endosome staining. 
Based on the general understanding that colloidal drug carrier systems taken up by 
phagocytosis remain in the endosomes (Maitra 2005), a complete co-localization 
of the TMR–dextran labeled GNPs with the lysotracker stained endosome. But a 
closer look at the CLSM overlay also reveals a clear blue fluorescence that is not 
co-localized with the red stained nanoparticles. This information confirms that not 
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all endosomes are involved in the uptake process of plain GNPs. 
Of subsequent interest was if oligonucleotide (ODN)-loaded GNPs (see chapter 
IV, 1.1) can be localized as well in cells capable of phagocytosis. Therefore, 
GNPs were labeled with Texas red and loaded (2.5% [w/w]) with Alexa Fluor 488 
labeled ODNs. Kupffer cells generated from rat liver were incubated with these 
GNPs and subsequently stained for nucleus (Hoechst 33342) and endosomal 
membrane (VibrantTM Did cell staining). From the overlay of single CLSM 
channels a co-localization of GNPs, ODNs and endosomes was derived  (Zillies 
2007).  
Furthermore, fluorescence microscopy could provide information beyond static 
cell evaluation, but also in an in vitro flow model where bloodstream-like sheer 
forces can be simulated (Schultes 2009). In such conditions, endothelial cells 
adherent to the capable microscopic slide express different surface protein 
patterns compared to static conditions. Therefore, cell-GNP interactions can be 
more realistically evaluated which is of particular importance for endothelium 
targeting in nanoparticle-mediated anti-neovascularization strategies 
(Schultes 2009).  
For in vivo fluorescence imaging, macroscopic systems such as fluorescence 
reflectance imaging devices for surface use (up to 3-5 mm depth resolution) and 
tomographic fluorescence devices such as FMT which can reconstruct three 
dimensional maps of fluorochromes are available (Weissleder and Pittet 2008). 
The latter is quantitative and can be combined with CT for better in vivo 
localization (Weissleder and Pittet 2008). However, from a regulatory point of 
view, radionuclide labeling is the only technique that can give full quantitative 
mass-balance information after administration in vivo (Hargreaves 2008). Its 
major ability is to account for the full administered dose and its fate which is 
detrimental for drug safety (Brindle 2008). Radio-labeling of nanoparticles 
requires a chemical conjugation of appropriate emitters. Technically, either a 
radioisotope is introduced into the biological structure such as [18F]-Fluor-Deoxy-
Glucose and coupled to the nanoparticle or a metal radionuclide is bound via a 
chelator to the carrier.  
So far, biodistribution studies were mostly carried out on small animal models 
(Schnockel et al. 2008). Traditionally, the dose of radionuclide-based 
nanoparticulate formulation was administered, tissues were sectioned post mortem 
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and tissue gamma counting was performed. For different time points of interest, 
sets of new animals had to be scarified (Franc et al. 2008). While this method is 
accurate to reflect the distribution at a specific moment, it does not allow studying 
distributions over time within the same living animal. Therefore, positron 
emission tomography (PET) as well as PET combined with computer tomography 
(PET-CT), a technique already in use for human diagnostics in oncology was 
applied for small animal use as a non-invasive system for online whole body 
monitoring (Riemann et al. 2008). This system uses radionuclides that undergo a 
β
+ decay such as 18F in deoxy-glucose or 64Cu, 68Ga or 111In as metal radionuclides 
which emit a positron. This positron gets annihilated when inevitably 
encountering its ubiquitary antiparticle electron in the tissue. In the annihilation 
event, two gammaphotons are created and depart the place of origin in a 180° 
angle.  The PET scanner subsequently detects this pair of photons simultaneously 
and correlates this double event of detection to the single place of origin. Readout 
electronics assist in creating a 3D picture out of the sum of all detected events at a 
time. Resolutions reach below 1 mm.      
Zwiorek et al. employed both the PET and the ex vivo tissue sectioning as a 
quantitative reference to track nanoparticles in vivo (Zwiorek 2006).  
The strategies for optimized radiolabeling of nanoparticles by grafting specially 
designed ligands capable of binding radionuclides by coordination for in vivo PET 
imaging were shown by (Sun et al. 2007).  
Kaul et al found prolonged blood circulation times of GNPs when decorated with 
5 kDa PEG (Kaul and Amiji 2004). Furthermore, higher in vivo β-galactosidase 
gene expressions and consequently superior tumor transfection as per colorimetric 
enzymatic activity assays were found in a GNP-based gene delivery attempt to 
target tumors when the carrier was PEGylated (5 kDa) which led to their 
conclusion of a PEG-related better passive tumor targeting. Kommareddy linked 
the anhydride of diethylenetriaminepentaacetate (DTPA) as a chelator to both 
thiolated and 2 kDa-PEGylated GNPs for 111In radiolabeling (Kommareddy and 
Amiji 2006). Moreover, PEG-modified thiolated GNPs were found to show 
sensitivity towards reducing environments and thus featured a tumor-selective 
accumulation. Summarizing, half-lives upon i.v. administration exhibited to be 
higher for the PEGylated and thiolated protein nanoparticles in comparison to 
PEG-only modified or plain particles. In parallel, high percentages of injected 
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dose per gram organ tissue were reduced in spleen and liver depicting a lower 
undesired accumulation of the carrier here. However, a proof for the coexistence 
of particle and radionuclide in vivo as a fundamental precondition for activity data 
interpretation was not given yet. This should be implemented by the present study 
involving double-labeled GNPs both with a radionuclide and fluorescent dye. 
Furthermore, the benefit of PEGylation for enhanced nanoparticle biodistribution 
was not yet confirmed to be a general rule and should be assessed for GNPs 
hereby. Besides these points, this study was to clarify whether the starting 
macromolecular of gelatin or the nanoparticulate shape contributed predominantly 
to GNP circulating properties after i.v. administration. 
 
4.2 Materials and Methods 
4.2.1 Preparation and characterization of PEGylated gelatin nanoparticles 
4.2.1.1 Preparation of PEGylated gelatin nanoparticles 
First, a 0.2 M borate buffer was prepared as follows: 2.50 g of boric acid were 
dissolved in 200 ml of HPW under stirring. The pH was adjusted to 8.5 with a 
40% solution of NaOH. Afterwards, about 250 µl of a 1 % (w/v) solution of α-
methoxy-ω-aminopoly(ethylene glycol) (13 000 Da) in  borate buffer pH 8.5 were 
prepared (PEG solution). Then, the aqueous GNP dispersion and the PEG solution 
were mixed in EppendorfTM tubes in three different weight to weight ratios: 1:0.3, 
1:0.2 and 1:0.1. 24 µl, 16 µl and 8 µl of the PEG solution were employed, 
respectively. Each tube was finally filled up to 800 µl with borate buffer pH 8.5 
(in a variant approach each tube was filled up to only 200 µl). Incubation was 
performed under constant shaking (800 rpm) for at least two hours at 35 °C. 
 
4.2.1.2 Characterization of PEGylated gelatin nanoparticles via PEG    
assay 
At first, two basic solutions were prepared as follows: 5.00 g of BaCl2 were 
dissolved in 100 ml of 0.1 M HCl by shaking (BaCl2 solution). Furthermore, 1.25 
g of I2 and 2.00 g of KI were dissolved in 100 ml completely desalted water under 
overnight stirring (iodine solution). About 250 µl of a 1 % (w/v) solution of α-
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methoxy-ω-aminopoly(ethylene glycol) (13 000 Da) in 0.2 µm filtered HPW were 
then prepared. 50 µl of this solution and 450 µl of borate buffer pH 8.5 were 
mixed in an EppendorfTM tube (PEG solution, 0.1 % (w/v)). Afterwards, the 
following solutions were each pipetted in an extra cap:  
 
 
borate buffer pH 8.5 
[µl] 
PEG solution,           
0.1 % (w/v)             
[µl] 
1 720.0 - 
2 718.2 1.8 
3 716.4 3.6 
4 714.6 5.4 
5 712.8 7.2 
6 711.0 9.0 
7 707.4 12.6 
 
Table 1: Scheme for the preparation of a PEG standard curve. 
 
As a reference to the PEGylated GNP, the same volume of GNP dispersion 
already used for the preceding PEGylation was pipetted in an EppendorfTM tube 
and mixed with 720 µl of borate buffer pH 8.5. After the centrifugation (25 155 g 
for 15-30 min) of the reference and PEGylation caps, 36 µl of each supernatant 
were transferred into EppendorfTM tubes and mixed with 684 µl of borate buffer 
pH 8.5. Then, 180 µl of BaCl2 solution and another 180 µl of iodine solution were 
added. The solutions for the standard curve were also treated in this way. At last, 
300 µl of the reference, PEGylation and standard curve caps were each triply 
plated on a 96 well plate and immediately red out with a photometer (Tecan 
Systems Inc, San José, USA) at 590 nm. 
 
4.2.2 Preparation and characterization of PEGylated and glycine-linked 
GNPs 
4.2.2.1 Preparation of PEGylated and glycine-linked GNPs 
The starting PEG solution was prepared as 600 µl of a 0.3 % (w/v) solution of α-t-
butyloxycarbonylamino-ω-carboxy succinimidyl ester poly(ethylene glycol) 
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(11700 Da) in borate buffer pH 8.5 were prepared. About 1 ml of a 0.1 % (w/v) 
solution of glycine in 0.2 µm filtered HPW was also confected as an amino-group-
carrying model for this coupling trial. 19 µl of this solution were then pipetted 
into the PEG solution so that a molar excess of glycine was existent. Incubation 
took place for 60 minutes at 28 °C and under constant shaking (750 rpm). 
Afterwards, 40 µl of 2 M HCl were added and shaking was continued for another 
30 minutes. The pH was finally adjusted to 8.6 with 1 M NaOH and the solution 
was diluted to 0.1 % (w/v) of PEG. So, it was used to PEGylate fluorescent-
labeled GNP analogous to the standard preparation protocol. However, this time 
volumes of 240 µl, 160 µl and 80 µl of the glycine-linked PEG solution were 
necessary. 
 
4.2.2.2 Characterization of PEGylated and glycine-linked gelatin 
nanoparticles via TNBS assay 
First, a 0.1 M borate buffer pH 9.2 was prepared by dissolving 2.00 g of borax in 
approximately 90 ml of HPW by heating and under stirring. When this solution 
was completely cooled down to room temperature, further HPW was added until 
the 100 ml mark was reached. Thereafter, about 1 000 µl of a 0.1 % (w/v) solution 
of glycine in 0.2 µm filtered HPW were prepared. 100 µl of this solution and 900 
µl of 0.2 µm filtered HPW were mixed in an EppendorfTM tube (glycine solution, 
0.01 % (w/v)). Afterwards, the following solutions were each pipetted in an extra 
cap: 
 
 
borate buffer pH 9.2 
[µl] 
glycine solution,      
0.01 % (w/v)           
[µl] 
1 640.0 - 
2 633.6 6.4 
3 627.2 12.8 
4 620.8 19.2 
5 614.4 25.6 
6 608.0 32.0 
Table 2: Scheme for the preparation of a glycine standard curve. 
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After the centrifugation (25 155 g for 10 min) of the sample caps, 288 µl of each 
supernatant were transferred into EppendorfTM tubes and mixed with 352 µl of 
borate buffer pH 9.2. Then, 200 µl of the sample and standard curve caps were 
each triply plated on a 96 well plate. Right before the photometric analysis at 405 
nm, 2 µl of 2.5 % (w/v) 2,4,6-trinitrobenzene sulfonic acid (TNBS) solution were 
added to each well. 
 
4.2.3 Preparation of DOTA- and RGD-linked radio labeled gelatin 
nanoparticles 
All experimental work related to radioactivity and was conducted in cooperation 
with the group of Prof. Wester, Department of Nuclear Medicine, Technical 
University Munich. The DOTA-Ga-labeling concept was conceived together with 
Dr. J. Auernheimer. Injections, sectioning and PET imaging of animals were 
performed by veterinarian K. McGuire and admitted staff.  
At first, about 1.1 ml of a 0.1 % (w/v) 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) isothiocyanate (NCS) solution in dimethyl sulfoxide 
(DMSO) were prepared (DOTA-NCS solution). About 1 ml of a 0.1 % (w/v) 
arginine-glycine-aspartic acid (RGD) solution in DMSO was also confected 
(RGD solution). Both solutions were stored at - 20 °C. Furthermore, a third 
solution consisting of 1650 µl of 0.1 M HCl and 150 µl of 2.5 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer was prepared 
(reaction solution). Thereafter, a volume of aqueous fluorescence labeled and 
PEGylated GNP dispersion according to 1 mg of completely dried particles was 
twice pipetted into an EppendorfTM tube and mixed with 20 µl of DOTA-NCS 
solution and another 20 µl of  RGD solution (in a variant approach no RGD 
solution was added). Then, both reaction tubes were filled up at 400 µl with 0.2 M 
borate buffer pH 8.5. Alternatively, RGD was first coupled to PEG and 
subsequently the construct was coupled by at pH 8.4 to the GNPs (Fig. 1). 
Incubation took place for 4.5 hours at 36 °C and under constant shaking (750 
rpm). Finally, the particles were purified by centrifugation (20 000 g for 8 min) 
and redispersion in 400 µl of 0.2 µm filtered HPW. They were stored as 
dispersion in darkness at 4 °C. Right before application, this dispersion was 
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centrifuged again at 13 000 rpm for ten minutes (Heraeus, Langenselbold, 
Germany). Then, the sediment was dissolved in 150 µl of reaction solution. After 
the addition of 1650 µl of Ga-68 eluate and 150 µl of 2.5 M HEPES buffer, both 
samples were incubated for ten minutes at 80 °C in an oil bath. Afterwards, they 
were centrifuged again at 13 000 rpm for nine minutes (in a variant approach two 
purification steps by centrifugation were employed). Each sediment was dissolved 
in 200 µl of 0.9 % (w/v) NaCl solution. The resulting dispersions were finally 
filtrated through a 5 µm filter and 100 µl were each filled into a syringe. 
Radioactivity was measured with a CRC 15-R dose calibrator (CAPINTEC, 
Ramsey, USA). 
 
Fig. 1: Reaction scheme for a RGD-PEG construct coupled to the GNP surface.  
 
4.2.4 Preparation of Alexa 633 and 111In-labeled gelatin in solution 
Fluorescent labeling by covalent coupling of Alexa 633 (Invitrogen, Carlsbad CA, 
USA) to gelatin molecules was carried out after the first desolvation step 
according to the standard protocol. Afterwards, the gelatin gelatin solution freed 
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from the low molecular weight fraction was allowed to react with DOTA-NCS 
100:1 (w/w) in borate buffer 0.2 M at pH 8.4 for 2 h. After covalent binding of the 
chelator to the macromolecule, the radiolabeling was performed by the addition of 
0.2 M NH4Ac buffer till pH 4.5 was reached and 40 µl of 111In solution for 
radionuclide introduction at 80°C for 10 min. Total volume did not exceed 1.5 ml. 
After radiolabeling, fractionation and separation from free 111In was performed. 
Finally, 12 fractions of 1.0 ml each were collected after introducing the 1.5 ml 
reaction volume and 12 ml of HPW onto disposable PD-10 desalting columns 
(medium: SephadexTMG25; GE Healthcare Europe, Munich, Germany). The 
fractions were subsequently analyzed for contained activity by the CRC 15-R 
dose calibrator and further used depending on their measured activity.  
 
4.2.5 Biodistribution study via non-invasive positron emission tomography 
(PET) 
GNPs tumor-bearing CD-1 nude mice (Charles River, L’Arbresle, France; M21 
melanoma cells injected s.c. in house) were first anesthetized with 2 % (v/v) 
isoflurane and fixed on the PET examination table. 200 µl of 68Ga-labeled GNP 
dispersion (were then injected subcutaneously 0.5 cm away from the tumor. PET 
pictures (small animal PET MOSAIC, Philips Healthcare, Eindhoven, 
Netherlands) were taken over a period of two hours. 
 
4.2.6 Conventional biodistribution study via γ counter 
Bulb/c mice and tumor-bearing CD-1 nude mice were anesthetized with diethyl 
ether. After 100 µl of GNP dispersion or gelatin solution were either injected into 
the tail vain (bulb/C mice for biodistribution studies) or subcutaneously 0.5 cm 
away from the tumor or on the opposite body site (CD-1 nude mice for tumor 
targeting study), the mice awoke from narcosis and survived further 2 – 24 hours 
before they were scarified by CO2. PET mice were scarified the same way. Then, 
the following organs and were explanted and examined using a γ counter (Wallac 
1470, Turku, Finland): heart, lung, liver, pancreas, spleen, kidney, adrenal gland, 
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bladder, muscle (tumor and opposite body site), stomach, small and large 
intestine, tail and not least tumor. Also blood and urine were investigated.  
4.2.7 Confocal laser scanning microscopy (CLSM) of tumor tissue 
After the organs were explanted and radioactivity was determined via γ counter, 
tumor tissue frozen sections of 10 µm of thickness were prepared and stained with 
Hoechst 33342 to identify nuclei. Consecutively, they were examined with a Zeiss 
510 LSM NLO confocal laser scanning microscope (Carl Zeiss Microscope 
Systems, Jena, Germany). 
 
4.3 Result and Discussion 
4.3.1 The impact of particle size and concentration on biodistribution 
Intravenous administration of nanoparticles deserves careful evaluation of 
possible risks by particle accumulation in sensitive organs and aggregation in 
spots of the circulation system that might cause undesired side effects. Zwiorek 
observed a massive lung accumulation of positively charged 18F-labeled GNPs 
(Zwiorek 2006).  
Consequently, a new challenging scenario with a concentration of 2 mg/ml and 
large 68Ga-labeled GNPs of 390 nm was approached in the experiment reported in 
Fig. 2. 
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Fig. 2: (A) Ex vivo biodistribution of 68Ga-labeled GNPs of 390 nm after 4 h of 
i.v. injection in bulb/C mice (n=3, ± S.D.). The sum of individual organ values 
exceeded 100% to some organs’ weight below 1.0 g. (B) Matched CLSM and 
autoradiography pictures confirm GNP accumulation in the lung but not in liver 
tissue. 
 
Clearly, after 4 h almost the whole injected dose ended up in the lung. Although 
the animal survived till the time point of sacrifice without any clinical symptoms, 
this situation constituted a potential danger. Therefore, concentrations were kept 
below 1 mg/ml in all further applications and injected volumes did not exceed 250 
µl even for the PET examinations to ensure not more than 250 µg of GNPs enter 
the bloodstream at a time. 
 
4.3.2 Quantification of PEGylated gelatin nanoparticles via PEG assay 
PEG-coated nanoparticles are expected to exhibit a prolonged circulation in blood 
so that a better targeting effect towards tumor cells can be achieved (Torchilin 
2007). As PEGylation of drug carrier systems was discussed to provide further 
advantageous effects, this study focused on PEGylated GNP both for s.c. and i.v. 
administration.  
Before the first in and ex vivo experiments with PEGylated GNP were started, we 
tried to establish a method for the indirect quantification of successfully bound 
PEG based on the Childs assay (Childs 1975). Therefore, an aliquot of aqueous 
B 
liver 
lung 
120                                   Enlargi  the analytical oolbox for gelatin nanoparticles                         
Formulation development of plain gelatin nanoparticles   121 
 
 
GNP dispersion was incubated with a solution of α-methoxy-ω-
aminopoly(ethylene glycol) in borate buffer so that the residual aldehyde groups 
on the GNP surface reacted with the terminal PEG amino groups (Fig. 3). GNPs 
were then separated via centrifugation. Finally, the supernatant theoretically 
consisting of only non-bound excessive PEG in borate buffer was further diluted 
and photometrically analysed after the addition of both, BaCl2 and iodine solution. 
With the aid of a standard curve (data not shown), the amount of non-bound PEG 
was determined. This rendered possible to make a statement concerning 
PEGylation success.  
N
O
HCH3
H
+ mPEG-NH2
N
HCH3
H
N mPEG
> 2h, 35 °C, pH 8.5, 800 rpm
+ H2O
 
Fig. 3: Reaction scheme for the PEGylation of GNP; mPEG-NH2: CH3O-
(CH2CH2O)n-CH2CH2-NH2.  
 
Fig. 4 shows the percentage of non-bound excessive PEG in six different 
PEGylation approaches. Three different PEG:GNP weight to weight ratios were 
investigated as well as two different total PEGylation volumes. Every data point 
in the figure below displays the mean of three individual samples. Measurement 
data was obtained in time intervals of one minute. 
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Fig. 4: Percentage of non-bound excessive PEG in six different PEGylation 
approaches; 0.1/0.2/0.3:1: weight to weight ratio of PEG:GNP, (1): 800 µl of 
total PEGylation volume, (2): 200 µl of total PEGylation volume; each point 
represents the mean of three individual samples (n=3). 
 
As values indicate, far more than 100 % of non-bound PEG [see 0.2:1 (1) and 
0.1:1 (2)] was found as artefacts. Consequently, this quantification method should 
be considered critically. False positive values obviously contribute to non-
representative results. Due to the fact that the causes for these results still remain 
unclear, future quantifications of successfully bound PEG should be carried out by 
another method. Asymmetrical flow field-flow fractionation combined with 
refractive index detection for example is an established method for the 
quantification of PEGylated GNP drug carrier systems (Zillies et al. 2007). 
Nevertheless, this assay permits to make some qualitative statements. Thus, a 
smaller total PEGylation volume seems to be more capable for a successful 
PEGylation than a larger one. Also PEG:GNP ratios of more than 0.1:1 in 200 µl 
of total volume lead to better PEGylation results. Not least, the assay does not 
depend on time as we first expected because of decreasing absorption values. 
Further experiments (data not shown) confirmed this hypothesis by showing that 
the results for the amount of non-bound PEG were almost constant over a time 
period of at least half an hour. 
However, a further PEG assay experiment showed a PEGylation success of 
approximately 91 %. This time, α-t-butyloxycarbonylamino-ω-carboxy 
succinimidyl ester poly(ethylene glycol) was used instead of α-methoxy-ω-
aminopoly(ethylene glycol). Future experiments will show if this approach is 
generally superior to the one generally employed before. Reproducibility for 
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example needs to be tested in more detail.   
 
4.3.3 Quantification of PEGylated and glycine-linked gelatin nanoparticles 
via TNBS assay 
The use of peptides as targeting agents leads to an increased intracellular drug 
delivery in different murine tumor models. In this study, GNPs were therefore 
coupled to RGD which is the ligand of cell adhesion integrins on endothelial cells 
(Peer et al. 2007). 
It was aimed to quantify successfully bound RGD by using the TNBS assay, we 
first had to find a model peptide or amino acid that reacts the same way RGD does 
but is less expensive. It was finally decided in favor of glycine. 
At first, a molar excess of glycine was incubated with a solution of α-t-
butyloxycarbonyl-amino-ω-carboxy succinimidyl ester poly(ethylene glycol) in 
borate puffer so that the glycine amino groups were allowed to react with the 
terminal carboxyl succinimidyl ester groups. Thereafter, 2 M HCl was added to 
free the boc-shielded PEG amino groups. The resulting solution was finally 
alkalized again and diluted so that it could be used for the PEGylation of GNP 
analogous to the reaction scheme described in Fig. 3. Afterwards, GNPs were 
separated via centrifugation. The supernatant was further diluted and 
photometrically analysed after the addition of TNBS solution. As TNBS generally 
binds to free amino groups, not only residual glycine molecules are detected. 
Glycine-linked PEG molecules that did not bind to the aldehyde groups on the 
GNP surface also give positive results due to their free PEG amino group. This 
renders it possible to make a statement concerning the success of GNP glycine-
linkage. Whether glycine was directly bound to the GNP surface or via a PEG 
spacer can not be determined with this assay. Therefore a combination of both, 
PEG and TNBS assay is recommended for further experiments.  
Tab. 3 shows the amount of non-bound excessive glycine and glycine-linked PEG 
per well in three different PEGylation approaches. Thus, PEG:GNP weight to 
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weight ratios of 0.1:1, 0.2:1 and 0.3:1 were investigated. Every calculated value 
displays the mean of three individual samples. 
 
PEG:GNP ratio 0.1:1 0.2:1 0.3:1 
non-bound glycine 
and glycine-linked 
PEG per well [µg] 
-0.170 0.072 0.183 
Tab. 3: Amount of non-bound glycine and glycine-linked PEG per well [µg] in 
three different PEGylation approaches; 0.1/0.2/0.3:1: weight to weight ratio of 
PEG:GNP; every calculated value displays the mean of three individual samples 
(n=3). 
 
Although the amino acid was initially added in a molar excess, no residual glycine 
or glycine-linked PEG could be determined when the PEG:GNP weight to weight 
ratio was 0.1:1. Glycine that was not coupled to PEG was presumably directly 
bound to the GNP surface. In the next investigated weight to weight ratios of 0.2:1 
and 0.3:1 residual glycine or glycine-linked PEG could be detected, respectively. 
In both cases, the possible amino group binding sites on the GNP surface seemed 
to be saturated. According to this, the weight to weight ratio of 0.3:1 led to a 
larger amount of excessive glycine or glycine-linked PEG than the weight to 
weight ratio of 0.2:1 did. Due to several dilution and pH adjustment steps during 
the preparation procedure, we were unfortunately not able to retrace the 
concentration of glycine in the PEGylation solution. Therefore, the results could 
not be presented in percentages.    
 
4.3.4 In vivo and ex vivo studies of s.c.-administered modified GNPs  
In the following experiments, we continuously employed fluorescence and 
radioactive labeled GNP to track biodistribution in tumor-bearing CD-1 nude 
mice. That way, the success of an active tumor targeting could be proved. Our 
main results are presented below. 
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4.3.4.1  Biodistribution study via non-invasive positron emission 
tomography (PET) 
In comparison to ex vivo experiments, PET offers the possibility to follow 
biodistribution in living individuals. PEGylated and fluorescence labeled GNPs 
were therefore coupled to DOTA-NCS and RGD. The former was absolutely 
necessary because it directly binds deprotonated amino groups on the GNP 
surface and complexes later added radioactive Ga-68 that can be detected by PET. 
RGD was incidentally added due to its supposed active tumor targeting properties. 
Finally, 100 µl of the radio-labeled GNP dispersion purified from free, 
uncomplexated radionuclides were administered subcutaneously to a tumor-
bearing CD-1 nude mouse. Injection took place 0.5 cm away from the tumor. 
Thereafter, PET pictures of the anaesthetized mouse were taken over a period of 
two hours.   
                     
 Fig. 5: CT picture (left) of a tumor-bearing CD-1 nude mouse (posterior view)    
and PET pictures (right) indicating GNP biodistribution one minute post injection 
(top) and 120 minutes post injection (down); the pictures aren’t identical in scale.  
 
Fig. 5 firstly shows a computer tomography (CT) picture (left) of a tumor-bearing 
CD-1 nude mouse in posterior view. The tumor as well as the injection site are 
marked. Further, PET pictures (right) indicating GNP biodistribution one as well 
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as 120 minutes after s.c. GNP application are mapped. They confirm that GNP 
remain at the injection site where they form a depot or partially immigrate into 
tumor tissue. Due to the half-life of Ga-68 (68.3 min), the PET picture down right 
shows a lower signal than the one above.  
 
4.3.4.2  Conventional biodistribution study via γ counter 
In this study, we examined murine GNP biodistribution by measuring 
radioactivity with a γ counter in several organs explanted 120 minutes after s.c. 
injection of a radio labeled GNP dispersion.  
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Fig. 6: Biodistribution of Ga-68 labeled but non-RGD-linked GNP (180 nm) in 
tumor-bearing CD-1 nude mice 120 min after s.c. injection either on tumor side 
(blue) or on the opposite body side (purple; % ID/g). Each point represents the 
mean of three investigated mice (n=3 ± S.D.).  
 
Fig. 6 shows the biodistribution of Ga-68 labeled but non-RGD-linked GNP of 
180 µm in diameter in tumor-bearing CD-1 nude mice. The GNP dispersion 
(radioactive yield: 65 %) was either injected subcutaneously 0.5 cm away from 
the tumor or on the opposite body site. Each point in the figure above displays the 
mean of three investigated mice. 
This study clearly demonstrates that GNP tumor uptake is only successful when 
the GNP dispersion is injected subcutaneously close to the tumor. Injection on the 
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opposite body side obviously does not lead to higher GNP concentrations in the 
tumor than in all the other examined organs. However, biodistribution was only 
investigated over a period of two hours before the mice were scarified and the 
organs were explanted. As this time-frame was very tight, the major part of GNP 
remained in blood or in the depot at the injection site. Probably, an active tumor 
targeting also of the particles that were injected on the non-tumor-bearing side 
could be observed by elongating biodistribution time. Nevertheless, such a high 
GNP tumor site accumulation was not expected due to an increased GNP uptake 
in other organs such as the kidney.        
Fig. 7 also shows the biodistribution of Ga-68 labeled GNP in tumor-bearing CD-
1 nude mice. This time, the GNP dispersion was injected subcutaneously 0.5 cm 
away from the tumor. We employed either a dispersion of RGD-linked GNP (250 
nm; radioactive yield: 52 %) or a dispersion of non-RGD-linked GNP (180 nm; 
radioactive yield: 65 %). Each point in the figure below displays the mean of four 
and three investigated mice, respectively. 
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Fig. 7: Biodistribution of Ga-68 labeled GNP in tumor-bearing CD-1 nude mice 
120 min after s.c. injection on tumor site (% ID/g); green: RGD-linked GNP, 250 
nm, n = 4, blue: non-RGD-linked GNP, 180 nm, (n = 4, ± S.D.).  
 
This experiment indicates that GNP accumulation in the tumor is dependent from 
particle size and/or possibly from RGD-linkage. We were able to observe that 
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non-RGD-linked smaller particles considerably led to higher tumor uptake rates 
than RGD-linked larger particles. This is surprising because RGD is generally 
known for its active tumor targeting properties. However, particle size should not 
be underestimated. Maybe, higher GNP tumor uptake occurs due to smaller 
particles and is not influenced by RGD-linkage. Continuative experiments 
possibly using RGD-linked and non-RGD-linked particles of the same size could 
clarify this circumstance. We further found out that RGD-linked larger GNP led 
to higher uptake rates in the other organs than non-RGD-linked smaller particles 
did. This is probably due to the fact that RGD does not specifically bind to cancer 
cells but also to other integrin expressing cells (Peer et al. 2007). 
 
4.3.4.3 Confocal laser scanning microscopy (CLSM) of tumor tissue 
Aside from radioactive labeling, GNPs were additionally fluorescence labeled. 
Consequently cell trafficking could easily be tracked in tumor tissue frozen 
sections of 10 µm of thickness. To avoid interference with tissue 
autofluorescence, Alexa® 633 that is known for red light emission was used 
instead of standard Alexa® 488 for labeling GNPs. The dye directly bind to amino 
groups on the GNP surface and can be detected by CLSM.   
 
Fig. 8: Hoechst-stained frozen section (10 µm) of M21 tumor tissue comprising 
truncated vessels; blue: nuclei, red: GNP (see arrows). Inner diameter of 
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centrally pictured vessel about 20 µm. 
 
Fig. 8 shows a Hoechst-stained frozen section of M21 tumor tissue explanted 120 
minutes after s.c. GNP (180 nm) injection on tumor site. Hoechst 33342 is a 
fluorescence dye emitting blue light upon laser excitation. As it intercalates DNA, 
it is generally used for marking nuclei. Hence, cell nuclei appear blue in the 
CLSM shoot above whereas GNP emit red light (see arrows). This experiment 
finally confirms the preceding biodistribution results. Thus, PEGylated (13 kDa, 
Fig. 2) GNP are able to escape into tumor tissue and to accumulate there. 
 
4.3.5 In vivo and ex vivo studies of i.v.-administrated plain and PEGylated 
GNPs 
In this study, it was attempted to gain more insight about the impact of 
PEGylation on the circulation properties of GNPs. This was of special interest as  
recently Cho et al. could not confirm a higher blood circulation time or superior 
passive tumor targeting of all PEGylated GNP-doxorubicin formulations in 
general (Cho et al. 2006; Cho et al. 2007). This backs previous findings of our 
group (Zwiorek 2006), as no significant difference in prolonged circulation time 
or increased passive tumor accumulation between PEGylated and non-PEGylated 
GNPs could be found.  
In brief, GNPs were grafted with 5 kDa PEG via an imine bond between the PEG-
polymer and the GNP surface as described earlier (Zillies et al. 2007) and labeled 
by 123I radioiodination (Zwiorek 2006). 15 and 60 min post injection organ 
inspection by a γ-counter, GNP concentrations did not differ in all examined 
organs including the blood (Zwiorek 2006).  
Additionally, when coupling larger 13 kDa PEG covalently to the GNP surface by 
stronger amid bonds as described above for the s.c.-related administration, no 
increased blood circulation times were found (Fig. 9). The latter setup ruled out 
that an early hydrolysis of a too weak linkage was the reason for the missing 
differentiation of PEGylated versus non PEGylated GNPs. As a conclusion from 
these findings, it can be hypothesized that colloidal carriers that already feature 
high hydrophilic properties such as gelatin and an in situ steric heterogeneous  
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Fig. 9: Ex vivo biodistribution and PEGylated (13 kDa) 111In-labeled GNPs of 
250 nm in balb/C mice (n=4, ± S.D) after injection into the tail vain. Radioactivity 
Concentrations are given as per cent of the injected dose per g (%ID/g). 
 
surface with hindrance properties are less accessible for the proven and 
undoubtful PK enhancements attributed to PEG when combined with hydrophobic 
delivery systems or therapeutic proteins (Jevsevar et al. 2010).  
Evaluating the full blood recovery of GNP-linked activity of another batch 
confirmed the finding depicted in Fig. 10. 
 
 
 
 
 
 
 
 
 
 
Fig. 10: Full blood recovery of 111In-labeled PEGylated and non-PEGylated 
GNPs over a time period of 24 h (n=3, ± S.D.).  
 
Here it is shown, that the PEGylation (13 kDa) had no significant influence on the 
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circulation time of GNPs. 
Another finding from the ex vivo sectioning was that GNPs biodistribution is size 
depending at least in part, as the lung accumulation rises with the mean diameter 
and vice versa. This was in accordance with previously reported size effects on 
distribution and even intracellular effects (Jiang et al. 2008; Minchin 2008).  
While radiolabeling was widely conducted with protein nanoparticles for 
conservative biodistribution studies and PET was applied for a variety of 
nanoparticle-based trials (Cheon et al. 20091112) no successful employment of 
PET studies was yet carried out on protein-based nanoparticles. Therefore, one 
attempt used N-succinimidyl-[18F] fluorobenzoate PET-suitable prosthetic group 
to be linked to the GNPs. While the labeling process was successfully performed, 
too high in vivo concentrations were needed for adequate imaging (Zwiorek 
2006). However, a safe formulation suitable for PET imaging was obtained when 
using DOTA as a chelator and 68Ga3+ as radionuclide (Fuchs et al. 2008). Here, 
radiochemical yield was up to 75% and radiochemical purity in the final 
preparation reached 98.5%.  
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Fig. 11: Combined PET/CT online imaging of 68Ga-labeled GNPs 10, 50 and 100 
seconds post injection into the tail vain with the left column representing coronal 
plane view (head upwards) and the right column representing sagital plane view. 
Brighter color represents respectively higher particle accumulation. 
 
The biodistribution of this protein nanoparticulate formulation could be tracked 
online for the first time by combined small animal PET/CT (Fig. 11).  
Furthermore, ex vivo sectioning of organs after administration of dually 
fluorescence and 68Ga3+ labeled GNPs revealed the co-localization of activity 
marker and particles. Therefore, the particle double-checked distribution data 
based on radiolabeling alone could be seen as robust. Furthermore, flanking ex 
vivo trials proofed the difference in biodistribution for the pure macromolecular 
gelatin and GNPs (Fig. 11). 
 
4.3.6 Differentiation of biodistribution profiles of soluble gelatin in from 
GNPs: particles matter. 
To evaluate the biodistribution properties of GNPs upon i.v. administration, it is 
essential to adequately attribute the acquired data to the particle quality. Gelatin as 
a hydrophilic macromolecular should decisively contribute to the particle surface 
characteristics such as the similarity to other PEGylated particles in hydrophilic 
properties. However, the proof that the GNP biodistribution properties were 
linked more to their particulate nature than to their constituting material alone was 
not yet provided. Therefore, a suitable 111In-labeld gelatin fraction was gained by 
employing a PD-10 desalting column to separate unbound nuclide (which was 
trapped in the column) from successfully labeled gelatin macromolecule 
(see 4.2.4). 
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Fig. 12: Histogram of 1 ml fractions of 111In-labeled gelatin solution, 
fractionized by a PD-10 desalting column with a size cut off of approx. 5 kDa. 
 
The forth fraction (3000 – 4000 µl) featuring the highest activity was chosen 
(Fig.12) to obtain high signal responses. Furthermore, this relatively early eluated 
fraction should represent a high molecular weight fraction which also served as 
starting material in the manufacturing process of GNPs. However, MWs could not 
be determined within this study. 
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Fig. 13: Ex vivo biodistribution of 111In-labeled soluble gelatin in balb/C mice 
after injection into the tail vain. Radioactivity concentrations are given as per 
cent of the injected dose per g (%ID/g) (n=1). 
 
In contrast to GNPs (Fig. 9), gelatin as a soluble molecule did not accumulate in 
lung, spleen or liver. On the contrary, it was renally eliminated rapidly as revealed 
by the activity peak in the urine after 90 min (Fig. 13). While the non-
accumulation could be seen as positive from a toxicological point of view -if 
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gelatin was toxic at all- the non-retention in the blood appeared as striking. 
Injected doses did not peak beyond 2% ID/g while GNPs initially could reach up 
to 10% despite PEGylation.  
Moreover, lower particle sizes such as 250 nm (Fig. 9) revealed beginning of lung 
clearance already between the 5 and 90 minutes measuring point. In the 
corresponding extend, accumulation progressed in the liver, although this process 
is size depending, too. Nevertheless, it could be concluded that the i.v. 
administration as for many other nanocarriers is not the first choice when a 
specific targeting beyond the preferential MPS organs is of interest. Surface 
grafting of targeting structures -in the present case the RGD tripeptide- may not 
always compensate the particle-associated undesired biodistribution patterns. 
Therefore, further studies concentrated on immunotherapy via alternative routes 
of administration such as s.c. and inhalative. They were chosen to ensure a 
sufficiently long time of pharmacodynamic action before degradation or 
elimination of the drug-loaded nanocarrier system could occur to a larger extend.  
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IV Gelatin nanoparticles as a valuable tool in immunotherapy 
1. Immunotherapy by nucleic acids – why? 
1.1 Historical perspective 
The idea to trigger the immune system for antitumoral action looks back on a long 
development originally coming from the observed interrelation of infections and 
tumor regression (Thotathil and Jameson 2007). Coley was the first to 
systematically introduce related research and reported a coherence between 
erysipelas and cancer remission (Coley 1893). Furthermore, he made a liquid 
preparation containing bacterial lysates of Streptococcus pyogenes and Serratia 
marcescens which was known for decades to elicit fever and immune activation in 
general. However, the biomolecular mechanisms and possible implications on 
more specified therapeutic applications were revealed only in the last 15 years. 
Specific short DNA strands were identified as the main trigger of 
immunostimulation within the bacterial lysate (Tokunaga et al. 1984). These short 
methylated oligonucleotides featured palindromic CpG-motifs responsible for B-
cell activation (Krieg et al. 1995). Furthermore, contained lipopolysaccharides 
(LPS) were shown to be involved in IL-12 induction, a cytokine which is known 
for its Th1 pathway inducing properties (Tsung and Norton 2006). Most recently, 
involvement of the CpG-ODN as pathogen associated molecular pattern (PAMP) 
recognizable by a pattern recognition receptor (PRR) was confirmed in Coley’s 
toxin (Hobohm et al. 2008). Today, synthetic CpG-motifs containing ODNs 
represent a potential new group of therapeutics involved in several clinical trials. 
The expected growth here is underlined by the fact that the CpG-manufacturing 
Coley Pharmaceutical Group was acquired by Pfizer in 2008. However, no CpG-
based product has yet reached the market beyond clinical phase III and a suitable 
carrier seems to be of advantage in related efforts (see Chapter I). 
 
1.2 The principle of CpG-mediated immunostimmulation 
Artificial CpG oligonucleotides are agonists for a member of the PRR family 
signalling through an endosomal membrane based type receptor, the Toll-Like 
Receptor 9 (TLR9) (Angel et al. 2008; Wernette et al. 2002). The name “Toll-like 
receptor” was not derived from the English word toll in the meaning of fee but 
instead was coined by Nobel price laureate Nüsslein Vollhard of Tübingen who 
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described the molecular biologic discovery as “toll” referring to “great” in 
German. The discovery was rather accidental by realizing that a knock out of 
TLRs resulted in increased sensitivity of Dosophila flies to fungical infection 
(Lemaitre et al. 1996). Subsequently, these structures were identified as highly 
conserved in higher species to include humans. 
 
 
Fig. 1: Survey on intracellular TLR-7 and TLR-9-mediated signalling MyD88-
dependent pathways and the role of GNPs as a potent TLR-agonist delivery 
device. MyD88 is an essential Toll/IL-1 receptor (TIR) domain-containing 
adaptor for the induction of inflammatory cytokines via all the TLRs. Upon 
stimulation, MyD88 recruits IL-1 receptor-associated kinase (IRAK) to TLRs 
through interaction of the death domains of both molecules. IRAK is activated by 
phosphorylation and then associates with the TNF receptor associated factor 
(TRAF6), leading to the activation of two distinct signaling pathways, and finally 
to the activation of c-Jun N-terminal kinases (JNK) and nuclear factor kappa-
light chain-enhancer of activated B cells (NF-kB) transcription factors for the 
translation of effector proteins such as cytokines. 
 
CpGs were shown to influence several signalling pathways in a variety of immune 
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cells, leading to cytokine production in many mammalian species (Zwiorek et al. 
2004; Zhao et al. 2010) (Fig. 1). It appears that the specific purines and 
pyrimidines surrounding the CpG motif, phosphothioated backbone, as well as the 
spacings between CpG motifs may influence both the level and the type of 
immune stimulation (Krieg et al. 1995; Mutwiri et al. 2003). CpG motifs improve 
the antigen presenting function of dendritic cells (DCs), monocytes and 
macrophages, induce the proliferation of B lymphocytes, stimulate the 
immunoprotective activity of natural killer (NK) cells, and recruit T cells to the 
site of ODN administration (Coester et al. 2006; Torchilin 2007; Zwiorek et al. 
2008). Recent studies showed that the immune system responds to CpG motifs by 
activating potent Th1-like immune responses which can be harnessed for immune 
therapy of cancer, allergy, infectious diseases (Krieg 2002), autoimmune diseases, 
and sterile inflammation (Kanzler et al. 2007). Consequently, CpGs may also be 
used as potent adjuvant for vaccines which was a central delivery application for 
the present GNPs  (Bourquin et al. 2006; Bourquin et al. 2008) also by directly 
activating plasmoidal dendritic cells (pDCs) and subsequently B-cells without the 
involvement of T-cells (Poeck et al. 2004). As illustrated in Fig. 1 (chapter V, 
3.1), the Th1 pathway activation elicits T cell (CD8) response (Bourquin et al. 
2006) e.g. via IL-12. This was proven in prophylactic anticancer studies involving 
GNP-bound CpG (Bourquin et al. 2008).   
 
1.3 Other nucleic acid-derived therapeutic strategies 
Molecular DNA or RNA therapy is an upcoming approach to controvert difficult 
to treat diseases by engaging in transcriptional processes. Transcriptional factors 
are nucleus based proteins that can have a boosting or alleviative effect on gene 
expression. These TFs recognize their own short binding region even in absence 
of neighbouring genomic DNA. This makes synthesized ODN with consensus 
base sequences a possible therapeutic option to manipulate gene expression 
(Mann and Dzau 2000).  
Decoy ODNs inhibit the binding of a TF, for example the promoter region of the 
cytoplasm based NF kappa B receptor. Thereby they prevent this transcription 
factor from inflammatory interactions with its target genomic DNA in the nucleus. 
Other transcriptional interfering strategies all target the mRNA level like antisense 
ODNs, ribozyme ODNs and RNAi. First therapeutic successes were achieved in 
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the fields of retinopathy, restenosis, glomerulonephritis and rheumatoid arthritis 
(Morishita et al. 2004). 
 
1.4 Nucleic acid-based immunotherapeutic strategies against cancer 
As mentioned above, Coley found prolonged resistance against cancer upon 
treatment by his bacterial-derived toxin. Since TLR-9 activation by CpG motifs 
was identified as decisive for antitumoral action, the insight into related 
immunologic fundamentals pathed the way towards CpG-based immunotherapy 
against cancer (Krieg 2002; Krieg 2006). Of central importance was the ability, to 
overcome T-cell anergy by the adjuvant properties of CpGs. However, this 
essential adjuvant ability was proven not to be applicable exclusively for TLR-9-
mediated CpG action (Hornung et al. 2002; Heil et al. 2004), but moreover for 
TLR-7-mediated RNA effects which is demonstrated in the following. In order to 
achieve a specific immune reaction against a cancer target, immune cells need to 
be primed against relevant cancer-specific antigens. In the current studies, 
Ovalbumine (OVA) was used as an established and potent model antigen. 
However, for future targeted therapeutic strategies, real tumor-expressed antigens 
need to be included such as pancreas cancer-expressed surface protein survivin 
(SVV) also referred to as BIRC5 (Altieri 2003). The importance of this field of 
tumor-specific antigen-directed anti-cancer immunotherapy is stressed by the fact 
that the FDA approved the first therapeutic cancer vaccine Provenge® 
(sipuleucel T) in April 2010 for the treatment of hormone-refractory prostate 
cancer (Bordon 2010). 
 
2. Antitumoral response triggered by GNP-bound RNA to agonist TLR7 
Introduction 
 
The capacity of GNPs to function as RNA carrier is demonstrated in the following 
insert which cites a joint pre-review manuscript for publication by the Center for 
Integrated Protein Science Munich and Divison of Clinical Pharmacology, 
Department of Internal Medicine (*), Ludwig Maximilan University Munich, on 
the one hand and the Department of Pharmacy, Pharmaceutical Technology and 
Biopharmaceutics (†), Ludwig Maximilan University Munich, on the other hand. 
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Delivery of immunostimulatory RNA oligonucleotides by gelatin-based 
nanoparticles triggers an efficient antitumoral response 
 
Carole Bourquin*, Cornelia Wurzenberger*, Sebastian Fuchs†, David Anz*, 
Sarah Weigel*, Nadja Sandholzer*, Gerhard Winter†, Conrad Coester† and 
Stefan Endres* (CB and CW contributed equally to this work.) 
     
Introduction 
 
Upon viral infection, a strong immune response is elicicited through recogniciton 
of viral components by specific receptors of the innate immune system. Molecular 
patterns within viral nucleic acids are recognized by the pattern-recognition 
receptors TLR7 (single-stranded RNA sequences), TLR9 (CpG DNA sequences) 
RIG-I (5’-triphosphate RNA) and MDA-5 (double-stranded RNA) (Heil et al. 
2004, Hemmi et al. 2000, Hornung et al. 2006, Kato et al. 2006). A highly 
selective immune response can be induced by Synthetic DNA and RNA 
oligonucleotides containing these molecular patterns are a powerful tool to 
simulate an immune response in a highly selective manner. It is for instance well 
established that binding of synthetic CpG ODNs to TLR9 both promotes innate 
immunity and triggers the generation of a protective Th1-type immune response 
(Krieg 2007). In experimental models and in cancer patients, CpG ODNs 
enhanced cytotoxic T cell responses to tumor antigens upon vaccination (Brigger 
et al. 2002; Wurzenberger et al. 2009; Brazolot Millan et al. 1998; Brazolot 
Millan et al. 1998; Speiser et al. 2005). Furthermore, we have recently shown that 
RNA oligonucleotides can stimulate innate immunity through both the Toll-like 
receptor 7 and RIG-I receptors (Hornung et al. 2006; Hornung et al. 2004) and 
thereby induce efficient antitumoral responses (Bourquin et al. 2009, Poeck et al. 
2008). 
TLR7-activating RNA oligonucleotides act on several components of both the 
murine and the human immune systems: they trigger T and B cell responses to 
antigen (Bourquin et al. 2007), activate neutrophils (Janke et al. 2009) and 
antitumoral NK cells (Bourquin et al. 2009) and block the suppressive function of 
regulatory T cells experimental models and in cancer patients (Anz et al. 2010). 
We have demonstrated previously that these effects on different immune cell 
populations are directed by TLR7-expressing dendritic cells that control immune 
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activation through the production of a panel of cytokines (Anz et al. 2010; 
Bourquin et al. 2007). The therapeutic potential of TLR7 agonists is supported by 
encouraging results with a recently developed class of antitumor agents, the 
imidazoquinoline, that act in part through the activation of TLR7 (Hemmi et al. 
2002). The lead compound, imiquimod, is however only approved for the 
treatment of skin tumors by topical use and is effective against solid tumors only 
when applied locally (Broomfield et al. 2009). RNA ODNs thus form a new class 
of TLR7 agonists with promising therapeutic potential. Furthermore, RNA ODNs 
can be designed to include other antitumoral properties in the same molecule. The 
introduction of an inhibitory siRNA sequence permits silencing of tumor-
promoting genes that synergizes with the immunostimulatory activity of the RNA 
oligonucleotides to block tumor growth (Poeck et al. 2008). 
A key challenge for the therapeutic application of RNA ODNs is the need for 
efficient in vivo delivery to protect RNA ODNs from degradation, to promote 
cellular uptake and to target the RNA to the desired intracellular compartment 
(Whitehead et al. 2009). In this study we have investigated the efficacy of 
previously described cationized GNPs (Zwiorek et al. 2008) for the delivery of 
immunostimulatory RNA ODNs. Gelatin represents the advantage of being 
biodegradable and non-toxic and has been used in patients as a plasma expander 
for decades (Ward et al. 1977b). GNPs are stable during storage, show high 
stability after administration and can be easily scaled-up for manufacturing 
processes. Highly homogeneous GNPs of well-defined diameter can be generated 
by a two-step desolvation method (Coester et al. 2000). Furthermore, we have 
previously demonstrated that GNPs delivery enhances the CD8 T cell response 
triggered by CpG DNA oligonucleotides (Bourquin et al. 2008).  
Here we examined the immunostimulatory capacity of GNP-delivered RNA 
ODNs both in vitro and in vivo. We show that nanoparticle-delivered RNA ODNs 
strongly activate immune responses in a TLR7-dependent manner. GNPs enhance 
the uptake of RNA ODNs by immune cells and protect them from degradation. In 
addition, immunization with nanoparticle-bound RNA ODNs and a model antigen 
protected from tumor growth. We thus characterize a new formulation for 
immunostimulatory RNA ODNs that enhances their ability to induce a strong 
Th1-type immune response to antigen and trigger efficient antitumoral responses. 
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Materials and Methods 
Mice 
Female C57BL/6 mice were purchased from Harlan-Winkelmann (Borchen, 
Germany). Mice were 6 to 12 weeks of age at the onset of experiments. TCR 
transgenic OT-I mice were kindly provided by Dr. T. Brocker (Institute of 
Immunology, Munich, Germany). Animal studies were approved by the local 
regulatory agency (Regierung von Oberbayern, Munich, Germany). 
 
Reagents and cell lines 
The fully phosphorothioated 20-mer RNA oligonucleotides 9.2dr (5’-
UGUCCUUCAAUGUCCUUCAA-3’) (Hornung et al. 2004) and polyA were 
purchased from CureVac (Tübingen, Germany). For some experiments, 
fluorescein-5’-tagged RNA oligonucleotides were used (Metabion, Martinsried, 
Germany). The unmodified 9.2 triphosphate RNA (PPP-5'-
GCAUGCGACCUCUGUUUGA-'3) was produced by in vitro transcription in our 
laboratory (Hornung et al. 2006). Gelatin type A from porcine skin (175 Bloom) 
and chicken egg ovalbumin (OVA) were purchased from Sigma-Aldrich (St 
Louis, MO). The OVA-transfected B16-F10 cell line was kindly provided by Dr. 
T. Brocker. 
 
Preparation of cationized gelatin nanoparticles 
Gelatin nanoparticles were prepared in the Division of Pharmaceutical 
Technology and Biopharmaceutics at the University of Munich as previously 
described (Coester et al. 2000). Subsequently, cationization of the nanoparticles 
was achieved through introduction of a permanent quaternary amino group by 
covalent coupling of cholaminechloride hydrochloride onto the particle surface, as 
previously described (Zwiorek et al. 2008). Cationized particles prepared by this 
protocol were shown by Limulus amoebocyte lysate assay to be endotoxin-free 
(Coester et al. 2006). Unloaded particles were stable in size and ζ potential when 
stored as stock dispersion at 4°C for several months. For formulation with RNA 
oligonucleotides, particles were loaded with 5% (w/w) RNA oligonucleotides by 
shaking for 2 h at 800 rpm at room temperature. To evaluate the physical stability 
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of RNA oligonucleotide attachment to the cationic nanoparticle surface, 
dispersions were incubated in PBS at a final pH of 7.4 or 4.9 for up to one week. 
Dispersions were then centrifuged at 25000 g for 30 min and the supernatant was 
analyzed spectrophotometrically at 260 nm for free RNA. Controls consisted of 
either RNA or gelatin nanoparticles in the equivalent buffer. Results of percentile 
successful loading were calculated as follows: 
 
                                
 
 
 
Bone marrow cell culture 
Bone marrow cells were harvested from murine femur and tibia and erythrocytes 
were lysed with ammonium chloride buffer (BD Biosciences, Heidelberg, 
Germany). Cells were cultured in RPMI 1640 medium supplemented with 10% 
FCS, 2 mM L-glutamine, 100 µg/ml streptomycin, and 100 IU/ml penicillin and 
activated with 10 µg/ml RNA oligonucleotides complexed to 200 µg/ml gelatin 
nanoparticles. Alternatively, 10 µg/ml RNA oligonucleotides were complexed to 
50 µg/ml DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-trimethylammonium 
methyl-sulfate; Roche, Mannheim, Germany) or 2.5 µg/ml lipofectamine 
(Lipofectamine 2000; Invitrogen, Carlsbad, USA) according to the manufacturers’ 
instructions. Polyethylenimine (PEI) was kindly provided by Dr. M. Ogris 
(Department of Pharmacy, Munich, Germany). 10 µg/ml RNA oligonucleotides 
were complexed to 7.5 µg/ml PEI directly before stimulation.  
 
Fluorescence microscopy 
Bone marrow cells were stimulated for 3 h with fluorescein-5’-tagged RNA 
oligonucleotides and carriers as described above, washed three times and adhered 
to poly-l-lysine-coated microscope slides. Cells were then fixed in 100% acetone 
for 10 min. Topro-3 (Invitrogen) was used for nuclear counterstaining. Stained 
cells were visualized using a fluorescence microscope (Carl Zeiss) and Adobe 
Photoshop was used for adjustment of contrast and picture size. 
RNA loading =  
 
OD of RNA control supernatant 
OD of GNP-RNA supernatant – OD of GNP control supernatant 
x 100 
 
1 - % 
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Quantification of cytokines and flow cytometric analyses 
Concentration of IL-12p70 and IL-6 in culture supernatants was determined by 
ELISA according to the manufacturer’s instructions (BD Biosciences). IFN-α was 
measured according to the following protocol: rat monoclonal antibody to mouse 
IFN-α (clone RMMA-1) was used as the capture antibody, rabbit polyclonal 
antibody to mouse IFN-α for detection (both from PBL Biomedical Laboratories, 
Piscataway, NJ) together with HRP-conjugated donkey antibody to rabbit IgG as 
the secondary reagent (Jackson ImmunoLaboratories, Bar Harbor, ME). 
Recombinant mouse IFN-α (PBL Biomedical Laboratories) was used as standard 
(IFN-α concentration in IU/ml). For flow cytometric analyses, cells were stained 
with fluorochrome-conjugated monoclonal antibodies (B220, CD11b, CD11c, 
CD69, and isotype controls) and propidium iodide from BD Biosciences. Data 
were acquired on a FACSCalibur or a FACSCanto (BD Biosciences) and 
analyzed using FlowJo software (Tree Star, Ashland, OR).  
 
Induction of OVA-specific CD8 T cell proliferation 
For the in vivo induction of antigen-specific CD8 T cell proliferation, splenocytes 
from OT-I mice were labeled with 15 nmol/ml carboxyfluorescein succinimidyl 
ester (CFSE; Molecular Probes, Eugene, OR) after erythrocyte lysis. 5 x 106 
labeled OT-I cells were adoptively transferred into wild-type mice on day 0. On 
day 1, mice were immunized s.c. with 75 µg OVA together with 100 µg free RNA 
oligonucleotides or 100 µg RNA oligonucleotides complexed to 2 mg gelatin 
nanoparticles. Two days later, freshly isolated splenocytes and cells from draining 
and contralateral lymph nodes were analyzed by flow cytometry. Antigen-specific 
T cell proliferation is expressed as percentage of dividing cells (CFSElo) within all 
CFSE-positive CD8 cells.  
Immunization with OVA 
For immunization of mice, 75 µg OVA were injected s.c. together with 100 µg 
free RNA oligonucleotides or 100 µg RNA oligonucleotides complexed to 2 mg 
nanoparticles two or three times at a 14-day interval. For the detection of OVA-
specific antibodies, serum was collected one week after the second immunization 
and serum IgG concentrations were determined by ELISA: plates were coated 
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overnight with 10 µg/ml OVA in PBS and blocked 1 h with 1 % BSA in PBS. 
After incubation of serum samples for 1 h at a dilution of 1:200, plates were 
washed with PBS/0.05% Tween 20. Goat-anti mouse IgG conjugated to HRP 
(SouthernBiotech, Birmingham, AL) was added at 1 µg/ml for 1 h. Plates were 
again washed and ELISA was developed by o-phenylenediamine (Sigma-
Aldrich). Reaction was stopped by 1 M H2SO4 and OD was read by photometer at 
490 nm. 
 
Tumor monitoring 
One week after the third immunization, 106 B16-OVA cells were injected s.c. in 
the right flank. Tumor growth was monitored three times a week and is expressed 
as the product of the perpendicular diameters of individual tumors. Mice were 
sacrified at day 35 after tumor induction. 
 
Statistics 
Statistical analyses were performed by unpaired, one-way analysis of variance 
(ANOVA) with the Newman–Keuls multiple comparison test. Significance was 
set at P < 0.05. Comparisons among groups regarding day of onset of tumors were 
made using the log-rank test. Statistical analyses were performed using SPSS 
software (SPSS, Chicago, IL, USA). 
 
Results 
 
Nanoparticle-delivered RNA oligonucleotides efficiently trigger an innate 
immune response 
We have recently described that immunostimulatory sequences within RNA 
oligonucleotides activate both innate and adaptive immune responses through 
TLR7 (Bourquin et al. 2007; Hornung et al. 2004). To assess the delivery 
potential of cationized gelatin nanoparticles for these immune-activating RNA 
oligonucleotides, murine bone marrow cells were stimulated with nanoparticle-
bound RNA 9.2dr oligonucleotides. Oligonucleotides contained a 
phosphorothioate-modified backbone (PTO) to enhance immunostimulatory 
activity (Bourquin et al. 2007). Nanoparticle-bound RNA induced production of 
144                               Gel tin nanoparticles as a valu ble tool in immunotherapy                         
Gelatin nanoparticles as a valuable tool in immunotherapy    145 
 
 
the pro-inflammatory cytokines IL-12p70, IL-6 and IFN-α in the culture (Figure 
1A). In contrast, no cytokine production was detected upon stimulation with free 
RNA oligonucleotides. Nanoparticles alone induced no IL-12p70 or IL-6 and only 
low levels of IFN-α. Cytokine induction by nanoparticle-bound RNA 
oligonucleotides was abolished in bone marrow cells from TLR7-deficient mice, 
confirming that the immunostimulatory activity was mediated by TLR7 (Figure 
1A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Nanoparticle-bound RNA ODNs activate innate immune responses 
 
Murine bone marrow cells from wild-type or TLR7-deficient mice were activated 
for 18 h with RNA ODNs complexed to different carriers as indicated. (A) Culture 
supernatants were analyzed by ELISA for IL-12p70, IL-6 and IFN-α production. 
A 
B 
C 
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(B and C) Surface expression of the activated marker CD69 on CD11c+ B220- 
myeloid DC (mDC) and CD11c+ B220+ plasmacytoid DC (pDC) within the 
culture was alayzed by flow cytometry. Data are expressed as % CD69-positive 
cells within the indicated populations. All results show the mean of triplicate 
samples +/- SEM. Data are representative of four independent experiments. 
Asterisks without brackets indicate comparison with unstimulated cells ***p 
< 0.001, ns not significant.  
 
Dendritic cells within the culture were activated by nanoparticle-bound 9.2dr PTO  
RNA with over 40% of both myeloid and plasmycytoid dendritic cells expressing 
the early activation marker CD69 (Figure 1B). Indeed, nanoparticle-delivered 
RNA induced a more potent activation of dendritic cells than RNA bound to the 
transfection reagents polyethylenimine (PEI) or lipofectamine (Figure 1B). As 
shown for cytokine induction, CD69 upregulation by RNA oligonucleotides was 
TLR7-dependent. Furthermore, cell activation was dependent on the RNA 
sequence since no activation was detected after stimulation with a PolyA 
oligonucleotide of the same length (Figure 1B). It has previously been shown that 
5’-triphosphate-modified RNA oligonucleotides target the cytosolic receptor RIG-
I (Hornung et al. 2006). Interestingly, nanoparticle-bound 5’-triphosphate RNA 
oligonucleotides also induced an activated phenotype in dendritic cells but did not 
induce cytokine secretion (Figure 1C). Stimulation by 5’-triphosphate 9.2dr 
oligonucleotides was independent of TLR7 (Figure 1C). 
 
Nanoparticle formulation of immunostimulatory RNA oligonucleotides 
promotes their uptake into intracellular compartments 
 
We have previously shown that efficient endosomal delivery of RNA 
oligonucleotides is required to induce TLR7-mediated immune activation (Anz et 
al. 2010). Here we examined the efficacy of cationized GNPs for the intracellular 
delivery of fluorescently labeled RNA oligonucleotides in direct comparison with 
the transfection reagents DOTAP, PEI and lipofectamine. RNA oligonucleotides 
bound to GNPs were rapidly taken up by bone marrow cells with over 80% of 
cells staining positive for labeled RNA after 6 h (Figure 2A). Free RNA 
oligonucleotides were not taken up by bone marrow cells (less than 1% 9.2dr 
RNA-positive cells). Uptake of RNA oligonucleotides complexed to the 
transfection reagents DOTAP, PEI or lipofectamine was less efficient with a 
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maximum of 38% of bone marrow cells staining positive for the fluorescently 
labeled RNA complexed to PEI (Figure 2A). Confocal microscopy revealed that 
nanoparticle-delivered RNA oligonucleotides can be observed as distinct dots 
after internalization, suggesting an endosomal uptake (Figure 2B). Complexation 
of RNA oligonucleotides to DOTAP resulted in a similar localization pattern, 
while RNA oligonucleotides bound to PEI or lipofectamine were evenly 
distributed in the cytoplasm of the transfected cells. Thus, nanoparticle-bound 
RNA oligonucleotides are efficiently taken up by immune cells and accumulate in 
intracellular compartments. 
 
 
 
 
 
 
 
Fig. 2: Nanoparticle formulationof immunostimulatory RNA ODNs promotes 
their uptake into intracellular compartments. 
Murine bone marrow cells were stimulated with 10 µg/ml fluorescein-labled RNA 
ODNs compexed to different carriers. (A) Histograms illustrate uptake of 
fluorescently labeled RNA by bone marrow cells analyzed by flow cytometry, 
(bold line: RNA with indicated carrier; line line: free RNA; dashed line: no RNA) 
(B) Graph shows percentage of RNA ODN-positive cells as mean +/- SEM of 
triplicate samples. Asterisks without brackets indicate comparisons with 
unstimulated cells and cells stimulated with either ORN or NP alone. 
*** P < 0.001. (C) Confocal microscopy of RNA ODN-stimulated cells shows 
intracellular localization of the fluorescently labeled RNA (green) after 3 h. Left 
panel shows a fluorescence image, right panel shows a differential interference 
contrast (DIC) picture merged with fluorescence. Results are representative of 
two independent experiments. 
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Nanoparticle formulation protects immunostimulatory RNA oligonucleotides 
from degradation by RNases 
In addition to facilitating the uptake of RNA oligonucleotides into the appropriate 
intracellular compartment, an effective delivery system must protect nucleic acids 
from degradation. This is an important requirement for the application of 
immunostimulatory RNA oligonucleotides in a therapeutic setting, as the 
widespread distribution of RNases results in a very short lifespan for unprotected 
RNA which was demonstrated in vitro earlier (Elmen et al. 2005).  
 
 
 
 
 
 
 
 
 
Fig. 3: Nanoparticle-bound immunostimulatory RNA ODNs are protected 
from RNase degradation. Bone marrow cells were activated with GNP-bound 
9.2dr PTO RNA ODNs digested with RNase A in the indicated concentrations 
either before or after the complexation of RNA to GNPs. Surface expression of the 
activation marker CD69 was analyzed by flow cytometry (A) and IL-6 
concentration in the supernatants was analyzed by ELISA (B). Data show mean 
and SEM of triplicate wells and is representative of five independent experiments.  
 
The complexation of RNA oligonucleotides to GNPs was assessed whether it 
provided protection from degradation by RNases. We observed that RNA loading 
onto the cationic GNP surface was stable for at least one week at both cytosolic 
(7.4) and endosomal pH (4.9) (Figure 3A). Immunostimulatory RNA 
oligonucleotides were then exposed to partial digestion by RNAse A either before 
or after complexation with GNPs (Figure 3B). Prior incubation with cationized 
gelatin nanoparticles protected RNA oligonucleotides from degradation by RNase 
A, as they still induced an activated CD69+ phenotype and cytokine production in 
a bone marrow cell culture after a one-hour RNase treatment (Figure 3B). In 
contrast, RNA oligonucleotides that were incubated with GNPs after the RNase 
treatment had lost their immunostimulatory potential.  
A B 
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Nanoparticle-bound RNA oligonucleotides trigger antigen-specific CD8 T cell 
and antibody responses 
To investigate the effect of nanoparticle-bound RNA oligonucleotides on the 
development of an immune response to antigen, CFSE-labeled OVA-specific T 
cells from OT-I mice were adoptively transferred into wild-type mice. 24 h later, 
mice were immunized s.c. with OVA protein together with free RNA 
oligonucleotides or nanoparticle-bound RNA oligonucleotides. Three days after 
immunization, proliferation of CFSE-labeled cytotoxic T cells (CTL) in draining 
lymph nodes and spleen was analyzed by flow cytometry. Proliferation was 
enhanced in mice immunized with OVA plus nanoparticle-bound RNA 
oligonucleotides. In contrast, free RNA oligonucleotides did not promote OVA-
specific proliferation. To examine the effect of immunization with nanoparticle-
bound RNA oligonucleotides on the development of an antibody response, mice 
were immunized with the model antigen ovalbumin (OVA) together with free 
RNA oligonucleotides or nanoparticle-bound RNA oligonucleotides twice at a 14-
day interval. One week after the second immunization, serum levels of OVA-
specific antibodies were measured. In mice immunized with OVA and 
nanoparticle-bound RNA oligonucleotides, levels of OVA-specific IgG were 
significantly increased compared to mice immunized with either OVA alone or 
OVA with free RNA oligonucleotide. Nanoparticle-bound RNA oligonucleotides 
did not induce a generalized immune activation, as we detected neither unspecific 
activation of immune cells in the spleen nor elevated serum cytokine levels after 
s.c. injection of nanoparticle-bound RNA (data not shown). Thus, nanoparticle-
bound RNA oligonucleotides act as potent adjuvants and elicit efficient antigen-
specific immune responses when administered with antigen while at the same 
time preventing an indiscriminate systemic activation of the immune system.  
Nanoparticle-bound RNA oligonucleotides induce an efficient antitumoral 
response 
The ability to stimulate cytotoxic T cell responses is a prerequisite for obtaining 
an efficient antitumoral immune response. To assess whether the antigen-specific 
responses induced by nanoparticle-bound RNA oligonucleotides protected from 
the development of a tumor, wild-type mice were immunized with OVA together 
with free RNA oligonucleotides or nanoparticle-bound RNA oligonucleotides 
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before s.c. challenge with OVA-expressing B16 melanoma cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Nanoparticle-bound RNA ODNs induce an antigen-specific antitumor 
immune response 
Mice were immunized three times with OVA together wit hfree RNA ODNs or 
RNA ODNs bound to GNPs. One week after the last immunization, mice were 
injected with OVA-expressing B16 melanoma cells and tumor growth was 
monitored. Results are shown as (A) mean tumor sizes per group and as percental 
tumor-free mice (B). Immunization with OVA together with GNP-bound RNA 
ODNs significantly increased (the onset point of) tumor-free survival compared to 
OVA together with free RNA ODNs or OVA alone (P=0.004). Similar results were 
obtained in two independent experiments.  
B
A
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While all mice immunized with OVA or OVA plus free RNA ODNs developed a 
measurable tumor from day 11 onwards, only two of five mice immunized with 
OVA and GNP-bound RNA oligonucleotides developed a tumor and this 
treatment group showed an improved tumor-free survival (P = 0.004; Figure 4A 
and B). Thus, immunization with GNP-bound RNA ODNs induces a potent 
antitumoral response that protects from a subsequent tumor challenge.  
 
Discussion 
RNA oligonucleotides containing specific molecular patterns trigger immune 
activation though a broad range of mechanisms and can potentiate antigen-
specific immune responses, block immunosuppressive mechanisms and inhibit 
tumor growth. Furthermore, RNA ODNs have emerged as a powerful tool to 
silence expression of specific genes, raising high expectations for the 
development of novel therapeutics (Castanotto and Rossi 2009). The combination 
of both gene-silencing and immunostimulation in one RNA molecule may further 
enhance the therapeutic potential of RNA ODNs (Poeck et al. 2008). A major 
issue for the application of RNA ODNs in the clinic is however the development 
of suitable drug delivery systems that are both safe and effective (Whitehead et al. 
2009).  
 
An efficient delivery system must protect RNA ODNs from degradation, facilitate 
uptake into target cells and deliver the RNA to the appropriate intracellular 
localization (Whitehead et al. 2009). Dendritic cells play a critical role in directing 
the immune response to RNA ODNs and therefore represent an important cellular 
target (Anz et al. 2010). We show here that gelatin nanoparticle-delivered RNA 
ODNs activate dendritic cells more efficiently than RNA delivered by frequently 
used transfection reagents such as lipid-based formulations or PEI. Indeed, GNPs 
greatly enhance uptake of immunostimulatory RNA ODNs into dendritic cells 
with over 80% of cells positive for fluorescently labeled RNA. This highly 
efficient uptake was not achieved by the other transfection reagents examined. We 
further show that complexes of gelatin nanoparticles and RNA ODNs are highly 
stable and that gelatin nanoparticles protect RNA from degradation by nucleases. 
The mode of delivery of RNA ODNs plays an important role in the type of 
immune response induced and directs the subsequent cytokine response (Ablasser 
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et al. 2009). For optimal efficacy, targeting of the appropriate intracellular 
compartment is essential. GNP-delivered RNA accumulates in endosomal 
compartments where TLR7 is located (Diebold et al. 2004), whereas RNA ODNs 
delivered by lipofectamine or PEI are found diffusely in the cytosol. DOTAP, a 
lipid-based transfection reagent, also enhances delivery to the endosome (Yasuda 
et al. 2005). Indeed, it was previously shown that RNA ODNs delivered by 
DOTAP induce TLR7-dependent immune responses in vitro and in vivo 
(Bourquin et al. 2007). However, DOTAP is highly toxic and forms unstable 
complexes that preclude an application in a clinical setting (Bouxsein et al. 2007). 
Interestingly, it was observed that 5'-triphosphate RNA bound to GNPs activates 
dendritic cells independently of TLR7, suggesting stimulation of the cytosolic 
RIG-I receptor. Thus, this may open the door for further beneficial GNP 
applications as carrier systems as they may also deliver RNA ODNs to the cytosol 
in amounts sufficient for immune activation of RIG-I. Moreover, they might be 
suitable for other RNA carrying tasks they demonstrated their ability to protect 
RNA from degradation in vivo and in vitro. 
Systemic administration of colloidal carriers often results in accumulation in the 
liver, kidneys and lungs (Whitehead et al. 2009). Importantly, it was shown here 
that antitumoral protection can be achieved by subcutaneous injection of 
nanoparticle-bound isRNA together with antigen, bypassing the need for systemic 
delivery. This proof of principle target was previously demonstrated 
oligonucleotides almost exclusively to the draining lymph nodes following 
subcutaneous injection, thus directing the oligonucleotides to the initiation site of 
the immune response (Bourquin et al. 2008). This enables the selective triggering 
of antigen-specific T and B cell responses without resulting in systemic immune 
activation. 
 
In addition to their essential role for the in vivo delivery of nucleic acids, gelatin 
nanoparticles may have an adjuvant effect of their own. Indeed, particulate 
adjuvants such as alum, poly(lactide-co-glycolyde) (PLG) and polystyrene 
microparticles enhance TLR-induced secretion of proinflammatory cytokines by 
dendritic cells through stimulation of the NALP3 inflammasome receptor 
complex (Sharp et al. 2009; Eisenbarth et al. 2008). It is thus possible that GNPs 
may themselves activate the NALP3 inflammasome. The induced immune 
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response may synergize with TLR7 activation by RNA oligonucleotides and 
contribute to the adjuvanticity of gelatin nanoparticle-delivered RNA 
oligonucleotides. 
In conclusion, it was shown that GNPs are an efficient delivery system for TLR7-
activating RNA oligonucleotides both in vitro and in vivo.  
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Outlook starting from the above study 
However, the immunologic antitumoral effects in Figure 4A and B was not yet 
optimal taking the large difference between soluble RNA and GNP-bound RNA 
observed in Figures 1-3 into account. Therefore, optimization of the setup 
conditions is a matter of ongoing follow-up experiments. In addition, the 
effector/memory T cell responses induced by OVA alone or OVA on 9.2dr 
nanoparticles will be addressed. Finally, to achieve crucial importance to clinical 
utility by this isRNA immunologic antitumoral concept, current follow-up studies 
explore the possibility of a treatment of existing tumors instead of the so-far 
employed prophylactic strategy. Therefore, OVA-expressing Pac02 pancreatic 
tumor cells are used to establish an eligible murine model instead of B16 
myeloma cells. Thereby, immune response can be built up within the established 
two-week-period of three-fold immunization while the individuals do not 
potentially die before that period due to a very aggressive tumor type (B16). In the 
future, loading of immunostimulatory ODNs together with antigen onto the same 
particles may further improve immunization outcome, as recent studies have 
shown that conjugation of TLR ligands and antigen result in superior activation of 
T cell responses. Thus, an all-in-one vaccine formulation in which GNP 
simultaneously deliver antigen and adjuvant may represent an advantageous 
delivery system. 
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3. In vitro effects of CpG oligodeoxynucleotides delivered by gelatin 
nanoparticles on canine peripheral blood mononuclear cells of atopic 
and healthy dogs 
3.1 Introduction 
Canine atopic dermatitis (AD) is very similar to the human equivalent and thus 
considered a relevant model for human atopic dermatitis (Marsella and 
Girolomoni 2009). It possesses characteristic clinical features and is associated in 
most but not all cases, with the formation immunoglobulin E (IgE) against 
environmental allergy (Olivry and Sousa 2001). The pathophysiology is due to an 
interplay of genetic, environmental and immunologic factors (DeBoer and 
Marsella 2001; Olivry et al. 2010; Schnabl et al. 2006). A defective epidermal 
barrier and cutaneous infections influence the course of the disease (DeBoer and 
Marsella 2001).  
Allergen-specific immunotherapy is a recommended therapeutic option for canine 
AD and was reported to be effective in controlling clinical signs in approximately 
60% of treated dogs (Olivry et al. 2010; Schnabl et al. 2006). In addition it is 
recommended to control infections if present and to restore skin barrier function. 
Glucocorticoids or calcineurin inhibitors may be needed in some patients, 
antihistamines and essential fatty acids may be beneficial in preventing recurrence 
of clinical signs and/or decreasing the dose of glucocorticoids needed. However, 
cases of refractory canine AD are an unfortunate fact in small animal practice. 
Thus, research on new immunomodulatory therapies and studies investigating the 
etiology and pathogenesis of this disease are obligatory. 
Novel therapeutic strategies for AD include cytosine-phosphate-guanine (CpG) 
oligodeoxynucoleotides (ODN), signaling through an endosomal membrane based 
type of pattern recognition receptor (PRR) the Toll-Like Receptor 9 (TLR9) 
(Angel et al. 2008; Wernette et al. 2002). CpGs were shown to influence several 
signaling pathways in a variety of immune cells, leading to cytokine production 
(Lee et al. 2009; Zhao et al. 2010) in many mammalian species (Fig. 1) (Olivry et 
al. 2010). 
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Fig. 1: CpG (class-A) GNPs directly stimulate pDCs which prime naive Th0 cells 
to CD4+ CD25+ T reg cells and subsequently lead to increased IL-10 release 
while Th2 responses are reduced and IgE release is suppressed. Red arrows 
represent pro-allergic and green arrows regulatory pathways. Orange arrows 
indicate the anti-allergic interactions by CpG-GNPs. 
 
It appears that the specific purines and pyrimidines surrounding the CpG motif, the 
phosphothioated backbone, as well as the spacings between CpG motifs may 
influence both the level and the type of immune stimulation (Krieg et al. 1995; 
Mutwiri et al. 2003). CpG motifs improve the antigen presenting function of 
dendritic cells (DCs), monocytes and macrophages, induce the proliferation of B 
lymphocytes, stimulate the immunoprotective activity of NK cells, and recruit T 
cells to the site of ODN administration (Coester et al. 2006; Torchilin 2007; 
Zwiorek et al. 2008). Recent studies showed that the immune system responds to 
CpG motifs by inducing potent Th1-like immune responses which can be 
harnessed for immune therapy of cancer, allergy, infectious diseases (Krieg 2002), 
autoimmune diseases, and sterile inflammation (Kanzler et al. 2007). As explained 
in 1.1, CpGs are also promising adjuvant for vaccines (Angel et al. 2008; Bourquin 
et al. 2008). In vitro testing of CpG showed that CpG ODN are powerful 
stimulators for dog and cat immune cells (Wernette et al. 2002). In humans, TLR9 
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was identified in DCs, B cells and other cell types (House et al. 2009; Hashimoto et 
al. 2005). Canine TLR9 mRNA expression was identified in macrophages (House 
et al. 2009) and in PBMCs, lymph nodes, spleen and kidneys (Hashimoto et al. 
2005). Adverse effects following CpG ODN treatment are possible. However, there 
is no evidence that modest doses of CpG ODN are directly toxic or cause 
autoimmune disease in healthy animals (Zwiorek et al. 2004).  
Colloidal particulate delivery systems fall within the same size range as microbes 
and thus are preferentially phagocytosed by DCs and are considered advantageous 
for subunit vaccines based on proteins, peptides and DNA (Hornung et al. 2002; 
Keppel et al. 2008). It was previously shown that gelatin nanoparticles (GNPs) are 
effectively taken up by TLR9 possessing cells (Coester et al. 2006). The GNP 
carrier system for ODNs in this study prevents enzymatic degradation, transports 
CpG to the desired site of action, and is biodegradable and biocompatible 
(Torchilin 2007). The combination of reduced dosing and more specific carrier-
induced targeting contributes to one of the major goals attributed to nanocarriers - 
less side effects (Zwiorek et al. 2008). Recent studies revealed that GNPs were 
superior to other established carriers such as DOTAP, PEI or lipofectamine in 
targeting the intracellular compartment endosome in DCs, where the target receptor 
TLR9 of CpG ODN is located (Bourquin et al. 2010, in revision).  
Our study aims were to demonstrate cellular uptake of CpG-GNP by canine 
PBMCs and to evaluate its direct influence on cytokine production by PBMCs of 
atopic and healthy dogs. Indirect influence of CpG and CpG-GNP on PBMCs thru 
stimulated macrophages was also investigated.  
 
3.2 Materials and methods 
This study was conducted at the Department of Veterinary Medicine, Small Animal 
Clinic, LMU Munich. All experiments were jointly performed by veterinarian Dr. A 
Rostaher and the author.  
 
3.2.1 Animals 
Dogs suffering from AD (n=8) and concurrent hypersensitivity to house dust mites 
on intradermal testing or serum testing for allergen-specific IgE were included. 
Control samples were taken from healthy control dogs (n=8) without history or 
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evidence of cutaneous or systemic illness. All dogs of both groups did not receive 
any form of immunosuppressive agents for at least 6 weeks prior to blood 
collection. 
 
3.2.2 CpG sequence 
ODNs with the sequence GGTGCATCGATGCAGGGGGG (Kurata et al. 2004) 
were employed with a full phosphotioate backbone (Biomers GmbH, Ulm, 
Germany). For demonstration of intracellular localization by confocal laser 
scanning microscopy (CLSM), a batch of CpGs was labeled with fluorescent dye 
Atto 540 (Biomers GmbH, Ulm, Germany). 
 
3.2.3 Preparation of GNPs 
The unloaded GNPs were prepared by a two-step desolvation method (Coester et 
al. 2000) as previously described in chapter II, 1.2.1. Fluorescence labeling 
comprised the covalent attachment of Alexa 633 dye (Invitrogen, Carlsbad, USA). 
Cationization was carried out as established earlier (Zwiorek et al. 2004). All 
involved chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany). 
GNP concentration was determined gravimetrically by a microbalance (Mettler 
Toledo UMX2, Greifensee, Switzerland). Intensity weighted particle sizes were 
obtained by dynamic light scattering (positron correlation spectroscopy, PCS) 
using a Zetasizer ZS Nano (Malvern Instruments, Worcestershire, England). To 
exclude the viscosity impact on PCS particle size results, the viscosity of particle 
samples was determined with an Anton Paar automated microviscosimeter (Anton 
Paar, Graz, Austria). For Zeta potential measurement before and after loading, 
GNP stock dispersions were diluted in 10 mM NaCl at a 1:10 ratio (V/V) and 
measured in folded capillary cells (Malvern Instruments, Worcestershire, England). 
 
3.2.4 ODN loading of cationized GNP 
Five mg of aseptically prepared nanoparticles were incubated with 250 µg of ODN 
in a total volume of 3339 µl filled up by PBS of pH 7.4 (5% w/w) for 2 h at 22°C 
and under gentle shaking using a Thermomixer™ (Eppendorf, Hamburg, Germany) 
device. As quality control, loading efficiency was analyzed photometrically at 260 
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nm (UV1, Thermo Fisher Scientific Inc., Waltham, USA) in the samples’ 
supernatant after centrifugation and accepted, if loading was at least 97% (w/w).  
 
3.2.5 Blood sampling and PBMC isolation 
20 ml of blood were collected from the jugular vein using EDTA containing tubes 
on day 0 and day 10. Canine PBMCs were isolated by density gradient 
centrifugation of peripheral blood according to the Ficoll-Hapaque method as 
previously reported (Stehle M. 2008). Briefly, 15 ml centrifugation tubes were 
filled with 7 ml Ficoll® separation solution (Biochrom, Berlin, Germany) featuring 
a density of 1.077 g/ml and covered with 7 ml blood previously diluted 1:1 with 
phosphate buffered saline (PBS). After centrifugation without brake (40 min, 1200 
g, room temperature), the concentrated PBMCs located at the white interface 
between plasma and separation solution were removed by pipetting. The cells were 
washed and re-suspended thereafter in 10 ml RPMI-1640 cell culture medium 
(Biochrom, Berlin, Germany) completed with 10 % bovine calf serum (Biochrom, 
Berlin, Germany) and 1 % penicillin-streptomycin (Biochrom, Berlin, Germany). 
PBMC viability and number were determined by trypan blue staining (Biochrom, 
Berlin, Germany) and by cell counting in a Neubauer chamber. In all experiments, 
98% to 100% of cells were viable. The isolated cells were stored at 4°C and used 
within 1 hour.  
 
3.2.6 Monitoring CpG-GNP uptake by cultured PBMCs of healthy dogs 
2.5 x 105 PBMCs were transferred into µ-slide 8 well ibiTreat microscopy chamber 
slides (Ibidi, Integrated BioDiagnostics, Martinsried, Germany), covered with 
300 µl composite medium and cultured for 10 days. The cell culture medium was 
changed every 2-3 days. Ten days old PBMCs were incubated with fluorescence 
labeled CpG-GNP for 2 h. The supernatant was carefully removed and the cells 
washed using 300 µl PBS. Thereafter, the PMBC membranes were labeled with 
100 µL Concanavalin A / Alexa 488 (Invitrogen, Carlsbad, USA) solution for 1 
min and washed three times with PBS. PBMC nuclei were stained with 50 µl 
Hoechst 33342® dye (Invitrogen, Carlsbad, USA) for 5 min. After the final 
washing step, cells were fixed with 4% paraformaldehyde (Roth, Karlsruhe, 
Germany). As reported earlier (Coester et al. 2000), chamber slides were finally 
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prepared with a cover medium consisting of 10% Mowiol 488 and 2.5% 
diazabicyclooctan (DABCO) (Sigma, Taufkirchen, Germany), and visualized 
employing a Zeiss 510 LSM NLO confocal laser scanning microscope (CLSM,Carl 
Zeiss Microscope Systems, Jena, Germany). 
 
3.2.7 PBMC cultivation and immunostimulation 
2 x 106 PBMCs  were cultured in 24-well flat bottom Nunc® plates (Thermo 
Fischer Scientific, Wiesbaden, Germany) in a total volume of 1 ml of standard cell 
culture medium for 10 days at 5% CO2 and 37ºC, which was exchanged every 2-3 
days. During cultivation, adherent cells acquired a macrophage-like phenotype. 
1.5 µg of the positive control Concanavalin A (Con A, Biochrom, Berlin, 
Germany), 75 µg CpG and 1500 µg of CpG-GNP containing 75 µg CpG were 
added to the wells containing cultured PBMCs and incubated for 2 h, respectively 
(Fig. 2).  
 
Fig. 2: Scheme of incubation setup: Either cultured canine PBMCs get incubated 
for 2 h by CpG-GNPs with subsequent fresh PBMC addition and supernatant 
evaluation after 24 h stimulation or direct stimulation of fresh canine PBMCs by 
CpG-GNPs for 24 h.  
 
Un-stimulated cells in cell culture medium only and cells incubated with GNPs 
alone served as negative controls. The supernatant was removed and the cells 
were washed twice. To prove an indirect effect of CpG and CpG-GNP on PBMCs 
through stimulated macrophages, 2 x 106 PBMCs from the same dogs were added 
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to the wells containing macrophages and incubated for 24 h at 5% CO2 and 37ºC 
(Fig. 2). The direct effects of CpG and CpG-GNP on PBMCs were explored by 
stimulating 2 x 106 PBMCs from the same dogs without presence of cultivated 
cells. The culture supernatants were collected after 24 h incubation (Fig. 2) and 
then stored at -80ºC until use.  
 
3.2.8 Quantification of cytokines 
Cell culture supernatant concentrations of interferon gamma (IFN-γ), interleukin 
(IL)-4, IL-6 and IL-10 were measured by Canine Cytokine Milliplex 
(C CYTO 90K-04, Millipore, Billerica, USA) according to manufacturer 
instructions. The cytokines were quantified by a Bio-Plex 200 reader (Bio-Rad, 
Hercules, USA) equipped with the Luminex® xMAPTM technology detection 
system. Result calculation was performed with the Bio-Plex Manager Software 
The used MILLIPLEX ® Map is based on Luminex® xMAP technology which is 
characterized by the feasibility to measure the four selected analytes in one 
sample well at a time. In brief, 5.6 µm microspheres internally color-coded with 
two fluorescent dyes are used to create a set of 100 distinctly colored beads by a 
specific concentration relation of the two dyes in each bead. Every single bead is 
coated with a capture antibody specific for an analyte. Here, anti-IFN-γ capture 
antibody is located in the 07 bead region, IL-4 in the 41, IL-6 in the 47 and IL-10 
66 bead region (Fig. 3). The bioassay steps to capture and detect the cytokines of 
interest take place on the bead surface instead of the plate surface or well bottom 
as it is with common ELISAs. The capture antibodies are bound covalently by 
amid-bonds to the microsphere surface.  
If these coated beads encounter their specific analyte in the reaction mixture, 
binding occurs which is followed by the introduction of the biotinylated detection 
antibody and the incubation with the reporter molecule Strepavidin-PE conjugate 
(Fig. 4). After completion of the bead surface reactions quantification analysis can 
be performed.  
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Fig. 3: Milliplex ® microspheres: 100 separately addressable microsphere sets. 
So theoretically 100 different sets are obtainable, each representing a single well 
of a plate (www.millipore.com). 
 
 
Next, the samples are taken up by the Luminex® detection system as a particulate 
suspension and lined up in single before passing through the detection chamber. 
In there, two lasers are applied to identify the bead and there fore the analyte on 
the one hand, and the PE label of the conjugate to quantify the relevant cytokine 
on the other hand: The red laser to excite the internal microsphere dyes and the 
green laser to excite the report dye associated to the cytokine conjugate. (Fig. 4) 
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Fig.4: Dual laser detection to classify and quantify cytokines in FACS-like 
analysis chamber (www.millipore.com). 
 
Each individual signal is finally processed to a quantitative bioassay result giving 
the concentration of each cytokine in the original solution. The four detection 
antibody conjugated beads can be added to each single sample to obtain four 
results from each sample. 
 
3.2.9 Statistical Analysis  
An analysis of variance with a Tukey post test (or with non-parametric data a 
Kruskal Wallis test with Dunn post test) was used to compare the cytokine 
production in the various groups. The level of significance was set to p<0.05. 
 
3.3 Results 
3.3.1 Formulation quality control 
GNPs featured a hydrodynamic diameter of 247 nm (S.D. ±1.13 nm) before and 
243.1 nm (S.D. ±2.51 nm) after loading. The zeta potential measured in 10 mM 
NaCl remained constant at +18.0 mV and at a conductivity of 1.18 mS/cm. CpG 
surface loading remained at 98% (m/m) or higher 2 h post complexation (II, 2.1). 
 
flow 
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3.3.2 CpG-GNP uptake by cultured PBMCs of healthy dogs 
Fluorescent labeled plain GNPs were taken up by cultured PBMCs and 
accumulated in distinct intracellular regions. In a next step, CLSM confirmed 
cellular uptake of the CpG loaded GNP formulations in cultured PBMCs (Fig. 5). 
The fluorescent labeled CPG-GNPs appear as yellow spots within the cells but 
outside the nucleus stained blue.  
 
Fig. 5: Exemplary CLSM picture illustrating cellular uptake of CpG-GNPs 
(yellow, Alexa 594 staining) by cultured PBMCs (nucleus blue, Hoechst 33342 
staining and cell membrane green, Concanavalin A / Alexa 488 staining) after 
120 min of incubation. 
 
3.3.3 Cytokine quantification  
There was no significant increase triggered by any formulation in IL-4 
concentration in any group (Fig. 6a and 6b). While supernatants of untreated 
macrophages of atopic and non-atopic dogs featured 137 pg/ml and 171 pg/ml and 
those of untreated fresh PBMCs of atopic and non-atopic dogs 182 pg/ml and 194 
pg/ml, respectively, IL-4 concentrations of all other treated groups lay below. IL-
6 concentration was below the detection threshold in all groups and consequently 
could not be evaluated.  
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Fig. 6a: IL-4 release of fresh PBMCs (PBMC) and 10-day cultured macrophages 
(M) of atopic individuals upon stimulation by GNPs alone, Concanavalin A 
(ConA) as a positive control, CpG alone or CpG loaded GNPs (CpG-GNP) or 
without stimulation (neg. contr.) (n=8, ± S.D.).  
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Fig. 6b: IL-4 release of fresh PBMCs (PBMC) and 10-day cultured macrophages 
(M) of non-atopic individuals upon stimulation by GNPs alone, Concanavalin A 
(ConA) as a positive control, CpG alone or CpG loaded GNPs (CpG-GNP) or 
without stimulation (neg. contr.). The y-axis scale was chosen for better 
comparison to expression of other cytokines (n=8, ± S.D.).  
 
In contrast, direct CpG-GNP stimulation of PBMCs in atopic and healthy 
individuals resulted in significantly higher concentrations of IL-10 compared both 
to negative control and to CpG alone. In addition, Con A significantly increased IL-
10 in comparison to the negative control and to CpG alone, but not compared to 
CpG-GNPs (Fig. 7a).   
For healthy dogs, IL-10 release upon Con A stimulation did not differ significantly 
from CpG alone (Fig. 7b), the latter did not significantly differ from the negative 
control. However, indirect stimulation of PBMCs through macrophages did not 
exhibit any IL-10 increased release upon any stimulus compared to negative control 
both in atopic and healthy dogs. 
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Fig. 7a: IL-10 release of fresh PBMCs (PBMC) and 10-day cultured macrophages 
(M) of atopic individuals upon stimulation by GNPs alone, Concanavalin a 
(ConA) as a positive control, CpG alone or CpG loaded GNPs (CpG-GNP) or 
without stimulation (neg. contr.). Relevant interrelations’ levels of significance 
are indicated by * for p< 0.05 and ** for p< 0.01 (n=8, ± S.D.). 
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Fig. 7b: IL-10 release of fresh PBMCs (PBMC) and 10-day cultured 
macrophages (M) of non-atopic individuals upon stimulation by GNPs alone, 
Concanavalin a (ConA) as a positive control, CpG alone or CpG loaded GNPs 
(CpG-GNP) or without stimulation (neg. contr.). Relevant interrelations’ levels of 
significance are indicated by * for p< 0.05 and ** for p< 0.01 (n=8, ± S.D.). 
 
IFN-γ was released by macrophages (198 pg/ml) and fresh PBMCs (237 pg/ml) in 
atopic and non-atopic dogs only upon Con A stimulation and not after incubation 
with CpG or CpG-GNPs (Fig. 7). Standard deviations of mean were observed as 
very high. Thus, no levels of significance could be obtained. 
* 
* 
** 
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Fig. 8a: IFN-gamma release of fresh PBMCs (PBMC) and 10-day cultured 
macrophages (M) of atopic individuals upon stimulation by GNPs alone, 
Concanavalin a (ConA) as a positive control, CpG alone or CpG loaded GNPs 
(CpG-GNP) or without stimulation (neg. contr.) (n=8, ± S.D.). 
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Fig. 8b: IFN-gamma release of fresh PBMCs (PBMC) and 10-day cultured 
macrophages (M) of non-atopic individuals upon stimulation by GNPs alone, 
Concanavalin a (ConA) as a positive control, CpG alone or CpG loaded GNPs 
(CpG-GNP) or without stimulation (neg. contr.) (n=8, ± S.D.). 
 
3.4 Discussion 
In this study, CLSM demonstrated successful uptake of stable CpG-GNPs by canine 
cultured PBMCs within 2 h. In addition, direct stimulation of PMBCs with CpG-
GNP resulted in a significant increase of IL-10 production.  
It was previously shown in proliferation assays, that CpGs alone are taken up by 
canine immune cells (Wernette et al. 2002). In this study, CpG uptake was 
visualized directly by ultrastructural analysis for the first time to the authors’ 
knowledge. This demonstrated uptake is a precondition for CpG and/or CpG-GNP 
related immunologic effects. In vitro immunologic effects of CpG-GNP or CpG 
alone were compared to controls. The bead-based flow cytometric method used in 
this study facilitates simultaneous quantification of different cytokines within one 
sample (Lee et al. 2009; Zhao et al. 2010).  
There was no significant increase in any of the analyzed cytokine concentrations 
Gelatin nanoparticles as a valuable tool in immunotherapy    170 
 
 
after stimulations with CpG-GNP or CpG alone in canine macrophages. This can 
be explained by the fact that TLR9 is not the primary PRRs pathway in canine 
macrophages, as was previously shown (House et al. 2009). The production of 
cytokines is controlled by RNA and proteolytic processing (Abbas AK et al. 
2010). Therefore, degradation of pre-existing cytokines in the 24 h incubation 
time is possible but rather unlikely as cytokine production was shown in PBMCs 
subjected to the same incubation conditions. The stimulation time may have been 
too short. However, based on the demonstrated uptake of CpG and CpG-GNP 
after 2 h, this time period should be sufficient for macrophage stimulation. It is 
unlikely that a low viability of cells in the macrophage cultures was responsible, 
as in the atopic group there was a high production of Th1 cytokine IFN-γ after 
stimulation with Con A. Therefore, the present observation is in accordance with 
the previous finding that macrophages require other partner cells for effective 
response to the CpG challenge such as pDCs contained in the fresh PBMCs 
preparation (Hornung et al. 2002).  
A shift towards a Th1 and T regulatory immune response during allergen specific 
immunotherapy (Keppel et al. 2008; Shida et al. 2004) for treatment of canine AD 
was shown in vivo and in vitro. The same was found for CpG employment in cats 
(Reinero et al. 2008) and CpG-allergen conjugates in humans (Simons et al. 
2004). Clinical efficacy of CpG-allergen conjugates (Creticos et al. 2006) and 
CpG-virus-like-particle formulations administered together with allergens were 
demonstrated in humans (Senti et al. 2009).  
No in vitro production of IL-4 was observed in the atopic or healthy group. This is 
in concordance with previous studies. The first in vivo study in canine atopic 
patients using liposome-plasmid DNA complexes showed a significant decrease 
in serum IL-4 and pruritus scores (Olivry et al. 2010). Although IL-4 is a key 
mediator in pathogenesis of AD it cannot always be detected in atopic individuals 
(Kim et al. 2003). IL-4 was also not detectable in a study evaluating rush 
immunotherapy with CPG in a colony of asthmatic cats, consistent with the 
present results (Reinero et al. 2008).  
The most essential finding was a significant increase in IL-10 in atopic and 
healthy dogs after direct PBMC stimulation with CpG-GNP compared to CpG 
alone and negative control. These differences in IL-10 production suggest that 
GNPs can enhance the immunomodulatory effects of CpG and provide 
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preliminary evidence for the use of GNP formulated CpG in dogs. The source of 
IL-10 could be B cells, dendritic cells and/or CD4+CD25+ Treg cells (Krieg 
2006). Kurata et al (Kurata et al. 2004) used the same ODN sequence which was 
employed here. However, in this study a fully phosphorothioated backbone was 
used which probably enhanced the CpG action on B cells in this study and which 
consecutively produced more IL-10 (Krieg et al. 1995). This backbone 
modification was also selected to achieve an increased resistance to 
endonucleases, longer half-life and thus greater immunomodulatory effect. 
Moreover, the higher charging of this modification might have let to repulsion 
effects and consequently to a lower tendencies of self-association. Instead, these 
CpG strands were more easily fixed to the GNP surface and thus the 
immunomodulative impact might have been enhanced. Interestingly, elevated IL-
10 mRNA transcription after in vitro stimulation of canine PBMCs with ODN 
rich in CpG34 and  elevated IL-10 protein levels after stimulation with synthetic 
agonists of TLR935 were reported earlier. In contrast, the in vivo use of CpG in 
adjuvant rush immunotherapy in experimental feline allergic asthma did not 
reveal any changes in IL-10 in bronchoalveolar fluid (Reinero et al. 2008).  
IL-6 release by any cellular setup was not detected in this study. This finding is 
concordance with a study evaluating synthetic agonists of TLR9 where only a 
mild increase in IL-6 was detected (Im Hof et al. 2008). This is of particular 
importance as IL-6 was shown previously to have a suppressive effect on Treg 
cells (Pasare and Medzhitov 2003). Due to the fact that Treg cells are the primary 
mediators of peripheral tolerance playing a pivotal role in modulating chronic 
inflammatory diseases (Vignali et al. 2008), a downregulation by released IL-6 
would have been detrimental to the desired development of immunotolerance in 
the treatment of dogs with AD.  
IFN-γ, the Th1 signature cytokine, was not detected after stimulation with CpG in 
contrast to the findings of Kurata et al (Kurata et al. 2004) and others (Krieg 
2002). This needs to be elucidated in further studies, but could be due to 
inhibition of IFN-γ production by high IL-10 concentrations. IL-10 reduces 
proliferation of DCs, blocks IL-12 secretion and thus suppresses IFN-γ indirectly 
(Pasare and Medzhitov 2003; Im Hof et al. 2008).  
 
In summary, the concurrent use of CpG with a GNP carrier increased IL-10 
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production by PBMCs in both, atopic and healthy dogs. Macrophages seemed not 
to be the primary CpG canine cell target. Clinical studies in humans suggest that 
allergens in combination with CpGs are an efficacious and safe treatment option 
for asthma and allergic disease. Such studies in canine patients with AD are 
currently in preparation as this treatment may result in higher clinical efficacy and 
possibly less adverse effects. 
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4. Nucleic acid-based immunotherapy against hypersensitivity – 
preformulation studies for an inhalative CpG-GNP formulation for 
RAO therapy in horses 
 
4.1 Recent developments in nanoparticle administration by inhalation 
 
Pulmonary delivery as a non-invasive route of drug administration still constitutes 
a vivid research field in the treatment and diagnosis of respiratory and non-
respiratory diseases (Smola et al. 2008). Within, nanoparticulate delivery is a 
clear but dynamic quota offering an advantageous perspective e.g. for a lung 
application of GNPs in future immunotherapeutic settings. 
GNPs have demonstrated their feasibility as a carrier in several settings to include 
mediating antitumoral immunotherapy by adjuvant CpG deoxyoligonucleotides 
(Bourquin et al. 2008). By addressing toll-like 9 receptors (TLR9) on plasmoidal 
dendritic cells, T effector cells are subsequently activated by interleukins (IL) 
such as IL-12 to overcome agony and CD8 T cells engage in the desired cytotoxic 
action. However, besides immune activation, a reduction of immune response in 
events of hypersensitivity can be generated via TLR9 agonists as well (Jurk and 
Vollmer 2007; Krieg 2006). Equally, a promising field is the treatment of 
hypersensitivity such as allergies and asthma. Recurrent airway obstruction 
(RAO), also referred to as chronic obstructive bronchitis (COB), is a common 
equine incident which is to date not yet completely curable (Horohov et al. 2005; 
(Kunzle et al. 2007). Therefore, an administration of GNP formulated CpG to the 
lung seems to be a valuable direct delivery attempt without painful parenteral 
injection. In order to conduct related in vivo studies, the impact on GNP integrity 
must be evaluated for appropriate aerosol-forming devices. They should provide 
adequate droplet sizes with embodied GNPs for successful lung deposition, 
preferably ranging from 1 – 5 µm known as the fine particle fraction (FPF) 
(Ghazanfari et al. 2007). 
The lower airways with respiratory brochioles and alveolar sacs (WEIBEL and 
GOMEZ 1962) offer a large surface area for drug interaction. Most common are 
local therapeutic strategies involving steroids or bronchodilators in the treatment 
of COB, asthma or cystic fibrosis as well as antimicrobial agents against 
infectious diseases such as tuberculosis (Purewal 1998; Rytting et al. 2008). 
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Direct targeting of the area of therapeutic interest enables a reduction in 
administered drug amount compared to e.g. oral or i.v. route (Vaughn et al. 2006) 
leading to reduced side effects (Keller 1999). Systemic delivery is facilitated by 
the alveolar sacs morphology including an extraordinary thin epithelial barrier of 
0.1-1 µm, high blood flow, low enzymatic activity and finally the avoidance of the 
first past effect (Butz et al. 2002; Rytting et al. 2008). However, despite intense 
research, which concentrated mostly on the applications of antibiotics and insulin, 
systemic access via the inhalative route has suffered a major drawback since the 
withdrawal of inhalative insulin Exhubera® in late 2007.  
The abolishment of ozone depleting chlorofluorocarbons (CFC) following the 
Montreal protocol led both to its replacement by hydrofluoroalkanes (HFA) in 
pressurized metered dose inhalers (pMDI) and to an increased use of non-
pressurized systems (Kawashima et al. 1999). Pressurized pMDIs were among the 
earliest and are still among the most established systems in use for the delivery of 
dissolved or suspended active ingredients to the respiratory tract (Brown and 
George 1997). They were successfully employed in the aerosolization of protein 
formulations such as insulin-containing nanoparticles or emulsions (Butz et al. 
2002; Nyambura et al. 2009; Butz et al. 2002; Nyambura et al. 2009). Non-
pressurized systems comprise dry powder inhalers (DPIs), pneumatic jet inhalers, 
ultrasound nebulizers and most recently vibrating mesh (VM) devices (Waldrep 
and Dhand 2008). DPIs were meanwhile widely employed for standard asthma 
medication but were also used to deliver complex formulations such as dry 
powder microparticle-bound nanoparticles. Examples were polyacrylate NP-
bound Salbutamol sulfate (Hadinoto et al. 2007) and Chitosan-NP-bound Insulin 
(Grenha et al. 2005). However, pure nanoparticle formulations cannot be 
delivered in that manner due to too small particle size (< 1µm) and thus missing 
lung deposition and consequently exhalation of the formulation (Sung et al. 2007). 
Therefore, excipients like micronized lactose were identified as beneficial (Finlay 
et al. 20050127) and e.g. GNP aerosols were successfully formulated as DPI after 
spray drying loaded with a placebo drug (Sham et al. 2004).  
Pneumatic jet nebulizers were available since the 1950ies and possess the ability 
to nebulize preparations of high viscosity such as suspensions. Negative attributes 
were their limited portability, high residual dead volumes making dosage of drugs 
featuring critical therapeutic ranges difficult. Moreover, high shear forces 
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represented another problematic factor impacting the drug formulation during the 
application process (Waldrep and Dhand 2008; Ghazanfari et al. 2007). Still, 
Insulin solid lipid nanoparticles were delivered to the lung by this means and 
resulted in prolonged plasma glucose and insulin profiles (Liu et al. 2008). The 
newer type of ultrasound nebulizers suffered from heat generation during the 
nebulization process which negatively affected sensitive materials such as protein 
and nucleic acids while suspensions cannot be processed due to their viscosity 
(Lentz et al. 2006; Ghazanfari et al. 2007). Hence, ultrasonic nebulizers could not 
be successfully introduced for nanoparticulate or liposomal applications (Elhissi 
and Taylor 2005). For instance, Dailey et al. received sufficient mass median 
aerodynamic diameters (MMAD) by ultrasonic nebulization but reported 
inconsistent output and increased particle aggregation (Dailey et al. 2003). On the 
contrary, VM devices proved their feasibility to nebulize both delicate and slightly 
viscous formulations (Ghazanfari et al. 2007; Lentz et al. 2006; Waldrep and 
Dhand 2008; Elhissi and Taylor 2005). Among them fall passively VM devices 
such as the Omron Microair nebulizer which can be distinguished from active VM 
devices such as the AeroNeb Go of Nektar (Ghazanfari et al. 2007). The first 
group featured a perforated plate with approximately 3 µm-diameter holes. The 
plate was passively induced by an attached piezo crystal via a transducer horn. 
The fluid got extruded through the microholes and consequently, the aerosol was 
formed. As a result, very high nebulized drug output efficiency was achieved 
while output rates tended to be relatively low and ceased early when viscous 
formulations were involved. Conversely, the actively VM devices featured a plate 
with dome-shaped apertures which are moved up- and downwards 105 times per 
second in a micrometer range by an electric vibrating element. This micropump 
extruded the fluid and thus created the aerosol (Ghazanfari et al. 2007). Described 
advantages of the active VM device were a more rapid aerosol generation and a 
relatively high nebulized output over 70%. Approximately 50% of the nebulized 
droplet output were sized as FPF below 5.21 µm and therefore reached the lower 
airways’ area of interest without inactivation or denaturation of delicate active 
pharmaceutical ingredients (API) (Haroon et al. 2005). A comparable VM device 
was employed recently to successfully nebulize complex PLGA-PVA 
nanoparticles loaded with a model drug (Beck-Broichsitter et al. 2009). 
Compressor or jet nebulizers apparently were not suitable in our application of 
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fragile CpG. Nevertheless, jet nebulized GNPs gave promising results such as 
enabling targeted lung cancer delivery of chemotherapeutic agent cisplatin (Tseng 
et al. 2007; Tseng et al. 2009). While the median droplet size was determined and 
lung deposition was proved in vivo, no further characterization of the data of the 
nebulization process itself was given. Therefore, two established devices with 
different VM techniques were compared in addition to the pMDI for GNP 
integrity, its impact on various parameters’ influence of viscosity, its importance 
of administration time and recovered concentration after quantitative 
recondensation. In vitro, the ability of nebulized CpG loaded GNPs was tested in 
comparison to original non-nebulized ones to trigger IL-10 release from relevant 
cultured equine lymphocytes gained from bronchoalveolar lavage fluid (BALF). 
Bronchoalveolar lavage is an established method to recover respiratory secretions 
in peripheral airways and alveoli by a flexible fiberbronchoscopy and make them 
available for subsequent cytological investigations (Bernstein 1984; Hoffman 
2008). The presented findings constituted a prerequisite for further equine in vivo 
studies.    
 
4.2 Materials and Methods 
4.2.1 Materials  
The immunomodulative single stranded mixed phosphothioester/-diester 
backbone CpG-ODN 2216 class A with the sequence 5`-
G*G*GGGACGATCGTCG*G*G*G*G*G*-3` was received as lyophilisate from 
biomers (Ulm, Germany), diluted in sterilely filtrated highly purified water 
(HPW) produced by a purelab plus device (Elga labwater, Celle, Germany) to a 
final concentration of 1 mg/ml and stored at -80°C till final use. IL-10 quantifying 
equine Duo set ELISA was purchased from R&D Systems (Minneapolis, USA). 
Liquefied gas propellant HFA 134a was obtained from Schick GmbH (Stuttgart, 
Germany). 
 
4.2.2 Preparation of the CpG-GNPs 
Plain, cationized and fluorescent labeled GNPs were prepared as described in 
chapter II, 1.2.1 according to the established protocols (Coester et al. 2000; 
Zwiorek et al. 2008). 20 bases long CpG-ODN 2216 (Biomers, Ulm, Germany) 
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was loaded onto the GNP surface in HPW by electrostatic attraction. To ensure 
colloidal stability, the CpG concentration was set to 5 % (m/m) based on the GNP 
mass. For this, the aseptically prepared samples of cationized GNPs were 
subsequently incubated for 1 h at 22 °C and 300 rpm using a Thermomixer™ 
device (Eppendorf, Hamburg, Germany). The concentration of the GNP 
dispersion was set to 0.5, 1.0 or 1.5 mg/ml for subsequent different nebulization 
setups.  
 
4.2.3 Determination of nanoparticle properties and dispersion viscosity 
Particle sizes were determined by PCS using a Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, England) as described above in chapter II. Intensity 
weighted particle mean diameter (Z-average) and PDI as the width of the fitted 
Gaussian distribution were calculated by the DTS V. 5.10 software from at least 
15 subruns. For Zeta potential measurement before and after loading GNPs were 
diluted in 10 mM NaCl to maintain a sufficient but not too high ionic strength in 
terms of conductivity and electrode corrosion. GNP concentration was determined 
gravimetrically (Mettler Toledo UMX2, Mettler, Greifensee, Switzerland). 
Viscosity of GNP formulations was determined prior nebulization by an 
automated microviscosimeter (AmV) device by Anton Paar GmbH (Graz, 
Austria). Percentile loading efficiency was proven indirectly by UV-spectroscopy 
at 260 nm wavelength (UV1, Thermo Fisher Scientific Inc., Waltham, USA) 
Therefore, the supernatant(s) of CpG-GNP samples, supernatants of GNP controls 
(without CpG) and supernatants of CpG controls (without GNP) were taken into 
account as given below:  
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4.2.4 GNP aerosolization 
For aerosolization by pMDIs, 12 ml aluminium pMDI containers were filled with 
3, 5 or 10 g of a 1 mg / ml GNP dispersion and a cap with dosing chamber and 
purging valves was positioned on top of the container. Crimping and subsequent 
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liquefied propellant filling trough the dosing chamber was conducted by a hand 
operated laboratory plant 2005/2 (Pamasol, Pfaeffikon, Switzerland). The filling 
weight of propellant was kept constant at 1.5 g / pMDI resulting in 2:1, 4:1 and 
8:1 GNP dispersion : propellant ratios. To estimate consistency of dosing, a 
sequence of 30 spraying passes was performed for each formulation and the pMDI 
was weighted after each pass. Aerosols and droplets were collected in suitable 50 
ml tubes for subsequent GNP characterization. 
 
Fig. 1: Experimental setup of the 4 ±1°C chiller (a), collecting flask (b) and 
vacuum pump (c) to determine GNP concentration of precipitated vapors 
generated by the nebulizer Microair. 
 
VM-nebulization was performed by a passively vibrating NE-U22V Microair 
(Omron, Matsusaka, Japan) and an actively vibrating AeroNeb Go (Aerogen, 
Galway, Ireland) device. The Microair instrument was employed with the 
manufacturer-provided rubber supplement mouth piece (Fig. 1) while the 
AeroNeb Go was either (a) used with the manufacturer-provided “nebulizer body” 
connected to the essential medication cup/aerosol generator part or (b) with a 90° 
glass connector with joints that suitably matched the medication cup/aerosol 
generator part’s outlet side. Nebulization efficiency (NE) was determined for all 
three instrumental setups by weighing the VM device before nebulization and 
after operation to dryness. The latter was considered apparent when visibly no 
more vapor escaped from the aerosol generator. After division of the weights, the 
a 
b 
c 
B 
2 
2 
1 
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results were given in percent. To determine the post-nebulization weight, the 
whole instrument with all practically relevant adapters or nebulizer bodies was put 
on a lab balance (College, Mettler Toledo, Greifensee, Switzerland). Therefore, 
only those portions of the nebulized formulation that completely escaped the 
apparatus (nebulizer plus auxiliary parts) and consequently contributed to the 
deposition study were considered relevant for the NE calculation. 
 For size and concentration evaluation of post-nebulized GNPs, the resulting 
aerosol was collected in a closed glass system equipped with a water cooled 
chiller at 4°C to quantitatively condensate vapors. Either the Mircoair VM device 
(Fig. 1) or the AeroNeb Go VM device with attached glass connecter was fitted to 
the closed glass system.  An applied vacuum of 700 mbars which translated to a 
flow rate of approximately 30 l/min (Vaccubrand CVC200, Wertheim, Germany) 
was introduced to assure high yields of GNP dispersion in the collection round 
bottom flask. 
Subsequently, intercepted samples were analyzed for size, size distribution and 
concentration. Results were compared to the pre-nebulized ones, respectively.  
 
4.2.5 Droplet size analysis 
Droplet sizes of dispersions nebulized by the two VM devices were assessed by 
laser diffraction. Therefore, 0.5 ml of a GNP dispersion (1 mg/ml) were nebulized 
and the vapor was directed through the 633 nm laser beam of a Mastersizer X 
long bench (Malvern Instruments, Malvern, UK) in 4.5 cm distance to a 300 mm 
lens. Droplet sizes were calculated by the version 2.19 Mastersizer software using 
an implemented model based on a particle refractive index of 1.45 and a 
dispersion optical density of 0.276 at 633 nm. Results are the mean diameter of 
three runs each with 1000 measuring events. Corresponding FPFs defined as the 
particle fraction below 5.21 µm were given in percent. 
 
4.2.6 Deposition study 
For deposition studies, fluorescence labeled GNPs with covalently bound 
Alexa 633 dye were employed at a concentration of 1 mg / ml and characterized 
according to Ph. Eur. by apparatus type A twin-stage glass impinger apparatus 
(Copley Scientific Ltd., Nottingham, UK, Fig. 2). HPW was introduced in the 
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upper (7 ml) and lower (30 ml) stages of the impinger and a steady flow rate of 
60 l / min was maintained during the aerosolization process by a Glax. Sing. Sta. 
pump (Erweka GmbH, Heussenstamm, Germany) to mimic physiologic breathing 
air flow. Additionally, a 500 ml aerosol spacer (GSK, Brentford, UK) was 
introduced as a pre-separator between the VM-nebulizer or pMDI and the 
impinger.  
 
 
 
 
 
 
 
 
 
 
Fig. 2: Experimental setup of the nebulizer – here Omron’s Microair- connected 
to the spacer (a) which was attached to the twin-stage impinger (Ph. Eur. device 
type A) with mouthpiece (b), stage one (c) and stage two (d). 
 
FPF to be found in stage 2 of the impinger was considered the respiratory fraction 
(RF) as part of the whole nebulized fraction. Results of single fractions were 
calculated (standard curve) by referring the mass per stage calculated from the 
detected fluorescence intensity of Alexa 633 labeled GNPs to the whole applied 
mass of GNPs in the nebulizer and given in percent. 
 
4.2.7 Cell culture and immunostimulation 
Bronchoalveolar lavage fluid (BALF) was collected from a 20 years old male 
horse of 520 kg body weight with RAO condition sedated by detomedine (0.01 
mg/kg) and butorphanol (0.01 mg/kg) i.v. as previously described . An endoscope 
was passed nasotracheally for visual inspection of the trachea (Hoffman 2008; 
Jackson et al. 2004). For local anaesthesia, 10 ml of a 2% mepivacaine solution 
were passed through the endoscope channel and afterwards the endoscope was 
pulled back up towards larynx. Subsequently, a BALF catheter (Bivona Inc., 
a b 
c 
d 
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a
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Gary, USA) was inserted as far as the bifurcation tracheae, firmly adjusted by a 
balloon and then employed to introduce two 100 ml aliquots of sterile 0.9% NaCl 
solution. The 200 ml were immediately aspired again by new sterile syringes and 
transferred to sterile 50 ml centrifugation tubes. Samples were refrigerated at 4°C 
shortly until subsequent centrifugation at 1200 g for 6 minutes to spin down 
contained cells. The pellet was resuspended in RPMI medium (Biochrom AG, 
Berlin, Germany) supplemented with 10% FCS and 67.8 µg/ml penicillin and 113 
µg/ml streptomycin. Cell numbers were counted using a Neubauer chamber 
(Laboroptik GmbH, Friedrichsdorf, Germany). 2 x 105 cells per well were 
transferred to a 96 well polystyrene cell culture plate (Techno Plastic Products, 
Trasadingen, Switzerland). Per individual well, 0.275 mg were GNPs loaded with 
13.5 µg (5% (w/w) CpG, they were (a) transferred directly without further 
processing to a cell culture 2 x 105 cells of BALF cells per well or (b) first 
nebulized by the active VM-device, completely regained from the vapor and 
added to the cell culture.. Incubation was set to 24 h at 37°C in a 5% (V/V) CO2 
atmosphere. Afterwards, culture plates were centrifuged at 1200 g for 6 min. and 
cytokine IL-10 was quantified from collected supernatants by an equine IL-10 
ELISA (Duoset, R&D systems, Minneapolis, USA) according to manufacturer’s 
instructions. Detection wavelength was 450 nm. Remaining cell pellets in the well 
plate were immediately resuspended in 300 µl of 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) working solution consisting of 82% PBS, 
9% FCS and 9% of a 5 mg/ml MTT stock solution. Hence, 0.135 mg MTT 
reagent was applied per 2x105 cells. After two hours of incubation at 37°C and in 
5 % (V/V) CO2 culture plates were centrifuged at 1200 g for 6 min., supernatants 
were discarded and the remaining pellets resuspended in 200 µl DMSO and 
subsequently analysed at 590 nm.
 
All samples and related analysis were 
conducted in triplicate. 
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4.3 Results 
4.3.1     Particle characterization upon nebulization by pMDI and VM-
devices 
 
First, the impact of nebulization by pMDI was assessed. Therefore, vapor 
fractions were collected, and PCS measurements revealed initial high particle 
sizes and size distributions (PDI values) that diminished in the course of 
application (Fig. 3). Over a storage time of 48 h, pMDI formulation exhibited no 
negative impact on unloaded GNPs’ stability. As per differential weighing, 
maximum achieved NE with the pMDI was 77.4% for the 4:1 GNP dispersion : 
propellant ratio formulation while the others (2:1, 8:1) remained slightly below. 
After this degree of drawdown, pressure was too low to ensure aerosolization 
upon liquid’s exit from the container via the purging valve. Average dosing was 
68 mg formulation per pass. However, the S.D of 20 mg indicated a high 
variability translating to a relative standard deviation of 29.4%.   
0
100
200
300
400
500
1 to 10 11 to 20 21 to 30
number of spraying passes
pa
rt
ic
le
 s
iz
e
 
[n
m
]
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
PD
I
size GNP : propellant 2:1 size GNP : propellant 4:1 size GNP : propellant 8:1
PDI  GNP : propellant 2:1 PDI  GNP : propellant 4:1 PDI  GNP : propellant 8:1
 
Fig. 3: Particle size and size distribution characterized by the PDI value of GNPs 
nebulized by pMDI in dependence of the aqueous GNP to propellant ratio and of 
the number of praying passes (n=3, ± S.D.). 
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GNP integrity was indeed not altered over time by the formulation with HFC 
propellant as most likely no interaction occurred between the hydrophilic GNPs 
and the inert simultaneously hydrophobic and lipophobic liquid gas (Table 1). 
 
time point [h] s ize [nm] S.D. PDI S.D.
 
0 163.8 3 .8 0.173 0.036
1.5 150.2 1 .3 0.072 0.007
3 152.7 1 .8 0.063 0.028
48 153.9 2 .4 0.076 0.015
 
 
Table 1: Particle size and size distribution characterized by the PDI value of 
GNPs nebulized by pMDI in dependence of the storage time within the pMDI 
container (n=3). 
 
For unloaded, fluorescing GNPs with an original size of 145.5 nm (±1.76 nm) and 
a very low PDI of 0.038 (±0.025), neither VM-nebulization process altered the 
assessed parameters significantly (Table 2).  
 
  
Omron’s Microair® 
 
c [mg/ml] size [nm] S.D. PDI S.D. 
0.5 149.9 1.373 0.027 0.017 
1.0 147.4 2.061 0.059 0.035 
1.5 146.2 1.601 0.024 0.015 
 
 Nektar’s AeroNeb Go® 
 
c [mg/ml] size [nm] S.D. PDI S.D. 
0.5 144.9 1.084 0.037 0.025 
1.0 144.6 0.989 0.021 0.014 
1.5 145.6 0.734 0.032 0.023 
 
 
Table 2: Sizes and size distributions of plain GNPs after nebulization 
(n=3, ± S.D.). 
 
As shown before (Fuchs et al. 2010), particle sizes determined by PCS grow after 
cationization. Accordingly, above mentioned particles of 145.5 nm were 
considerably larger (250 nm) after cationization compared to the state before the 
modification. This size did not change considerably by CpG loading to the GNP 
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surface which was important to guarantee overall colloidal stability. However, 
CpG-loaded GNPs of being sized 256.2 nm (±3.63 nm) pre-nebulization turned 
out to be significantly smaller at 222.3 (±1.42 nm) after nebulization by the 
Microair while not being significantly different at 248.2 (±7.34 nm) with the 
AeroNeb Go device. 
 
4.3.2    Nebulization efficiency of VM-devices 
NE remained consistent within the repeated measurements for each single device 
as demonstrated by low S.D. values. Furthermore, the GNP concentration has 
hardly any impact on the NE. A negligible tendency of higher percentile NE 
values with rising concentration is visible as it is 93.8, 97.0 and 95.9% and 94.4, 
97.0 and 97.8% for the Microair and for the glass adapter-supplemented AeroNeb 
Go, respectively (Fig. 4). However, the applied VM system has an impact. While 
the above given values peak near 100%, using the commercial nebulizing body, 
the AeroNeb Go’s NE ranks only half at about 50% while the rest is trapped in the 
device (Fig. 4). Recovered masses of re-precipitated samples in the round flak 
collector were 70.2, 71.7 and 79.1% (m/m), respectively. 
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Fig. 4: Nebulization efficiency (NE) of GNP dispersions concentrated 0.5, 1.0 and 
1.5 mg/ml in dependence of the applied nebulizer and/or the applied adapter 
(n=3, ± S.D.). 
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4.3.3    Output rates of VM-devices 
The passive VM-device required a significantly longer period of time to nebulize 
constantly employed volume of 1 ml of GNP dispersion completely to “dryness” 
compared to the active VM-device (Table 3). Viscosity rose linearly with GNP 
concentration and accordingly output rates dropped. 
 
Nektar’s AeroNeb Go® Omron’s Microair® 
  
c [mg/ml] time [min:sec] S.D. time [min:sec] S.D. viscosity [mPa*s] S.D. 
0.5 01:43 0.001 08:21 0.013 0.9137 0.0003 
1.0 01:46 0.003 08:49 0.005 0.9201 0.0008 
1.5 01:53 0.002 10:57 0.024 0.9283 0.0024 
 
 
Table 3: Required nebulization times for three GNP concentrations by the active 
(ledt) and the passive (right) VM device and related viscosity (n=3).  
 
With rising GNP concentration, the output rates by the passive VM device were 
only 0.12, 0.11 and 0.09 mg/min, respectively. In comparison, the active VM 
device achieved 4.9 to 5.8 times higher output rates of 0.58, 0.57 and 0.53 ml/min, 
respectively. 
 
4.3.4    Consistency of concentration after nebulization 
All three employed GNP concentrations were determined gravimetrically before 
and after nebulization. Post-nebulized concentrations were gained from 
dispersions precipitated by the nebulizers as shown in Figure 1. Results and 
corresponding deviations of the post-nebulized concentration values to the pre-
nebulization values are given in Table 4. Negative deviations indicating lower 
GNP concentrations are found for all three Microair runs. For the AeroNeb Go, 
two deviations were positive indicating a concentration increase and only one was 
negative. As a trend, deviations got smaller with rising GNP concentration for 
both VM devices. 
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Table 4: Comparison of the recovery (absolute and percentile) of three GNP 
concentrations before and after nebulization by a Microair and an AeroNeb 
GoVM-device. 
 
4.3.5    Aerosol particle size characterization 
Analysis of nebulized droplet sizes revealed slightly higher diameters for droplets 
created by the Microair device. Here, the mean diameter of the AeroNeb Go-
generated droplets accounted for 6.60 ± 0.03 µm while those by the Microair was 
determined at 7.46 ± 0.10 µm (n=3, ± S.D.). Accordingly, the FPF defined below 
5.21 µm (Ghazanfari et al. 2007) was 37.13% (± 0.57) and 30.24% (± 0.97) for 
the two VM devices, respectively. When nebulizing HPW alone by the AeroNeb 
Go, a mean droplet sizes of 6.34 µm and a FPF of 36.28% were received. 
 
4.3.6     Deposition study 
Deposition characteristics were assessed by an impinger to estimate the feasibility 
of each aerosol-producing device to deliver GNPs in a high RF to the 
therapeutically relevant lower airways. GNPs delivered by an pMDI generated 
aerosol showed a bad deposition related to lower airway targeting as 65.66% 
(±0.84%) of the nebulized GNP mass were trapped in the spacer and only 0.76% 
(±5.46%) could be found on the last stage representing the RF (Fig. 5). The 
passive VM-device featured a prospective lung deposition of 47.65% (±18.04%) 
with 1.95% (±0.91%) ending up in the spacer while the active VM-device 
exhibited the highest RF value of 65.68% (±11.20%) with 3.43 (±0.40%) to be 
found pre-separated in the spacer (Fig. 5). 
Some particles were deposed on the glass connections and could not be 
  
Nektar’s AeroNeb Go® Omron’s Microair® 
concentration 
prior 
nebulization 
[mg/ml] 
concentration 
after 
nebulization 
[mg/ml] 
S.D. 
deviation 
through 
nebulization 
[%] 
concentration 
after 
nebulization 
[mg/ml] 
S.D. 
deviation 
through 
nebulization 
[%] 
0.5 0.534 0.057 6.8 0.458 0.003 -8.5 
1 0.956 0.131 -4.4 0.974 0.102 -2.6 
1.5 1.516 0.202 1.1 1.448 0.182 -3.5 
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quantitatively assigned to single distinguished stages. They constituted the amount 
lacking to 100%. 
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Fig. 5: Mass deposition of fluorescent labeled GNPs in the twin-stage impinger in 
dependence of the applied aerosolization device (n=3, ± S.D.). 
 
4.3.7    Stimulation of IL-10 release in vitro  
CpG-ODN loading onto the GNPs’ surface was 98.51% (±1.29) according to the 
gravimetrical differential determination. The Zeta potential was determined to be 
23.0 mV (±0.4 mV) before and 21.7 mV (± 1.0 mV) after the loading. 
Conductivity dropped accordingly from 0.943 mS/cm (± 0.002) to 0.884 mS/cm 
(± 0.003) due to the reduced amount of chargings present in the dispersion. 
Analysis for the central immunomodulating cytokine IL-10 revealed significant 
higher release for both the nebulized and the non-nebulized formulation compared 
to the control, untreated BALF cells’ supernatant. Difference in release between 
the two applied GNP groups was not significant and accounted for 225.2 pg/ml (± 
56.3 pg/ml) and 230.7 pg/ml, respectively (n=3, ± S.D.). Additionally, cell 
viability was very high in both cases, reaching 102.2% (± 3.8%) compared to the 
negative control of amount of untreated viable cells as per MTT assay. Plain, non-
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loaded GNPs did not trigger IL-10 release in a quantifiable manner and had no 
negative effect on viability over 24 h (data not shown). 
 
4.4 Discussion  
In this study, we evaluated for the first time the most suitable administration 
technique for pulmonal GNP delivery. In the perspective of ongoing in vivo 
studies involving the immunotherapeutic application of CpG-GNPs in equine 
RAO, the basis of a reliable dosage form is given hereby. 
First, the possibility to generate an aerosol of aqueous GNP dispersions by pMDI 
was tested. Nanoparticle size and size distribution after aerosolization, 
consistency of dosing and deposition characteristics were of central interest to 
assess this dosage form’s feasibility. Although a standard proof dosing chamber 
was used for the pMDI, a constant aerosol dosing was not given with RSD of up 
to 29%. The collected vapors contained GNPs of appropriate size and size 
distribution after the early spraying phase was completed (Fig. 3) and GNP 
quality was constant over the observed time of 48 h (Table 1). Remarkably, 
particles’ PDIs were lower for high GNP to propellant ratios in the early spraying 
phase but equalized after an increased amount of spraying passes (Fig. 3). But 
visibly, aerosols featured heterogeneous droplet size distributions as larger 
droplets were trapped on the mouthpiece’s inner surface of the pMDI. 
Accordingly, most of the generated aerosol was held back as coarsely dispersed 
fraction in the spacer and only a small amount was subsequently found on the 
final impinger stage (Fig. 5). 
Apparently, the FPF was too low to contribute to a high RF. The likely reason was 
the high surface tension of the aqueous phase which hindered the propellant to 
enable sufficient aerosolization. Therefore, surfactants would have been required 
to reduce the hindering high surface tension. However, their amount, their 
possibly negative impact on CpG activity and their physiologic harmlessness 
needed to be determined in this case. Furthermore, pMDIs required pressurized 
propellant filling with a special apparatus. As CpG-GNP formulations needed to 
be prepared freshly, a pMDI filling system might not always be available. 
Therefore, as long as a storage stable formulation is not at hand, pMDIs remain 
inappropriate for practical use in addition to their so far poor FPF generation from 
GNP dispersions. 
188                            Gelatin nanoparticles as a valuable tool in immunotherapy                        
Gelatin nanoparticles as a valuable tool in immunotherapy    189 
 
 
On the contrary, VM-nebulizers showed an overall good performance which was 
in accordance with previous studies on their employment in nebulization of 
delicate dispersion. Furthermore, once the CpG-GNP formulation was prepared it 
could easily be transferred to the VM-device’s medication cup without the need of 
any special instrument such as a pressurized propellant filling station. As a central 
finding, particle sizes and size distributions both of loaded and loaded GNPs were 
not significantly affected by the nebulization process (Table 1). This was observed 
for both devices and for all applied therapeutically feasible concentrations.   
Ghazanfari et al. (2007) revealed in detail how the liquid’s properties such as 
viscosity, surface tension and ionic background influenced the NE and FPF. The 
latter was defined as droplet sizes below 5.21 µm in diameter and was decisive for 
a resulting preferably high RF for potential alveolar deposition. As present GNP 
dispersions were determined in a viscosity range close to water, it is referred to 
the FPF and average droplet size cited in literature. Viscosity was proven by 
Ghazanfari et al. to be a critical factor for the overall generation of vapor by VM-
devices. Related values above 2.45 mPa/s resulted in absence of aerosol 
generation. In this study, a GNP concentration of 1.5 mg/ml constituted the upper 
chosen limit for a reasonable and stable formulation for loaded GNPs. 
Consequently, the corresponding viscosity, rising linearly with GNP 
concentration, did not extend beyond 0.9283 mPa/s and aerosol generation was 
feasible without obstacles related to the formulation’s viscosity (Table 3). 
However, although NE was very high both for the actively and the passively VM-
device (Fig. 4), a huge difference was observed between the output rates. They 
were 4.9 to 5.8 times higher with AeroNeb Go compared to the Mircoair 
(Table 3). This trend was also observed for various solutions by Ghazanfari 
accounting for factors from 1.4 to 3.3. The viscosity was coined to be the crucial 
parameter in output rates for the Microair. This is in accordance with our findings 
where output rates dropped by 6.29% and by 24.74% for the 1 mg/ml and 1.5 
mg/ml formulation when nebulized by the passive VM-device compared to the 0.5 
mg/ml dispersion (Table 3). On the contrary, output rates were reduced for the 
equivalent GNP concentrations by only 3.83% and 9.85% when nebulized by the 
active VM-device, respectively. The latter is supposed to occur due to the higher 
energy input by the active VM micropump which overcame resistance of fluids to 
shear forces more easily (Elhissi et al. 2006).  
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Furthermore, with regards to the present deposition study, the maximum RF was 
proven to be produced by the active VM-device (Fig. 5). Equalizing this RF with 
the droplet sizes determined by laser diffraction and with previous FPF results by 
Ghazanfari (2007), this RF value is considerably higher. However, the present 
deposition results in Fig. 5 refer to the fluorescent NP signals themselves and not 
to directly to the generated droplets in the micrometer range. As droplets might 
burst in flight and release contained nanoparticles, a higher lung deposition than 
expected due to the droplet size-associated deposition is likely. Furthermore, the 
fact that the highest FPF was generated by the active VM device was revealed by 
all analytic methods alike. Moreover, the potential in vivo target of the CpG-GNP 
formulation is not restricted to the alveoli but rather comprises the segmental, 
terminal and respiratory bronchioles as well because RAO affects the complete 
lower airways e.g. by brochospasm of smooth muscles and excessive mucus 
production. Thus, a deposition both in alveoli and bronchioles facilitated by 
droplet sizes of 5 µm (± 2 µm) are desirable and were achieved in the present 
setting. As a decreasing surface tension was determined to correspond to a higher 
FPF outcome (Elhissi and Taylor 2005; Ghazanfari et al. 2007), this parameter has 
to be considered for the GNP formulations as well.  
Gelatin is known to reduce the surface tension significantly from 72 dyn/cm 
(water) down to about 55 dyn/cm in concentrations above 0.25 mg/ml depending 
on temperature and prevalent pH value (Sato and Ueberreiter 1979). It was shown 
that gelatin molecules are surface active and accumulate at interfaces due to their 
hydrophobic segments rich in proline, hydroxyproline, alanine, valine and leucine 
(Sato and Ueberreiter 1979). Here, the surface reducing effect might be mediated 
both by residual soluble gelatin in the dispersion as well by the nanoparticles 
themselves, featuring the gelatin amphipilic properties on the surface.  
This is in accordance with findings on reduced surface tensions and consequently 
higher FPF produced by VM-devices when liposomal formulations were 
employed (Aboudan et al. 2004; Elhissi and Taylor 2005).  
Furthermore, nanoparticles themselves were previously proven to enrich in liquid-
gas interfaces (Vafaei et al. 2009). This inclusion led to a reduction of effective 
surface energy because related values for nanoparticles-water, nanoparticles-air 
and resulting air-water interfaces are lower than for the original air-water interface 
(Vafaei et al. 2009). Therefore, a combination of the gelatin properties and the 
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nanoparticulate properties combined seem to contribute to a reduction in surface 
tension and consequently to the final desired augmented FPF. As the active VM-
device showed the overall best performance in output rate and RF generation, it 
was exclusively used to generate nebulized CpG-GNPs for the in vitro cytokine 
stimulation test. 
Finally, it was shown that after nebulization CpG-GNPs are still capable of 
inducing the same immune response in BALF cells as if they were not nebulized. 
Comparing IL-10 releases over 24 h, no significant changes were quantified 
between nebulized and non-nebulized formulations. This demonstrated the gentle 
character of the employed aerosolization technique and proofed the feasibility of 
intact nebulized CPG-GNPs to be later used in inhalative immunotherapy. The 
manufacturing of CpG loaded GNPs was meanwhile well established and could 
be quickly performed in a clinical lab equipped with sterile working facilities. 
Yet, the formulations needed to be employed within hours to avoid the remaining 
risk of aggregation which was associated with CpGs class A earlier (Kerkmann et 
al. 2005). Therefore, DPIs could constitute an advanced strategy to provide a 
long-term stable application form of CpG-loaded GNPs. Freeze drying of ODN-
loaded GNPs was introduced before (Zillies et al. 2008) and could be used to 
develop an inhalative powder formulation. Consequently, sealed single doses such 
as introduced in commercial disk haler could constitute a feasible and storable 
alternative to so far successful nebulization of aqueous CpG-GNP dispersions in 
future every-day use. 
 
4.5 Conclusion 
A protein-based carrier system, gelatin nanoparticles, was developed to deliver 
immunostimulatory CpGs in an aerosol for the first time. Characterization 
revealed no negative impact onto the colloidal stability of the formulation when 
nebulized by vibrating mesh devices. Concentration remained unaffected by this 
process, thus enabling predictive dosing. Nebulization could be accomplished 
within reasonable timing in clinical terms and consequently led to a generation of 
a fine respirable fraction of up to 65.7% as shown by impaction studies. 
Furthermore, nebulized CpG-GNPs elicited significant IL-10 release from equine 
BALF cells in vitro to the same extend as non-nebulized did and are therefore 
considerable in immunotherapy. The hereby available formulation holds great 
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potential e.g. for the treatment of RAO in the premier equine in vivo study 
involving nanocarriers.    
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5. Immunostimulation of bronchoalveolar lavage cells from recurrent 
airway obstruction-affected horses by different CpG-classes bound to 
gelatin nanoparticles  
This work was conducted in close and essential cooperation with the Equine 
Clinic, LMU Munich. All experiments -besides gaining of BALF- were conducted 
together with veterinarian John Klier. 
 
5.1 The significance of RAO and the potential of CpG immunotherapy in 
horses 
In the last decades, allergic airway diseases have dramatically increased in the 
northern hemisphere of industrialized countries in horses and humans (Kline 
2007; Braun-Fähränder 2009). Equine recurrent airway obstruction (RAO) has 
become one of the most common airway diseases (Fey 2006). Housing of horses 
in stables with permanent exposure to potentially allergenic organic and inorganic 
particles was reported to be a major trigger factor (Schmallenbach et al. 1998; 
Robinson 2001; Millerick-May 2009). Keeping horses on pasture leads to 
improved clinical signs, however, complete avoidance of allergens is not always 
possible (Robinson 2001). The permanent inhalation of various antigens from 
moldy hay, mite dust as well as endotoxin, β-glucan and other organic and 
inorganic particles causes airway neutrophilia and inflammation with a mixed 
Th1/Th2 immune response (Horohov et al. 2005; Cordeau et al. 2004). Although 
the clinical signs of RAO were well defined (Robinson 2001), immunological 
mechanisms are still controversy discussed. However, a predominant Th2 allergic 
response was recently presumed (Horohov et al. 2009). In several studies, signs of 
predominant Th2 response such as high IL-4, IL-5 in bronchoalveolar lavage fluid 
(BALF) of RAO horses exposed to antigens were reported (Lavoie et al. 2001; 
Cordeau et al. 2004). Due to persistent chronic inflammatory reaction in small 
airways of the affected horses, Th1 participation was also confirmed (Ainsworth 
et al. 2003). Recently, proinflammatory and chemotactic IL-17 from Th17 cells 
has been demonstrated to be involved in the progression of RAO pathology 
(Debrue et al. 2005; Ainsworth 2009) Thus, IL-17 pathway is of special interest in 
the progress of chronic airway inflammation (Iwakura and Ishigame 2006). 
As a potential therapeutic option for RAO, unmethylated Cytosin-Phosphate-
 
Gelatin nanoparticles as a valuable tool in immunotherapy    194 
 
 
Guanin-Oligodeoxynucleotides (CpG-ODN) have been explored (Fonseca and 
Kline 2009). CpG-ODNs were introduced as effective immune stimulating agents 
to cause a Th2/Th1 immune shift (Kline 2007). This shift further promoted an 
immunoglobuline isotype switch from IgE to IgG2 (Bohle 2002). The prevalence 
of IgE is a matter of ongoing debate (Halliwell et al. 1993; Marti 2009). In 
addition, a shift from pro-allergy mediating IL-4, IL-5 and IL-13 Th2 cytokines 
towards pro-inflammatory IFN-γ and IL-12 Th1 cytokines was observed. Anti-
inflammatory and antiallergic properties of Th2 cytokine IL-10 turned out to be of 
interest. Particularly, IL-10 producing T regulatory cells (Tregs) and its balance 
towards Th2 cells seemed to play an important role in immune homeostasis in the 
lung and thus could be used for therapy of RAO (Akdis et al. 2004; Lloyd and 
Hawrylowicz 2009). Consequently, besides a conventional symptomatic therapy 
the possibility to modulate cytokine level in order to avoid development of an 
allergic hypersensitivity may be a better therapeutic option. 
Three distinctive CpG classes (A-, B- and C-class) with varying immunologic 
effects were previously investigated (Krieg 2002; Krieg 2002). The key pattern-
recognition receptor for these “danger signals” is the Toll-Like receptor 9 (TLR-9) 
which is located in endosomes (Krieg 2002; Krieg 2002). Recently, equine TLR-9 
was detected in monocytes, airway epithelial cells, capillary endothelium in the 
lungs and pulmonary intravascular macrophages (Schneberger et al. 2009). 
Furthermore, species-specific immune stimulation depending on CpG motifs has 
been determined (Hartmann and Krieg 2000; Rankin et al. 2001). 
The beneficial use of delivery systems like lipid nanoparticles or gelatin 
nanoparticles (GNPs) to protect ODNs from degradation by nucleases and to 
enhance cellular uptake was recently demonstrated (Wilson et al. 2009; Zwiorek 
et al. 2008). GNPs from gelatin type A obtained from porcine skin were found to 
be immunologically inert and the use of GNPs showed amplified CpG-related 
TLR-9 activation (Zwiorek et al. 2008). Consequently, the aim of this study was 
to identify the optimal CpG motif to stimulate equine BAL cells in vitro for the 
first time and to detect  specific immunomodulating effect (Th2/Th1 shift) on the 
cells derived from RAO and healthy horses treated with GNP-delivered CpG-
ODN.  
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5.2 Materials and methods 
All works of this study have been conducted in close collaboration with the, 
Department of veterinary medicine, Equine clinic LMU, Munich. BAL was gained 
by veterinarian John Klier, all other experiments were performed alternating or 
together. 
 
5.2.1 Horses and physical lung examination 
Based on published schemes (Gerber et al. 2004) a lung scoring system was 
developed to assess critical clinical parameters (nasal discharge, coughing, 
breathing rate and thoracic percussion), blood gas chemistry, exercise 
examination, endoscopic exploration, cytology of tracheobronchial secret (TBS) 
and bronchoalveolar lavage fluids (BALF). In the present study eleven horses 
(eight trotter, one pura raza espanol, one warmblood and one knabstrupper) with 
an age range of 6-22 years and a weight range of 470-560 kg were scored and 
enrolled in the study. The scoring system allowed grouping patients into four 
categories of healthy horses and horses with mild, moderate and severe RAO.  
Two groups were established, whereby the first group consisted of seven horses 
with moderate RAO (mean age = 14.6 years) and the second group had four 
healthy horses (mean age = 12.3 years). 
 
5.2.2 Oligodeoxynucleotides 
To evaluate the optimal stimulating CpG motif in cultured equine BAL cells, 
three different CpG classes with previously employed motifs in horses in general 
were compared. Five different CpG ODNs and one non-CpG ODN were used 
(Biomers GmbH, Ulm, Germany). Each class was represented by two different 
sequences except the A-class where only one sequence was available. All CpG 
classes were single stranded ODN with a length of 20 to 30 bases. ODN 2041 (5`-
CTG GTC TTT CTG GTT TTT TTC TGG-3`) was used as control. The A class 
differs in backbone structure from the other classes. It consists of a backbone 
chimera of phosphorothioate* (PS) and phosphodiester (PD) modified 
deoxyribose: CpG A ODN 2216 (5`-G*G*G GGA CGA TCG TCG* G*G*G 
*G*G- 3`). Two different B-classes were compared: CpG B ODN 2142 (5`-TCG 
CGT GCG TTT TGT CGT TTT GAC GTT- 3`) and CpG B ODN 2006 (5`-TCG 
TCG TTT TGT CGT TTT GTC GTT- 3`). The C-class was represented by CpG C 
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ODN 2395: (5`-TCG TCG TTT TCG GCG CGC GCC G- 3`) and CpG C ODN 
M362: (5`-TCG TCG TCG TTC GAA CGA CGT TGA T- 3`). 
 
5.2.3 Preparation of ODN loaded GNP  
Cationized GNPs were prepared according to the standard protocol (Coester et al. 
2000; Zwiorek et al. 2008) as described in chapter II, 1.2.1. For cationization, the 
pH of solution was adjusted to 4.7. For purification, particles were centrifuged at 
18000 g for three times, washed and subsequently filtered through a membrane 
with a pore size of 1.2 µm (Pall Life Sciences, Lab Products, Ann Arbor, USA). 
Then, ODNs were bound onto prepared positively charged GNPs by electrostatic 
interaction as described earlier (Zwiorek et al. 2008). Particle size and surface 
charge (Zeta potential) were quantified in 10 mM NaCl by a Zetasizer ZS Nano 
(Malvern Instruments, Malvern, UK). A ratio of 5% (w/w) of ODN to GNPs was 
chosen to ensure colloidal stability (Zwiorek et al. 2008).  
A working concentration of 2.5 mg/ml for GNPs and 1.0 mg/ml for ODNs was 
used. Therefore, 76.5 µl of GNP stock solution were diluted by 230 µl highly 
purified water (HPW) and 43.8 µl of respective CpG ODN stock solution were 
mixed by gentle stirring to obtain a final ODN concentration of 0.125 mg/ml. As 
references, 0.125 mg/ml CpG ODN solution of each class (306.5 ml HPW, 43.8 µl 
CpG ODN stock solution) and 2.5 mg/ml GNP dispersion (274 µl HPW, 76.5 µl 
GNP stock solution) were prepared. All the samples were incubated for 90 
minutes at room temperature with constant stirring at 300 rpm in a Thermomixer 
(Eppendorf, Hamburg, Germany). The samples were stored at 4°C and used 
within 48 hours. 
 
5.2.4 Preparation of cells and cell culture 
From every horse BALF was taken by using 50 ml of sterile and 37°C temperated 
0.9% NaCl solution per 100 kg) packed on thermal packs and centrifuged 
immediately by 1200 g for 6 minutes. Supernatants were stored at -80 °C to 
conserve actual cytokine concentration. Total cell count was determined by 
manual counting using trypanblue with a Neubauer counting chamber (Laboroptik 
GmbH, Friedrichsdorf, Germany). 2 x 105cells (mixture of neutrophile 
granulocytes, alveolar macrophages and lymphocytes) in 230 µl RPMI medium 
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(Biochrom AG, Berlin, Germany) per well in a 96 well plate (Techno Plastic 
Products, Trasadingen, Switzerland) were incubated for 24 hours at 37 °C in 5% 
(V/V) CO2 atmosphere. The RPMI cell culture medium was supplemented with 
10% (V/V) FCS, 67.8 µg/ml penicillin and 113 µg/ml streptomycin.  
 
5.2.5 Immunostimulation by ODN and cytokine quantification (ELISA) 
Five different CpG sequences of three different classes and one ODN lacking a 
CpG motif, as described above, were incubated with the equine BAL cells in 
triplicates. In detail, 0.275 mg GNPs loaded with 13.5 µg (5% (w/w)) ODN or 
13.5 µg of soluble ODN were added per well to compare the effects of unbound 
ODNs and ODNs bound to GNPs. To estimate the immunostimulating response of 
ODNs in cell culture, supernatant was taken after 24 hours of incubation and 
analyzed by equine ELISAs (Duoset, R&D Systems, Minneapolis, USA). Three 
key-cytokines namely    IL-4, IL-10 and IFN-γ were evaluated. The ELISAs were 
performed according to the manufactures protocol. The limits of detection of the 
applied ELISA assays were 15.6 – 2000, 156.25 – 20000 and 31.2 - 4000 pg/ml, 
respectively. Results were throughout corrected by subtraction of relspective  
concentrations in supernatants of untreated BAL cells, which served as negative 
control.  
 
5.2.6 Cell viability by MTT-assay 
MTT assays were performed to evaluate cell viability following incubation with 
CpG and CpG-GNP. Cell pellets after removal of supernatant were immediately 
resuspended in 300 µl MTT (3-(4,5-Dimethylthiazol-2-yl) -2,5-
diphenyltetrazolium bromide) working solution consisting of 82% PBS, 9% FCS 
and 9% of a 5 mg/ml MTT stock solution. Thus, 0.135 mg MTT reagent was 
added per 2 x 105 cells. After two hours of incubation at 37°C and in 5% (V/V) 
CO2 the culture plates were centrifuged at 1200 g for 6 min. Then, the supernatant 
was discarded and the remaining pellets resuspended in 200 µl DMSO to 
solubilize violet formazan crystals. The absorbance of each well was measured at 
530 nm using multiwellplate reader (Wallac). Untreated BAL cells served as a 
reference for 100% viability. All the measured experiments were conducted in 
triplicate.  
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5.2.7 Statistical analysis 
Data from cytokine quantification by ELISAs and MTT assays were analyzed 
using the Prism 5 software (Graphpad software Inc., La Jolla, USA). An unpaired 
student t-test was employed to estimate significant differences between two 
independent groups such as stimulation of cells gained from RAO-affected versus 
healthy horses. P < 0.05 was considered as statistical significant data from 
experiments and the data reported as mean ± S.D. 
 
5.3 Results 
5.3.1 Quality control and formulation study of CpG-GNP 
Particle sizes and size distribution determined before and after loading exhibited a 
mean particle diameter of 250 nm and homogenous size distributions with 
polydispersity index values throughout below 0.15. CpG loading onto the GNP 
surface was at least 98% (w/w). 
After 48 hours GNP-bound CpG-ODN formed visible aggregations and cytokine 
stimulation was reduced significantly. Therefore, all GNP formulations were 
freshly prepared and used immediately for the experiments. 
 
5.3.2 Cytokine release in cell culture upon stimulation by CpG/CpG-GNP 
5.3.2.1 IL-10 release  
 In order to compare the effect of CpG-GNP versus soluble CpG on cytokine 
release from BAL cells, six sequences of ODNs (to include five CpGs) were 
tested. IL-10 showed the highest release in absolute concentration values of the 
three quantified cytokines on average. As a general observation, cells from 
healthy horses secreted significantly (P = 0.0047) higher amounts of IL-10 than 
those of RAO affected horses regardless of the employed ODN.  
 
 
 
 
 
 
 
198                            Gelatin nanoparticles as a valuable tool in immunotherapy                        
Gelatin nanoparticles as a valuable tool in immunotherapy    199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: IL-10 expression from BALF cells from healthy and RAO-affected 
horses with different CpG classes. BAL cells derived from RAO (black bars) or 
health horses (white bars) were incubated with 13.5 µg of soluble ODN (A) or 
GNP-bound ODN (B). Cells from healthy horses secreted significantly higher 
amounts of IL-10 than those of RAO affected horses (P = 0.0047). CpG A 
triggered the highest IL-10 release for both cells groups. Depicted values are 
group means ± S.D and corrected by subtraction of the negative control. (Klier 
2010) 
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Fig. 1a shows IL-10 stimulation efficiency of soluble CpG. Out of the six 
different ODNs, CpG 2216 (A-class) showed the highest IL-10 release for both 
examined groups. IL-10 release was 400 pg/ml in cells from healthy horses and 
220 pg/ml in those from RAO horses. However, CpGs of the B and C class did 
not trigger release in RAO derived cells, with relatively low concentrations of 
about 125 pg/ml. C-classes appeared to result in higher stimulation (350 pg/ml) 
than B-class (200 pg/ml) in cell culture for healthy horses. Consequently the 
employed B-classes (ODN 2142 and ODN 2006) and C-classes (ODN M362 and 
ODN 2395) showed almost identically release behavior for RAO horses. In Fig. 1 
b IL-10 stimulation by CpG-GNPs is shown. Most noticeable is the significant 
higher release of IL-10 of the cells from healthy horses (P = 0.0051). Furthermore 
the GNP-bound CpG 2216 induced the highest IL-10 concentration (540 pg/ml) 
which surpassed the release value by soluble CpGs as shown in Fig 1 a. On the 
contrary the stimulation by all particle-bound CpGs are lower than those by 
soluble. 
 
5.3.2.2 IL-4 release 
In contrast to IL-10, IL-4 release upon stimulation by six soluble CpG did not 
differ (P = 0.614) between RAO and healthy horses derived cells (Fig. 2 a).  
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Fig. 2: IL-4 expression from BALF cells from healthy and RAO-affected horses 
with different CpG classes. BAL cells derived from RAO (black bars) or health 
horses (white bars) were incubated with 13.5 µg of soluble ODN (A) or GNP-
bound ODN (B). Cells from healthy horses secreted significantly lower amounts 
of IL-4 than those of RAO affected horses (P = 0.001) when treated with GNP-
bound ODNs (B). Incubation with soluble ODNs did not result in such 
significantly distinguishable release (A). Depicted values are group means (n=3, 
± S.D.) and corrected by subtraction of the negative control. (Klier 2010) 
 
Both absolute values were low and inter and intra variations were high. However, 
as shown in Fig. 2 b difference of high significance (P = 0.001) was found when 
comparing GNP-bound CpG stimulated cell cultured from RAO and healthy 
horses for IL-4 release. The latter resulted negative values (Fig. 2 b) while those 
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of RAO were positive and comparable to those provoked by soluble CpG 
(P = 0.9469). Furthermore GNP-bound CpG lowered IL-4 release of cells of 
healthy horses considerably more than soluble CpG (Fig. 2 a) (P = 0.0018). 
 
5.3.2.3 IFN-γ release 
In Fig. 3 an IFN-γ release from RAO and healthy horses-derived cell cultures is 
displayed after stimulation by soluble CpGs. On average, no significant difference 
could be observed between the mean values of both groups (P = 0.3514). 
However, the six employed ODNs revealed distinctive effects. As seen for IL-10, 
the highest release was induced by CpG 2216 A-class and accounted for 94 ±10 
pg/ml in RAO and 135 ±19 pg/ml in healthy derived cell cultures. All other ODNs 
induced lower amounts between 15 and 50 pg/ml (Fig. 3 a). A tendency towards 
higher release by healthy horses-derived cells could be presumed but was not 
statistically significant (Fig. 3 a). In contrast, GNP-bound ODNs led to a clear 
discrimination between RAO and healthy derived cells in terms of IFN-γ in Fig. 3 
b (P = 0.008). Here, CpG 2216 A-class stimulated the highest IFN-γ secretion as 
well, accounting for 76 ± 14 pg/ml (healthy) and 25 ± 10 pg/ml (RAO).  
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Fig. 3: IFN-γ expression from BALF cells from healthy and RAO-affected 
horses with different CpG classes. BAL cells derived from RAO (black bars) or 
health horses (white bars) were incubated with 13.5 µg of soluble ODN (A) or 
GNP-bound ODN (B). Depicted values are group means (n=3, ± S.D.) and 
corrected by subtraction of the negative control. (Klier 2010) 
 
In this individual example (CpG 2216) marginally statistically significant 
difference was found (P = 0.05). Besides, no or slight release from RAO cell 
cultures was found (Fig. 3 b), while no statistical significance occurred between 
the healthy derived cell cultures treated by CpG in comparison by CpG-GNP 
(P = 0.45).  
 
5.3.3 MTT assay 
BAL cells from RAO affected and healthy horses were employed to investigate in 
vitro cell viability after 24 h of incubation with regard to detectable differences 
after administration of soluble ODN compared to GNP bound ODNs. Four mean 
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CpG or with CpG-GNP and cells from (b) healthy horses on the other hand treated 
with CpG or CpG-GNP), were averaged out of the individual viability results of 
the sixth employed ODNs (Fig. 4). In the healthy group no significant differences 
were detectable in viability between soluble CpG or CpG-GNP administration. No 
significant differences were seen between the six individual examined ODNs. Of 
all evaluated means of the four groups, lowest viability was observed in cells from 
RAO affected horses treated with soluble CpG (69.7% ± 6.6%). In contrast, cells 
from RAO horses treated with CpG-GNP showed the highest viability on average 
104.3% ± 6.4% which was a statistically significant higher value (P < 0.0001). As 
an example, the difference between cells treated with CpG-ODN 2216 A-class 
and cells treated with GNP-bound CpG-ODN 2216 A-class was found significant 
(P = 0.0405).  
 
 
 
 
 
 
 
 
 
 
Fig. 4: Percentile cell viability of BALF cells from healthy and RAO-affected 
horses challenged with six different CpG classes as per MTT assay. (Klier 2010) 
 
However, mean viability of cells from healthy horses exposed to soluble CpG was 
94.2% ± 4.0% and with CpG-GNP administration 91.7% ± 8.0%. No significant 
differences were observed between these two mean values (P = 0.512). 
Accordingly, no significant difference was identified in the example of CpG-ODN 
2216 A-class (P = 0.5319). Moreover, cells derived from RAO and healthy 
individuals did not differ in viability when challenged with GNP bound CpG-
ODN 2216 A-class (P = 0.808). Summarizing, BAL cells gained from RAO 
horses showed significant higher cell viability in MTT assay when incubated with 
CpG-GNP in comparison to soluble CpG. This difference was not seen in assays 
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with cells gained from healthy horses. 
 
5.4 Discussion 
The major aim of this study was to identify optimal stimulating CpG motifs in 
horses, concerning Th2/Th1 shift via TLR-9 activation.  Optimal TLR-9 agonist 
sequences were reported to be 5`-GACGTT-3` (Bauer et al., 2001) and 5`-
GTCGTT-3` (Hartmann and Krieg, 2000) for murine and human use, 
respectively. The same motif was found to be beneficial for different animal 
species including the horse (Rankin et al., 2001). In contrast, ODN sequences 
containing this motif (2142 and 2006 B-class) were not most effective in 
stimulating BAL cells in the present study. This contrary could probably be due to 
different prevalent cell populations between PBMCs and BAL cultures. For 
horses, Olafsdottir et al. (2004) described an ideal sequence 5`-CTCGTT-3` which 
indeed hasn’t been confirmed by other groups yet. Due to deficiency of 
knowledge in the action of various CpG motifs on equine BAL cells, motifs with 
a record of any equine employment were chosen and their distinctive effects were 
compared. Previously, CpG B 2142 and CpG C 2395 as well as ODN 2041 were 
used in vitro only in equine PBMCs cultures which is a known and well 
established model (Liu et al., 2008 and 2009). However, as RAO is located in 
small airways in this study cells were harvested from this specific region to 
investigate effects on this specialized group of lung cells.  
 This is the first study which compared the effects of all three CpG classes in vitro 
on equine BAL cells. Furthermore, two different motifs per class except the A 
class were investigated to gain more insight into motif depending CpG 
immunostimulation on equine BAL cells. First studies on equine BAL cells were 
often based on cytokine quantification by mRNA detection instead of translational 
products themselves by ELISAs. The advantage of measuring proteins directly 
instead of mRNA is the possibility to exclude posttranscriptional modifications 
which could influence results quantitatively. 
With regard to the results, the optimal stimulating sequence among five explored 
CpG-ODN in equine BAL cells was the A-class 2216. The detectable IL-10 up 
regulation was higher than expected as CpGs were previously known for potent 
IFN-γ release in general and CpG A-class for IFN-α release in particular (Krieg 
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2002). Characteristics of the A-class which could influence the efficacy are its 
exceptional backbone structure (backbone chimera), palindrome motif and poly 
guanine tail which all contributes to a special structure-effect interaction (Krieg 
2006). The actual IL-10 cytokine release profile was related to heterogeneous cell 
composition in BAL (macrophages, neutrophile granulocytes and lymphocytes). 
TLR-9 receptors were identified as the primary target of CpG-ODNs (Krieg, 
2002). Among other cells human plasmacytoid dendritic cells (pDCs) are known 
to express constitutionally TLR-9 in the endosome. Furthermore pDCs build the 
first line of antigen presenting cells at the interface between the body surface and 
the environment and are expected to take up CpG formulations. Human pDCs 
were shown to form a tight network in the epithelium of conducting upper and 
lower airways (Garnier and Nicod, 2009). Similarly, it can be assumed that pDCs 
are located in equine lungs and serve the same functions as in humans. Via the 
TLR-9 pathway CpG 2216 induced human pDCs which activated CD4+ CD 25- 
towards IL-10 producing CD4+ CD 25+ T-regs by direct cell contact (Moseman et 
al. 2004). 
The potency of employed ODN 2041 (which was lacking a CpG motif) in 
stimulation of IL-10 probably showed a CpG independent TLR-9 activation 
mechanism and the importance of sugar backbone on TLR-9 activation (Haas et 
al., 2008). Synthetic CpG-ODN possesses a modified phosphorothioate sugar 
backbone which acts as strong TLR-9 antagonist by competitive inhibition (Haas 
et al., 2008). CpG motifs inverse the antagonistic effect towards a desired TLR-9 
stimulation. The high efficiency of phosphorothioate modified CpG-ODN is 
explicable by 100-fold higher affinity towards TLR-9 in contrast to the original 
phosphodiester structure in natural prokaryotic DNA as basal TLR-9 agonist 
(Haas et al., 2008). With regard to participation of IFN-γ in chronically airway 
inflammation in vivo this observation is interesting as a possible therapeutic 
alternative.  
All six ODNs treated cells in BAL from healthy horses showed higher releases of 
IL-10 and IFN-γ as compared to RAO horses. This was observed regardless of the 
formulations (CpG, CpG-GNP). The most likely explanation is a difference in cell 
types. As RAO is expected to be associated with Th2 upregulation less 
stimulation of Th1 and Treg effects is likely to happen. On the contrary, healthy 
individuals should have normal regulatory T cell capability which is demonstrated 
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here by high level of the cytokine IL-10. 
All three cytokines detected in cells obtained from healthy horses could serve as 
important parameter for non allergic lungs under homeostatic immunologic 
conditions without excessive Th2 response. Therefore, detected cytokine 
concentrations in healthy individuals could be regarded as benchmarks for a CpG-
based immunotherapy of RAO-affected individuals.  
With regard to the observation that no significant difference of IL-10 release by 
cells from RAO-affected horses within CpG classes B and C was detectable, it 
could be hypothesized that the class is more determining than the individual CpG 
sequence.  
IL-10 decreases IL-4, IL-5 and IFN-γ release (van Scott et al., 2000; Taylor et al., 
2006) and could therefore be beneficial to interfere with pathophysiology of RAO. 
With regard to an expected up regulation of proinflammatory Th1 cytokines by 
CpG-ODN, IFN-γ release was interestingly relatively low. A possible explanation 
could be the high amounts of IL-10 which could have inhibited IFN-γ release.  
The absolute values of IL-4 concentration were considerably low and below the 
detection limit of 15.6 pg/ml as given by the ELISA standard curve. However, 
raw data values were higher before being corrected by subtracting the untreated 
BAL cell result considered as a negative control. Therefore the observed trends 
that those cells obtained from healthy horses exhibited lower IL-4 release was 
considered convincing with regard to earlier findings (Cordeau et al., 2004; 
Horohov et al., 2005). This is in accordance with the presumption of Th2 
downregulation, according to expected Th2/Th1 shift and probably also due to 
high IL-10 amounts with negative feedback on IL-4 release. These results support 
the idea of CpG-ODN prominent role in the down regulation of allergic Th2 
cytokines (Bohle 2002; Vollmer and Krieg, 2009). Furthermore, GNPs obviously 
discriminated CpG action towards IL-4 release in cells derived from healthy 
horses.  
CpG-ODN also induces B cells to produce IL-10, which acts in a counter 
regulatory fashion to limit the inflammatory response to CpG (Kline and Krieg, 
2001). This would be beneficial in chronic inflammatory responses like RAO. It is 
known that a pure Th1 response with IFN-γ could contribute to exacerbation of 
allergic disease (Umetsu and DeKruyff, 2006). IFN-γ is also produced in lungs of 
patients with asthma and seems to contribute to severity of the allergic reaction 
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(Umetsu and DeKruyff, 2006). Th1 cells on their own do not counterbalance Th2 
cells but even could augment inflammatory reactions in lungs in an in vivo model 
(Umetsu and DeKruyff, 2006). On the contrary, IFN-γ was found to contribute to 
inhibitory effects in asthma and allergy in combination with suppressive IL-10 
from T-regs (Stock et al., 2004). 
Moreover, the IL-4 receptor α (IL-4Rα) gene on chromosome 13 was identified as 
a candidate gene responsible for RAO (Gerber et al., 2008). IL-4Rα is also 
associated with asthma and atopy as well as with parasitic defense in humans and 
animals (Gerber et al., 2009). Gerber et al. found a coherency between intestinal 
helminthes burden and RAO wherein RAO affected horses showed a significant 
lower helminthes burden than healthy horses. The same group described the 
phenomenon as inverse relationship between asthma and the resistance to 
parasites which seems to correlate with IgE levels (preliminary data). Thus, the 
abolishment of intestinal helminthes in horses as in humans is supposed to 
contribute to a rising rate of allergic diseases. Altogether, environmental 
influences, genetic and epigenetic impacts, feeding and microbial infections 
which impair body’s defense increase the risk to develop allergic airway diseases. 
This applies to horses as well as humans.  
The MTT assay revealed that the various formulations had distinctive impacts on 
viability of tested BAL cells. The most important observation was the significant 
difference between CpG and CpG-GNP treated cells from RAO affected horses. 
The GNP formulated CpGs were less cytotoxic on average for the cell population 
present in the RAO BAL which is in accordance with earlier findings (Bourquin 
et al., 2008).  In summary, GNPs were shown as an effective and biocompatible 
nucleotide delivery system in equine in vitro. Furthermore, GNPs are expected yet 
to protect short active A-class from otherwise early degradation. The assignment 
of A-class CpGs in vivo has been limited because of its susceptible backbone 
structure but its use was recently reported in a clinical study (Senti et al., 2009). 
Soluble CpGs result in a significantly higher viability in healthy cells as compared 
to RAO cells, but still lower than the CpG formulation. This is evident from the 
IL-10 release profiles where release by healthy horses derived cells are 
significantly higher than by RAO cells. On the contrary, higher viability of CpG-
GNP treated cells does not correspond to higher IL-10 or IFN-γ release. One 
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explanation could be an overstraining phenomenon of the regulatory cytokine 
producing cells which were supposed to be present in lower number in BAL from 
RAO-affected horses than in BAL of healthy horses. The difference in treatment 
response could be a proof of distinction of RAO and healthy cells on cytokine 
level in vitro. Due to the fact that cell isolation kits for equine BAL cells are not 
commercially available, it was not possible to stimulate separately isolated cell 
types for quantification of cytokines. Although, the isolation of individual cells 
and their quantitative contribution to cytokine release as well as their viability 
following stimulation are desirable. This may be a necessary precondition for 
successful future in vivo applications. Here, comparable experimental conditions 
as in vivo are given where a heterogenic composition of relevant cells is present. 
Therefore, intercellular interaction could probably be better reflected to finally 
predict in vivo therapeutic effects. Interestingly, previous human pediatric studies 
found that numbers of CD4+CD25+ T-reg cells appeared in decreased amounts in 
children suffering from asthma (Hartl 2007). Extrapolating this finding to the 
present equine scenario, a lowered number of CD4+CD25+ Treg cells in BALF of 
RAO-affected horses could have caused the observed depletion in IL-10 
expression. 
In conclusion, CpG-ODN 2216 A-class was identified as most efficient 
stimulating motif out of the six examined here to trigger IL-10 and IFN-γ in 
horses. As a potent delivery system GNPs were partially able to enhance CpG 
impact (IL-4 and IL-10 in cells from healthy horses) and was found to be 
biocompatible. With regard to RAO, local administration of CpG-ODN/GNP by 
inhalation has been found to be promising. Besides the conventional symptomatic 
treatment either by systemic or aerosol administration of β2-sympathomimetic 
agents, mucolytic agents and corticosteroids this new approach need to be 
explored further as interfering with the immunologic pathogenesis could offer an 
effective anti-hypersensitivity therapy.  
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6. A nebulized gelatin nanoparticle-based CpG formulation is effective in 
immunotherapy of allergic horses.  
6.1 Introduction 
The previous sub-chapters IV.4 and IV.5 rendered obvious that GNPs are suitable 
for nebulization by active vibrating mesh devices to be administered to the lung. 
Moreover, this application process did not negatively affect a delicate payload 
such as CpG-ODNs which remained effective after nebulization. This was 
confirmed by in vitro assays beforehand. Furthermore, an A-class CpG-ODN 
sequence was identified which exhibited good activation of peripheral tolerance in 
horses as concluded from the induction of key cytokine IL-10 in vitro. 
Consequently, the next step was to establish a clinical application to proof the 
tolerability and the effectiveness of the new formulation and application route in 
vivo. Therefore, an aerosol formulation of biodegradable, biocompatible and non-
toxic (Bourquin et al. 2008, Zwiorek et al. 2008) GNP-bound CpG-ODN 2216 
was used to treat equine RAO in a clinical study. Accordingly, a novel technical 
combination of an equine spacer for eased application of aerosols and a suitable 
VM device needed to be introduced. Like human asthma, RAO in horses was 
considered common multifactor allergic airway hypersensitivity reaction elicited 
by environmental exposure to potential allergens (Robinson 2001) and heritable 
components (Gerber et al. 2009). A promising immunotherapeutic strategy against 
allergic conditions already entering human clinical phase IIa studies involved 
CpG-ODN (Senti et al. 2009) as synthetic analog of natural microbial CpG-DNA 
(Krieg 2002). This TLR9 agonist demonstrated efficiency in allergic diseases due 
to its immunomodulating potential  to cause a Th2/Th1 shift (Vollmer and Krieg 
2009, Kline 2007, Krieg 2002) which was associated with a downregulation of 
proallergic Th2 cytokines (IL-4, IL-5, IL-13) and an upregulation of antiallergic 
Th1 cytokines (IFN γ, IL-12) and an immunoglobulin isotype switch from allergy 
mediating IgE to IgG (Bohle 2002; Bohle 2002). Before, electrostatically GNP-
bound CpG-ODNs were proven to be protected against early degradation by 
nucleases via steric shielding. Furthermore, cellular uptake of CpG-ODN into 
target cells was enhanced by nanoparticulate delivery (Zwiorek et al. 2008). In the 
present study, bronchoalveolar lavage fluid was obtained from healthy and 
allergic horses to quantify Th1/Th2 cytokine levels before and after novel 
inhalation regimen to estimate regimen effectiveness on cytokine level. Of equal 
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importance, clinical symptoms were assessed to obtain information on a possible 
curative effect. Thus, this study was the first one to provide a proof effectiveness 
of colloidal nanocarrier-mediated immunotherapy in food-producing animals and 
constitutes the most advanced project within this thesis.  
 
6.2 Materials and methods 
This work was conducted in close and essential cooperation with the Equine 
Clinic, LMU Munich. Gaining of BAL and diagnosis of clinical symptoms was 
conducted by veterinarian John Klier. All other experiments were performed 
alone or in cooperation with him, depending on the individual case. 
 
6.2.1 Nanoparticle production and loading.  
GNPs were manufactured according to the standard protocol (Coester et al. 2000) 
as described in chapter II, 1.2.1 using porcine-derived gelatin type A Bloom 175, 
glutaraldehyde 25% solution, cholamine and 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC). All starting materials were purchased 
from Sigma (Taufkirchen, Germany). The cationization of GNPs and electrostatic 
binding of CpG-ODN onto the particle surface was described before (Zwiorek et 
al. 2008). Particle size and surface charge were quantified in 10 mM NaCl before 
and after loading by a Zetasizer ZS Nano (Malvern Instruments, Malvern, UK). 
The target surface loading of 5% (w/w) was checked photometrically to ensure 
colloidal stability of applied dispersions. 
 
6.2.2 Oligodeoxynucleotides.  
Five different CpG-ODNs and one ODN without CpG motifs were synthesized by 
Biomers GmbH (Ulm, Germany). All ODNs were single stranded with a length of 
20 to 30 bases. The following sequences covered all major three CpG-ODN 
classes (A-, B- and C-class): ODN 2041 without CpG motif (5`-CTG GTC TTT 
CTG GTT TTT TTC TGG-3`), CpG-ODN A 2216 (5`-G*G*G GGA CGA TCG 
TCG* G*G*G *G*G-3`) with its specific chimera backbone structure consisting 
of phosphorothioate* (PS) and phosphodiester (PD) modified deoxyribose. The 
latter sequence was the only one to be chosen for direct in vivo application (IV, 5) 
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All other employed sequences were throughout phosphorothioate backbone 
structured. Moreover, two different B-classes  and two different C-classes were 
matched: CpG B ODN 2142 (5`-TCG CGT GCG TTT TGT CGT TTT GAC 
GTT-3`), CpG B ODN 2006 (5`-TCG TCG TTT TGT CGT TTT GTC GTT-3`), 
CpG C ODN 2395 (5`-TCG TCG TTT TCG GCG CGC GCC G-3`) and CpG C 
ODN M362 (5`-TCG TCG TCG TTC GAA CGA CGT TGA T-3`). 
 
6.2.3 CpG-GNP formulation. 
 A working concentration of 3 mg/ml for GNPs and of 1.0 mg/ml for ODNs was 
adjusted. For in vitro cell cultures, 278 µg of GNPs loaded with 14 µg of ODN 
were applied per well which corresponded to 0.87 mg/ml GNP and 0.044 mg/ml 
of ODN. As references, CpG-ODN solutions of every class with a concentration 
of 0.044 mg/ml and GNP dispersion concentrated 0.87 mg/ml were added per 
applicable well. For inhalation studies, 3.75 mg GNPs were loaded with 187.5 µg 
ODN in a total volume of 2.5 ml highly purified water (HPW) were used per 
individual inhalation. 
 
6.2.4 Nebulization.  
 For inhalation studies, an Equine Haler™ spacer (Equine HealthCare Aps, 
Hoersholm, Denmark) and an AeroNeb Go™ vibrating mash nebulizer (Aerogen, 
Galway, Ireland) were combined by a 90° glass connector with ground joints that 
suitably matched the aerosol generator part’s outlet diameter and the spacer’s inlet 
(Fig. 1). 
 
 
 
 
 
 
 
Fig. 1: Technical setup of the combined VM-device with the equine inhalation 
spacer. 
 
 
The identical protocol was run for negative control placebo trial and for the 
medication trial. The negative control exclusively contained an aqueous (HPW) 
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GNP dispersion (1.5 mg/ml) while the medication was a combination of GNP 
(1.5 mg/ml) and CpG-ODN 2216 (0.075 mg/ml). Healthy and RAO-affected 
horses were inhaled three times alike with two-day intervals between individual 
administrations followed by a control BAL. Two additional subsequent 
inhalations and one final BALF examination for disease development monitoring 
were added if significant changes occurred after the third inhalation. Clinical 
examinations, blood gas analysis, endoscopic exploration and cytology of TBS 
were performed at the beginning, after three and finally after five inhalations.  
 
6.2.5 Clinical examination and lung scoring.  
A lung scoring system (Gerber et al. 2004) was further developed comprising 
clinical parameters (nasal discharge, breathing rate), blood gas chemistry, 
endoscopic exploration, cytology of tracheobronchial secret (TBS) and of 
bronchoalveolar lavage fluid (BALF). Accordingly, 14 horses of a mean weight of 
477.7 kg and aged 12.0 years on average were scored. The applied scoring system 
allowed grouping the patients into four categories (healthy, mild, moderate and 
severe RAO). For the clinical trial, three groups of horses were established, with 
the first group (n = 4) consisting of healthy horses (mean age of 8.8 years) for the 
placebo negative control, the second group (n = 4) consisting of healthy horses for 
compatibility study (mean age of 10.4 years) and the third group (n = 4) of 
moderate RAO-affected horses for therapeutic efficiency verification (mean age 
of 16.8 years). TBS scoring (grades 0-5) was performed according to Gerber et al. 
(2004): 0 = none, clean, singular TBS; 1 = little, multiple small blobs; 2 = 
moderate large blobs; 3 = marked, confluent/stream-forming; 4 = large, pool-
forming; 5 = extreme, profuse amounts. The key arterial blood gas parameter of 
partial pressure of oxygen (PaO2) was measured by a Radiometer Copenhagen 
NPT 7 series (Radiometer GmbH, Willich-Schiefbahn, Germany). Physiological 
values for PaO2 were set to 100 mmHg (±5 mmHg). Moreover, percentages of 
neutrophile granulocytes out of total cell count from TBS cytology were 
calculated after staining by Diff-Quick® staining set (Medion diagnostics, 
Düdingen, Switzerland). Physiological range of breathing rate was defined as 8 to 
16 breaths per minute while higher values were considered as pathological.  
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6.2.6 Cell culture and in vitro cytokine quantification.  
BALF was taken from every horse before and after inhalation regime 
(50 ml/100 kg body weight sterile, warm, isotonic NaCl solution). Gained cell 
suspension was centrifuged by 1200 g for 6 minutes. Supernatants were stored 
immediately at -80 °C on dry ice in the stable for cytokine conservation. Then, 
supernatants were analyzed for IL-4, IL-10 and IFN-γ by equine duo set ELISA 
kits according to the manufacturer’s protocol (R&D Systems, Minneapolis, USA) 
(Fig. 2). 
Total cell count was determined and subsequently cells were seeded, stimulated 
by six ODNs and checked for cytokines as described above in 5.2.4 and 5.2.5. The 
in vitro stimulation before and after in vivo inhalation was assessed due to the 
pictured design of experiment (Fig. 2). The study was approved and was 
designated the No 55.2-1-54-2531-31-10 by the legal agency for animal 
experiments (Regierung von Oberbayern, Munich, Germany). 
 
Fig. 2: Overview on the combined in vitro and in vivo study design to investigate 
the inhalative regimen’s influence both on changes in BALF cytokine composition 
and on changes in cell composition and activity after an additional CpG 
stimulation in vitro. As an example, the full set of experiments for a single horse is 
pictured. 
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6.2.7 Statistical analysis.  
Comparisons between groups (normally distributed) were carried out using the 
unpaired Student`s t-test. N is shown in parenthesis for each calculation in Figure 
legends. All statistical analysis was performed using Prism Graph (Version 5.0, 
GraphPad software Inc., La Jolla, USA). 
 
6.3 Results and Discussion 
6.3.1 Tracking the regimen’s therapeutic effect in vitro 
To evaluate the efficiency of envisaged inhalation therapy, BALF was obtained 
both from RAO-affected and healthy horses before and after the inhalation 
regimen GNP-bound CpG-ODN 2216. Data from healthy individuals served as 
physiological reference. First, BALF cells of RAO-affected horses were 
stimulated in vitro by six different ODNs as described in chapter IV.5 (scheme 
Fig. 2). Averaged results depicted in Fig 3a and 3b imply a major impact of the 
inhalation therapy in RAO-affected individuals. Fig. 3a shows in vitro IL-10 
expression of cells derived from RAO-affected horses treated by ODNs and GNP-
bound ODNs both before and after inhalation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Release of key cytokines from BALF cells gained from RAO-affected 
horses stimulated in vitro by ODN and ODN-GNP before (pre) and after (post) 
in vivo inhalation therapy, respectively. a, IL-10 release from cell cultures 
stimulated by soluble ODN and ODN-GNP is increased by inhalation therapy of 
GNP-bound ODN and subsequent in vitro stimulation (n=18, ± S.D ) by 6 
different GNP-bound ODNs or by 6 different soluble ODNs on average. b, IL-4 
release is accordingly decreased. 
After inhalation treatment, a significantly (P < 0.0001) higher IL-10 release 
(390 pg/ml) in BAL cell cultures stimulated by GNP-bound ODNs was observed  
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as compared to the state before inhalation treatment (83 pg/ml) (Fig. 3a). Similar 
trend of IL-10 release was observed after stimulation (389 pg/ml) by soluble 
ODNs (Fig. 3a) compared to the value of 139 pg/ml before inhalation regime 
(P = 0.0002). This could be due to the fact that the inhalation therapy triggered 
antiallergic IL-10 producing cells in BAL. Accordingly, IL-4 in vitro expression 
was decreased significantly after inhalations of both soluble (P = 0.0298) and 
GNP-bound (P = 0.0282) ODNs although the absolute values were comparably 
low (Fig. 3b). These findings indicated that Th2-mediated proallergic immune 
response was reduced.  In contrast to high IL-10 values in vitro, especially after 
inhalation treatment, low amounts of both IFN-γ and IL-4 could be regarded as a 
negative feedback mechanism by IL-10 (Taylor et al. 2006; Van Scott et al. 2000). 
In contrast, Th1 upregulation (IFN-γ) was expected after treatment with CpG-
ODN. Yet, measured IFN-γ values (data not shown) could not confirm the Th1 
upregulation and might have been influenced by high IL-10 values. However, low 
IFN-γ levels could be considered as beneficial in chronic inflammatory processes 
(Umetsu and DeKruyff 2006). 
Overall, IFN-γ release in vitro was low and did not reveal a general trend after 
treatment by GNP-bound ODNs (P = 0.1414) or by soluble ODNs (P = 0.4870) 
before (pre) versus after (post) inhalation treatment of RAO affected horses. 
However, CpG A-class exhibited higher stimulation before and after inhalation 
treatment as compared to all the other CpG-classes (data not shown).  
 
6.3.2 Therapeutic effect on cytokine level in vivo 
As a key cytokine to mediate tolerance, IL-10 was our primary interest in the 
evaluation of cytokine expression after administration of GNP-bound CpG-ODN 
in vivo.  Fig. 4a clearly depicts the in vivo increase of IL-10 expression detected in 
BALF supernatant in RAO-affected horses. While three inhalations led to a 
significant 3.8-fold increase (P = 0.0473) in IL-10 expression, a 6.9-fold increase 
was found after five inhalations (Fig. 4a). Therefore, the average IL-10 levels 
differ significantly (P = 0.034) before starting and after finishing the full five 
inhalation regimen applied to RAO-affected horses. Healthy horses exhibited a 
2.14 fold augmentation in IL-10 expression after pulmonal administration of 
GNP-bound CpG-ODN confirming the principle of action (Fig. 4a). 
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However, differences in expression levels before and after inhalation were 
marginally statistically significant (P = 0.089). In contrast, no significant 
difference (P = 0.289) was found when comparing healthy horses before and after 
three inhalative administrations of blank GNPs which was given as placebos 
(Fig. 4a). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Effect of GNP-bound CpG-ODN and plain GNPs on cytokine release in 
vivo before and after inhalation therapy. a, IL-10 release is expressed as n-fold 
increase based on 1 as initial value before inhalation. IL-10 release from RAO-
affected horses (n=4, ± S.D.) before and after three and five inhalation of GNP-
bound CpG-ODN (black bars), from healthy horses (n = 4, ± S.D.) before and 
after three inhalations of GNP-bound CpG-ODN (grey bars) and from healthy 
horses (n=4, ± S.D.) before and after three inhalations of plain GNP (white bars). 
b, IFN-g(amma) release from RAO-affected horses before and after three and five 
inhalation of GNP-bound CpG-ODN (black bars) and from healthy horses before 
and after three inhalations of plain GNP (white bars). 
 
Therefore, it was concluded that IL-10 could be induced following administration 
of CpG-GNP through inhalation in RAO affected horses. The studies of previous 
chapter V.5 led to the decision to employ CpG-ODN 2216 (A-class) in vivo due to 
superior IL-10 inducing properties from equine BAL cells compared to 
representatives of the B- and C-class. Likely, IL-10 could be beneficial in 
avoiding allergic inflammatory immune response towards allergen contact and 
could therefore prevent tissue injury by neutrophile degranulation. In humans, 
increase in IL-10 by established antiallergic medication such as glucocorticoids or 
allergen immunotherapy was frequently attributed to the activation of T-reg cells 
(Ryanna et al. 2009). Asthmatic human patients showed lower amounts of T-regs 
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in BAL compared to healthy ones which corresponds to the lack of peripheral 
tolerance (Hartl et al. 2007). Therefore, it was hypothesized that the found 
increased IL-10 expression could be related to higher or nearly physiologic 
(equivalent to healthy) Treg cell numbers in the lower airways. Furthermore, it is 
known that CpG-ODN activates plasmoidal dendritic cells (Moseman et al. 2004) 
which reside the lower airways (von Garnier and Nicod 2009). In addition, it was 
shown earlier that CpG-ODN promoted both IL-12 and IL-10 release by dendritic 
cells which led to increased IL-12 mediated Th1 and IL-10 mediated Treg 
induction (Jarnicki et al. 2008). Thus, it can be concluded from the present study 
that GNP-bound CpG-ODN induced release of IL-10 contributed to Treg cell-
mediated peripheral tolerance which would be beneficial as an innovative and 
alternative treatment of allergic airway diseases (Umetsu et al. 2006, Ryanna et al. 
2009, Moseman et al. 2004). 
In vivo secretion of IL-4 and IFN-γ was analyzed in BALF supernatants before 
and after inhalation regimens. IL-4 levels were below detection threshold in vivo. 
For IFN-γ, a significant impact of GNP-bound CpG-ODN was observed. Fig. 4b 
reveals a constant increase after three and five consecutive inhalations compared 
to IFN-γ levels in BAL supernatants before the regimen (P = 0.0034). Placebo 
administration did not result in altered cytokine expression (P = 0.8322) (Fig. 4b) 
while IFN-γ data could not be obtained from healthy individuals treated with 
GNP-bound CpG-ODN. However, increased IFN-γ expression by GNP-bound 
CpG-ODN met the expectation of CpG-ODN-driven Th1 activation. Furthermore, 
the parallel increase of IFN-γ in combination with suppressive cytokine IL-10 was 
reported to be beneficial in challenging allergic conditions (Stork et al. 2004). 
This finding also supports the previously discussed Th2/Th1 shift away from Th2 
associated proallergic pathways (Jurk and Vollmer 2007). 
 
6.3.3 Curative effectiveness of the GNP-based formulation  
Beside cytokine-based immunologic parameters, the clinical impact of the hereby 
proposed therapy was assessed. First, the breathing rate per minute was assessed 
as an easily accessible clinical parameter to discriminate healthy and RAO 
affected individuals. RAO affected horses exhibited a breathing rate of 
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19.6 (± 1.47) breaths per minute (bpm) before treatment (Fig. 5a) which was 
significantly higher than the measured bpm value 13.6 (± 0.98) of healthy horses 
(P = 0.0094). The regimen (five doses) lowered the rate significantly down to 12.8 
(± 0.80) bpm (P = 0.0036). After treatment the breathing rate no longer differed 
significantly from physiological values (8- 16 bpm) of healthy horses (P = 
0.5447) (Fig. 5a). Therefore, it can be concluded that the regimen potentially 
contributes to a normalization of bpm of RAO affected horses. 
The determination of blood gas was used to evaluate the extent of gas exchange 
and the response to treatment (Robinson 2001). The magnitude of gas exchange 
abnormality correlates with the severity of bronchiolitis and clinical signs 
(Robinson 2001). In this study, it was observed that healthy horses had a PaO2 of 
94 mmHg (± 2.07) (Fig. 5b). In contrast, RAO-affected horses showed a PaO2 of 
86.75 mmHg (± 2.29) (Fig. 5b). This mean value was significantly improved 
(P = 0.0153) towards 95.6 mmHg (± 1.69) by the full regimen of five inhalations 
(Fig. 5b). Thereafter, no statistically significant difference was observed 
compared with the healthy animals (P = 0.5384). Although not significant, 
variability in this study before and after treatment was considerable in healthy 
individuals. Therefore, this clinical parameter should not be regarded as robust as 
previously discussed criteria. 
Healthy individuals exhibit airways which are free of mucus deposition. A typical 
clinical sign of RAO is the appearance of excessive mucus accumulation within 
the trachea by dyscrine and hypercrine pathological action known as 
tracheobronchial secretion (TBS). 
This clinical sign was positively affected by the treatment of five inhalations as 
the graded TBS score decreased (P = 0.1078) from 2.7 (± 0.436) to 1.7 (± 0.34) 
(Fig. 5c). However, TBS values of RAO-affected horses did not dwindle to 
physiological levels which accounted for 0.3 (± 0.20) on average but remained 
significantly higher (P = 0.0019) than those of healthy subjects (Fig. 5c). 
Additional studies need to clarify whether a longer regimen can ameliorate the 
already observed positive trend in TBS reduction.  
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Fig. 5: Therapeutic effect of GNP-bound CpG-ODNs versus plain GNPs 
(placebo) on important clinical parameters. a, Breathing rate before and after 
treatment by GNP-bound CpG-ODN in RAO-affected horses (n=4, ± S.D.), before 
and after treatment by GNP-bound CpG-ODN in healthy horses (n=4, ± S.D.) and 
before and after treatment by GNPs (placebo) in healthy horses (n=4, ± S.D., left 
to right). b, Oxygen partial pressure in arterial blood before and after respective 
treatments. c, Occurrence of tracheobronchial secrete before and after respective 
treatments. d, Percentile of neutrophil granulocytes in the TBS before and after 
respective treatments. 
 
Within TBS, the percentage of neutrophile granulocytes represents a strong 
indicator for RAO (Lavoie et al. 2001). Moreover, it is regarded as one of the 
most decisive parameters to evaluate RAO. Consequently, determined levels were 
high (70% ± 0.50) in RAO individuals before treatment and differed significantly 
from values of healthy horses exhibiting 26% (± 6.0) (P = 0.0004) (Fig. 5d). 
Treatment by GNP-bound CpG-ODN contributed to a significant decrease down 
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to 50% (± 2.04) by three inhalations (P < 0.0001) and down to 40% (± 6.52) by 
five inhalations (P = 0.0048), respectively (Fig. 5d). The percentage of 
neutrophiles within the TBS was directly related to the severity of the RAO 
condition. Therefore, it can be deducted that the severity of the pathogenesis was 
significantly reduced after five applications of GNP-bound CpG-ODN as no 
statistically significant difference could be observed compared to healthy horses 
(P = 0.195). Furthermore, Fig. 5d shows that in healthy horses neither the GNP-
bound CpG-ODN (P = 0.3472) nor the placebo (P = 0.8171) resulted in a 
significant change of neutrophile percentages, respectively. Previously, T-reg 
activation was related to a reduction in activity and the number of neutrophile 
granulocytes by promoting their rate of apoptosis (Lewkowicz et al. 2006). 
Human neutrophiles are responsible to express all known TLRs except TLR3 
(Lewkowicz et al .2006). Moreover, TLRs were shown to possess a crucial impact 
on T-reg stimulation and function (Lewkowicz et al. 2006). Beyond, TLRs were 
referred to play an integral part in the organisation of innate immune responses 
and indirect control of the adaptive immunity by activating antigen presenting 
cells (Pasare and Medzhitov 2003). Previous investigations confirmed that T-reg 
cells inhibit neutrophiles other than by direct cell-cell contact mechanism (CTLA-
4/B7-1 mechanism) and especially through IL-10 action (Montagnoli et al. 2006). 
Furthermore, this mechanism was advantageous in the treatment of allergic 
diseases (Umetsu and DeKruyff 2006).   
 
6.4 Conclusion  
Above all, the GNP-based formulation was shown to be well tolerated in vivo. 
The observed impressive IL-10 induction by the hereby proposed treatment could 
directly be related to the clinically apparent decreasing neutrophile percentage. 
Therefore, IL-10 induction most likely contributed to the regimen’s anti-RAO 
effectiveness. Consequently, further studies with higher patient numbers and dose 
escalation are in planning state to elucidate the full potential of this first applied 
inhalative nanoparticle based immunotherapy in food producing animals.  
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V Final conclusion and outlook 
1. Enhanced production opportunities 
Up-scaling of the original manufacturing setup was technically possible and 
performed up to ten-fold increased batch sizes. Systematic correlation studies 
enabled the establishment of a set of equations to predict necessary GNP 
preparation parameters for each relevant batch size. This shall contribute to future 
higher GNP demand in clinical manufacturing. 
Moreover, the feasibility of replacing well-established but initially toxic starting 
material glutaraldehyde as a cross-linking agent by the enzymatic alternative 
Transglutaminase was demonstrated. 
 
2. Analytics  
Ultrasonic resonator technology was demonstrated as a capable tool in relative 
GNP size analysis and ODN surface binding detection which could serve in future 
as a non-destructive tool for online in-process control in continuous GNP 
production. Within this study, a variable response of cationized and non-
cationized GNPs towards distinctive buffers was observed. The swelling and size 
reduction was in accordance with the salts of the Hofmeister series. 
Of special importance was the successful radio-labeling of GNPs by radionuclides 
111In+ or 68Ga3+ respectively, to monitor their biodistribution after s.c. or i.v. 
administration both by conservative sectioning and PET. PEGylation was 
conducted and proofed for several molecular weights. However, no enhanced 
circulation properties could be obtained due the prevalent hydrophilic properties 
of the starting molecule gelatin. Nevertheless, the radio-labeling technique could 
be beneficial in new applications such as the monitoring of inhaled GNPs and in 
the quantification of the resulting lung deposition.   
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3. Immunotherapy 
3.1 Adjuvant cancer immunotherapy 
In continuation of promising in vitro and in vivo studies on the employment of 
GNP-bound CpG-ODN as an adjuvant in OVA-targeted cancer immunotherapy, 
initial trials on the isRNA-mediated immunostimulation clearly demonstrated that 
GNPs can be of benefit in facilitating to address also the TLR-7 in antitumoral 
settings. Here, isRNA superiorly entered the target lysosome when transport was 
GNP-mediated e.g. in contrast to DOTAP-mediated transport. GNPs effectively 
protected the isRNA from degradation upon RNAse challenge. 
Immunostimulation was successful as revealed by activation of relevant DC 
markers such as CD69 and most important, survival of pre-immunized and OVA-
expressing tumor challenged mice was significantly prolonged. Ongoing studies 
indicate that this promising strategy is working in a therapeutic model setting, too. 
Thus, GNP-based isRNA formulations could be capable to cure existing tumors.  
 
3.2 Immunomodulative effectiveness of GNP-bound CpG-ODN in a 
preclinical canine study  
The impressive benefit of CpG A-class delivery by GNPs to PBMCs in terms of 
antiallergic IL-10 release was revealed in a canine in vitro study. This laid the 
foundation for further, now starting, in vivo studies to elucidate the possibility of a 
therapeutic option against common canine atopic dermatitis by modulative CpG-
based immunotherapy.  
 
3.3 Immunomodulative therapy of RAO horses – preliminary clinical trial 
Finally, a novel approach in equine RAO therapy was established, constituting the 
first-time ever immunotherapeutic clinical study associated with a colloidal carrier 
system. First, an appropriate combination of nebulizer and spacer to nebulize 
CpG-GNP formulations was developed. Then, a suitable CpG sequence to 
stimulate equine BAL cells was identified. However, this chosen CpG 2216 
sequence was the prototype of CpG A-class and other sequences might even more 
potently initiate desired cytokine production. For instance, the potent A-class 
sequence used for the canine study would be an interesting approach because a 
CpG with a fully phosphothioated backbone was used. In addition to the 
originally intended higher backbone stability and resistance against nucleases of 
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the fully phosphothioated backbone CpG, an eased fashion of particle surface 
loading could have contributed to an enhanced effect. The fully phosphothioated 
CpG variant may lead to a lower extend to self-aggregation and auto-particle 
forming as CpG A-class with chimeric backbones tended to do. Consequently, 
individual ODNs may remain through increased inter-ODN electrostatic repulsion 
on the one hand and higher electrostatic attraction to cationized GNPs on the other 
hand.  
On cytokine detection level, it was remarkably possible to distinguish RAO-
affected from healthy horses in vitro. Most notably, regulatory cytokine IL-10 
expression was significantly triggered in vivo by five consecutive inhalations in 
RAO-affected horses. The entirety of clinical parameters assessed after 
nanoparticle treatment indicated a partial remission of the allergic condition. In 
particular, breathing rates were lowered to physiologic level, blood oxygen partial 
pressure was significantly elevated, the pathogenic TBS score values were 
moderately reduced and the RAO-determinant content of neutrophile granulocytes 
within the TBS was more than halved on average. Therefore, this preliminary 
clinical study showed for the first time safety and curative effectiveness of 
colloidal nanocarrier-mediated immunotherapy in food-producing animals.  
 
3.4 Outlook on further planned clinical studies on RAO  
To elucidate its full potential, the therapy’s effectiveness has to be validated in 
further steps. Therefore, higher patient numbers and patients affected with severe 
RAO will be employed in projected follow-up studies in cooperation with a large 
pharmaceutical company providing that the constant supply of high-quality GNPs 
can be maintained in the medium term. Of essential importance will be additional 
controls to include both placebo and soluble (non GNP-bound) CpG in RAO-
affected horses. Moreover, as the present preliminary clinical study just illustrated 
the effect of a five-fold inhalation protocol over a relatively short period of time 
(less than a month), evaluation of both immunologic and curative long-term 
effects and the establishment of a dose-response-curve will be crucial steps 
towards a possible future drug career.  
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4. Outlook on the perspective of nanoparticles in nanomedicine 
Translating laboratory innovation into clinical products with commercial success 
is challenging which applies especially to nanoparticle-based Nanomedicine. The 
Food and Drug Administration (FDA) addressed this issue by releasing the 
“Critical Path Opportunities List and Report”. Comparably, the European 
Medicines Agency (EMEA) set up a regulatory agenda for Nanomedicine. 
Essentially, the FDA identified seven main challenges for nanomedicine to 
achieve market registration approval that must be scientifically overcome. Such 
challenges range from biodistribution knowledge mentioned in chapter III.4 
gained by robust and reliable imaging techniques and insight into the detailed 
mass transport across compartmental boundaries in the body, new mathematical 
computer models to predict risk benefit and risk parameters of nanoparticles to 
finally establish an obligate standard and reference material system to which one 
can refer in nanomaterial research. The latter is promoted by the National Cancer 
Institute’s Nanotechnology Characterization laboratory. 
Future perspectives concerning the clinical use of nanoparticles include both the 
possibility to detect and treat diseases at earlier stages than available today.  
Moreover, nanoparticles could function as a platform for the detection of 
biomarkers including proteins, nucleic acids or metal ions and therefore be 
valuable in early stage diagnosis. 
Today, nanoparticle-enabled drug delivery stands at a decisive crossroad whether 
to proceed into the direction of highly complex systems towards “nanorobots” or 
to turn into a “keep it simple” strategy. At least mid-term orientated, the latter 
appears to be more reasonable at least for two basic fundamentals: regulatory 
issues and price. Clearly, the more complex the nanoparticulate device is, the 
more potential risks does it bear. This covers the manufacturing process, where an 
incredibly high monitoring effort for specification compliance must be accounted 
for and finally stretches to the animal or human patient. In vivo, a multitude of 
components might possess their own unique degradation and metabolism 
pathways. In the end, the two most crucial factors are safety and reproducibility. 
Resulting costs will be high and only reimbursed by public health authorities and 
insurances if convincing therapeutic benefits are guaranteed in the increasingly 
competitive pharmaceutical market. Nevertheless, nanoparticle-based 
226                                                                       Final conclusion and outlook                      
Final conclusion and outlook    227 
 
 
nanomedicine holds a great promise to contribute to improved health care, more 
efficient health economics and personalized medicine.    
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